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In recent years, great advances have been made in the field of stem cell differentiation.
Seminal insights in the area of developmental biology and tissue regeneration have made
ex vivo differentiated cells a realistic alternative for transplantation applications.  The
recent application of these murine-based insights to human systems has paved new paths
in autoimmune disease, chemotherapy, and immuno-deficiency research.  Such strides
would eliminate the hurdles associated with adoptive transfer including limited
availability of transplantable cells, site morbidity, difficulties in cell isolation and
expansion lag time.
Current approaches in ex vivo hematopoiesis and T cell differentiation have begun
to explore the effects of biomaterials on differentiation efficiency.  These approaches,
however, have not fully studied the quantitative effects of biomaterials and their
properties on hematopoietic and T cell differentiation generation.
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Our goal was to design biomaterials whose properties could be tailored to improve
differentiation efficiencies in T cell differentiation. Our work is dedicated to fabricating
and characterizing Notch ligand functionalized microbeads for T cell differentiation
applications.  Our work has shown stable functionalization of Notch ligands on
microbeads that can be quantitatively varied to achieve optimal Notch signaling.  We
have also demonstrated limited cellular toxicity and effective Notch signaling upon
exposure to Notch ligand functionalized beads.  Finally, we have successfully
differentiated T cell progenitors from hematopoietic stem cells using the functionalized
microbeads. As a side study, we have fabricated and characterized polymeric PLA
scaffolds that were systematically varied and studied for their effects on hematopoietic
differentiation efficiency.  Insights gained from these studies should provide a better
understanding of the microenvironmental signals in hematopoiesis and aid in the
development of efficient technologies for the production of hematopoietic progenitors
and T cells for therapeutic applications.
xi
Table of Contents
List of Tables ....................................................................................................xix
List of Figures....................................................................................................xx
CHAPTER ONE 1
Introduction: Specific Aims and Overview...........................................................1
1.1 Introduction .......................................................................................1
1.2 Specific Aims ....................................................................................3
1.2.1 Aim 1:To develop Notch ligand coated microbeads (artificial stromal
cells), effectively characterize successful ligand conjugation and
demonstrate bead cell compatibility.  .........................................3
1.2.2 Aim 2: To qualitatively and quantitatively demonstrate successful
Notch signaling using Notch ligand functionalized microbeads in a
dose-dependent manner. .............................................................4
1.2.3 Aim 3: To utilize Notch ligand coated microbeads to quantitatively
evaluate the effects of Notch signaling on hematopoietic stem cell
(HSC) differentiation towards the T cell lineage.........................4
xii
1.3   Overview.............................................................................................5
1.4   References ...........................................................................................6
CHAPTER TWO 8
Background and Significance ...............................................................................8
2.1 Overview of T Cell Related Immunodeficiencies and Transplantation
Strategies ...........................................................................................8
2.2 T Cell Development and Differentiation ..............................................10
2.3 Thymic microenvironment ..................................................................11
2.4 Notch signaling....................................................................................14
2.4.1 Overview of Notch Signaling ...................................................14
2.4.2 Importance in T Cell Development ..........................................15
2.5 Ex Vivo T Cell Differentiation Methods ...............................................16
2.5.1 Fetal and reaggregate thymic organ cultures.............................16
2.5.2 Recent methods: thymic stroma, cytokine cocktails, stromal cell
lines .........................................................................................17
2.5.3 Current method: OP9-DL1 cell line and spinoffs ......................19
xiii
2.5.4 Limitations of OP9-DL1 system...............................................21
2.5.5 Motivation for DLL4 based T cell differentiation .....................22
2.6 Beads in Cell Studies ...........................................................................22
2.6.1 Overview of beads ...................................................................22
2.6.2 Motivation for beads as a method for protein presentation........24
2.7 References ...........................................................................................27
CHAPTER THREE 40
Development and Characterization of Notch Ligand Coated Microbeads ...........40
3.1 Introduction .........................................................................................40
3.2 Materials and Methods.........................................................................42
3.2.1 Biotinylated polyhistidine antibody functionalization and
optimization .............................................................................42
3.2.2 DLL4 functionalization and optimization .................................43
3.2.3 Bead stability testing ................................................................44
xiv
3.2.4 Immunofluorescence and flow cytometry analysis....................45
3.2.5 Confocal microscopy ...............................................................47
3.2.6 Quantification of DLL4 conjugation using ELISA ...................47
3.2.7 MTT assay ...............................................................................48
3.2.8 Statistical analysis ....................................................................49
3.3 Results.................................................................................................50
3.3.1 Optimal conditions for biotinylated polyhistidine antibody
functionalization to microbeads................................................50
3.3.2 Optimal conditions for DLL4 functionalization to microbeads .52
3.3.3 Bead stability is compromised with the presence of DNA
linker ................................................................................................56
3.3.4 Viability of C2C12 myoblasts and embryonic stem cells is not





Qualitative and Quantitative Assessment of Dose-Dependent Notch Signaling...96
4.1 Introduction .........................................................................................96
4.2 Materials and Methods.........................................................................99
4.2.1 Bead fabrication .......................................................................99
4.2.2 C2C12 cell and R1 cell culture .................................................99
4.2.3 C2C12 myotube inhibition assay for Notch signaling ...............99
4.2.4 Intracellular Notch staining ....................................................101
4.2.5 Real-time RT-PCR studies of Notch gene expression .............102
4.2.6 Luciferase reporter assay........................................................103
4.3 Results...............................................................................................103
4.3.1 Immobilization of DLL4 is necessary for Notch signaling;
functionalization scheme does not affect myotube inhibition ..103
4.3.2 DLL4 functionalized microbeads can provide efficient Notch
signaling ................................................................................104
4.3.3 Basal levels of intracellular Notch staining exist in R1 embryonic
stem cells and C2C12 myoblasts ............................................105
xvi
4.3.4 Real-time and end point RTPCR analysis indicate upregulation of
Notch target genes in myoblasts .............................................106
4.3.5 Luciferase reporter assay indicates increase in Notch related CBF-1





T Cell Differentiation Using Notch Ligand Functionalized Beads ....................138
5.1 Introduction .......................................................................................138
5.2 Materials and Methods.......................................................................140
5.2.1 Conjugation of Notch ligand DLL4 to microbeads .................140
5.2.2 Bone marrow hematopoietic stem cell isolation and culture for in
vitro T-cell development ........................................................141
5.2.3 Flow cytometry ......................................................................142
5.3 Results...............................................................................................143
5.3.1 DLL4 functionalized microbeads direct BMHSCs to T-cell lineage
in OP9 co-culture systems ......................................................143
xvii





Conclusions and Future Directions ...................................................................155
6.1 Summary ...........................................................................................155
6.1.1 Conclusions and future directions on bead fabrication,
characterization and optimization studies ...............................155
6.1.2 Conclusions and future directions on qualitative and quantitative
characterization of dose-dependent Notch signaling ...............158
6.1.3 Conclusions and future directions on T cell differentiation using
Notch functionalized microbeads ...........................................161
6.1.4 Conclusions and future directions on scaffold properties and stromal
cell coculture effects on hematopoietic differentiation of embryonic
stem cells ...............................................................................162
6.1.5 Project design considerations .................................................164
6.2 References .........................................................................................167
xviii
Appendix A Influence of scaffold physical properties and stromal cell coculture on
hematopoietic differentiation of mouse embryonic stem cells ..................170






Table 2.1: Summary of T Cell Related Immunodeficiencies ...........................25
Table 3.1: Reduction in surface functionalized DLL4 microbead as compared to
original amount. (values represent percent) ....................................67
Table 3.2: Reduction in surface functionalized DLL4 microbead as a function of
time. (values represent percent)......................................................68
Table 3.3: Student’s t test analysis of statistical difference between uncoated and
DLL4 functionalized beads cytotoxicity in C2C12 myoblasts and R1
embryonic stem cells: p values.......................................................69
Table 3.4: Student’s t test analysis of cytotoxicity differences from differences in
bead to cell ratios for uncoated beads with C2C12 myoblasts: p values
......................................................................................................70
Table 3.5: Student’s t test analysis of cytotoxicity differences from differences in
bead to cell ratios for uncoated beads in R1 cells: p values.............71
Table 4.1: Student’s t test analysis of differences among bead to cell ratios for
varying DLL4 densities on Proactive® beads for luciferase reporter
assay............................................................................................117
Table 4.2: Student’s t test analysis of differences between varying DLL4 density
coated Proactive® beads, anti-6x HIS antibody coated beads and cells
for luciferase reporter assay .........................................................118
Table 4.3: Fold differences in luciferase activity between high DLL4 density coated
Proactive® beads, anti-6x HIS antibody coated beads and cells ...119
xx
List of Figures
Figure 2.1: T cell development in the thymic microenvironment ......................26
Figure 3.1: Schematic of Notch functionalized microbead................................72
Figure 3.2: Anti-6x HIS antibody saturation of magnetic beads for high
concentrations using flow cytometry analysis.................................73
Figure 3.3: Anti-6x HIS antibody saturation of magnetic beads using flow cytometry
analysis. .........................................................................................74
Figure 3.4: Bead concentration and incubation period optimization for anti-6x HIS
antibody coating using flow cytometry analysis. ............................75
Figure 3.5: Microbeads can be efficiently functionalized with Notch ligand
DLL4.............................................................................................76
Figure 3.6: Fluorescence microscopy confirmation of functionalized DLL4 on the
surface of Biotin Binder Kit beads. ................................................77
Figure 3.7: Fluorescence microscopy confirmation of functionalized DLL4 on the
surface of Proactive® beads. ..........................................................78
Figure 3.8: DLL4 saturation of magnetic beads using flow cytometry analysis.79
Figure 3.9: DLL4 saturation of Proactive ® magnetic beads using flow cytometry
analysis. .........................................................................................80
Figure 3.10: Bead concentration and incubation period optimization for DLL4
coating using flow cytometry analysis............................................81
Figure 3.11: DLL4 functionalized Biotin Binder Kit bead stability after 6 days in
native storage conditions................................................................82
Figure 3.12: Effect of temperature, serum and medium on the stability of DLL4
functionalized Biotin Binder Kit bead after 1 hr incubation. ...........83
xxi
Figure 3.13: Effect of temperature, serum and medium on the stability of DLL4
functionalized Proactive® beads after 1 hr, 1 day and 1 week of
incubation. .....................................................................................84
Figure 3.14: Cytotoxicity effects of uncoated and DLL4 functionalized Biotin Binder
Kit beads using MTT assay in C2C12 myoblasts............................85
Figure 3.15: Cytotoxicity effects of uncoated and DLL4 functionalized Biotin Binder
Kit beads using MTT assay in R1 embryonic stem cells. ................86
Figure 3.16: Cytotoxicity effects of uncoated Biotin Binder Kit beads using MTT
assay in C2C12 myoblasts..............................................................87
Figure 3.17: Cytotoxicity effects of uncoated Biotin Binder Kit beads using MTT
assay in R1 embryonic stem cells...................................................88
Figure 4.1: Summary of Notch signaling assays utilized in the study..............120
Figure 4.2: Surface immobilization of DLL4 inhibits myotube formation in C2C12
cells. ............................................................................................121
Figure 4.3: Myotube formation is inhibited in the presence of immobilized DLL4
....................................................................................................122
Figure 4.4: Neutravidin and biotinylated anti-6x HIS antibody immobilization do
not affect myotube inhibtion ........................................................123
Figure 4.5: DLL4 functionalized microbeads induce Notch signaling in C2C12 cells
....................................................................................................124
Figure 4.6: Basal levels of Notch signaling in C2C12 myoblasts....................125
Figure 4.7: Basal levels of Notch signaling in R1 embryonic stem cells. ........126
Figure 4.8:    Basal levels of Notch target gene expression in R1 ES cells evident after
one week of culture......................................................................127
xxii
Figure 4.9: Low bead to cell ratios increase Notch target gene expression in C2C12
cells after 2 day incubation...........................................................128
Figure 4.10: Low DLL4 functionalized bead to cell ratios result in HES1 gene
expression in Day 6 myoblasts .....................................................129
Figure 4.11: Proactive® beads functionalized with DLL4 upregulate Notch gene
expression in C2C12 cells after 4 hr of incubation........................130
Figure 4.12: DLL4 functionalized Biotin Binder Kit beads result in increased
luciferase gene activation in C2C12 myoblasts.............................131
Figure 4.13: DLL4 functionalized Proactive® beads result in increased luciferase
gene activation in C2C12 myoblasts ............................................132
Figure 5.1: Notch ligand-coated microbeads direct efficient commitment of ES cells
to T cells in both insert and mixed coculture systems ...................149
Figure 5.2: Defined ratios of notch ligand-microbead can be used for T-cell
commitment.................................................................................150




Introduction: Specific Aims and Overview
1.1 INTRODUCTION
Advances in stem cell transplantations laid down the foundation for a procedure
called adoptive T cell transfer where patient T cells are expanded and trained ex vivo and
infused back into the body to replenish the lymphocyte supply.  Although clinical studies
have demonstrated promising results in terms of little cytotoxicity and normal T cell
function, the challenge to treat severely immunocompromised individuals and at that in a
cost-effective and rapid amount of time still remains (Yee 2002).
T cell development takes place primarily in the thymic microenvironment where
bone marrow progenitors migrate in through post-capillary venules and undergo a series
of cell-cell and cell-matrix interactions that drive the development process forward.  Cell
surface signals such as Notch ligands, interleukins and growth factors, and chemokines
are instrumental in providing the differentiation, proliferation and survival and migration
cues necessary for the cells to become fully functional (Ciofani and Zuniga-Pflucker
2007).
Recent methods in ex vivo T cell differentiation have focused on the Notch
signaling in the thymus and its apparent dose-dependent role in T cell and lymphocyte
development.  Early studies exploited the thymic microenvironment for ex vivo
generation of T cells using fetal thymic organ cultures and thymic stroma (Weekx et al.,
2000; Yeomen et al., 1993).  These studies provided great insight in T cell development
but were severely constrained due to low cell yield and the complicated and cumbersome
nature of the setup (Zuniga-Pflucker 2004).  The generation of a Notch ligand transfected
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stromal cell line, OP9-DL1, benefited the field greatly and led to the successful
differentiation of both human and murine derived T cell progenitors from cord blood,
bone marrow and fetal liver sources.  These studies have also suggested a threshold for
Notch signaling in lymphocyte development where B cells require the least, NK cells
require medium levels and T cells require the greatest amount (Ciofani and Zuniga-
Pflucker 2007; de Pooter and Zuniga-Pflucker 2007; La Motte-Mohs et al., 2005; Schmitt
et al., 2004).
Despite its benefits, the OP9-DL1 cell line method of ex vivo T cell generation
suffers from two major disadvantages.  Failure to express major histocompatibility
complex II proteins have prevented the generation of CD4+ SP T cells.  Also, the
inherent dependence on the cell line to express the Notch ligand makes quantitative
characterization and scaling up difficult (Zuniga-Pflucker 2004).
Protein functionalized microbeads have been extensively used in antigen
presentation applications with recent studies showing up to 40 days of successful T cell
expansion with anti-CD3 and anti-CD28 antibody functionalized beads (Levine et al.,
1997).   Microbeads offer a cytocompatible, definable approach to protein presentation
without the biosafety concerns of cell surface ligands and the ability to scale up (Trickett
et al., 2002).  The use of such microbeads for T cell development and Notch signaling
applications could lead to a more quantitative understanding of Notch signaling and
potentially aid in the production of T cells for therapeutic applications.
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1.2 SPECIFIC AIMS
1.2.1 Aim 1:  To develop Notch ligand coated microbeads (artificial stromal cells),
effectively characterize successful ligand conjugation and demonstrate bead cell
compatibility.
We hypothesized that streptavidin-biotin and antibody-antigen interactions are
robust enough to present Notch ligands in a controlled manner on a microbead platform
in a cellular environment.  Furthermore, by presenting ligands on a microbead surface,
the effective ligand density the cell “sees” can be tailored both by varying the amount on
the surface of the bead and varying the amount of beads delivered.
In this aim, we propose the fabrication of Notch ligand (Delta-like ligand 4,
DLL4) coated magnetic microbeads through streptavidin-biotin and antibody-antigen
interactions as mentioned above.  Optimal conditions for bead fabrication were achieved
through in depth studies varying incubation period, bead concentration and ligand
concentration for both biotinylated antibody and DLL4 proteins.  Surface functionalized
DLL4 on microbeads was quantified using commercially available calibrated beads.  The
stability of functionalized DLL4 on microbeads was also assessed both at 4°C and 37°C
in various buffers and media.  All studies given above utilized immunofluorescence
staining and flow cytometry.  Immunofluorescence fluoroscopy and ELISA analysis
further demonstrated presence of DLL4 on bead surfaces.  These studies were carried out
with two different commercially available streptavidin coated magnetic microbeads, one
of which utilized a DNA linker to bind the streptavidin coating to the polystyrene bead.
 Cellular toxicity of uncoated and functionalized microbeads was also assessed
using (3-[4,5-dimethylthiazol-2-yl]2,5-diphenyl tetrazolium bromide) (MTT) assays
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where quantitative and temporal effects of Notch ligand coated microbeads on cells were
evaluated.
1.2.2  Aim 2:  To qualitatively and quantitatively demonstrate successful Notch
signaling using Notch ligand functionalized microbeads in a dose-dependent
manner.
Our hypothesis for the Notch functionalized microbeads was that the amount of
Notch signaling present in a cell could be controlled by varying the ligand density on the
bead and/or amount of beads present.  We explored our hypothesis through a classic
bioactivity assay demonstrating myotube inhibition when Notch signaling is present.
Inhibition was confirmed qualitatively through phase contrast microscopy.  Additional
studies examining intracellular Notch signaling namely staining for the presence of
activated Notch receptor (only present when Notch signaling is occurring) were
performed using intracellular staining, fluorescence microscopy and flow cytometry.
Next, real-time reverse transcriptase polymerase chain reaction (RT-PCR) techniques
were utilized to demonstrate quantitative differences in downstream Notch target gene
expression upon exposure to various bead to cell ratios.  Finally, transient transfection of
luciferase under the CBF1 promoter and luminescence evaluation were performed to
confirm dose-dependent effects of Notch functionalized beads on cells.
1.2.3 Aim 3: To utilize Notch ligand coated microbeads to quantitatively evaluate
the effects of Notch signaling on hematopoietic stem cell (HSC) differentiation
towards the T cell lineage.
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In this aim, our goal was to study the effect of quantitatively tunable Notch
signals on T cell commitment and differentiation efficiency of hematopoietic stem cells.
HSCs isolated from mice were cocultured with and without functionalized microbeads at
two different doses with appropriate supportive stroma and cytokines and evaluated for T
cell commitment efficiency after 1 week of incubation using immunophenotype staining
and flow cytometry. Effect of cell-cell contact was also assessed using insert culture.
1.3 OVERVIEW
Chapter 2 provides the necessary background and significance of the project with
respect to issues that illustrate how the study aids in the understanding of the field, such
as therapeutic relevance, current techniques in providing Notch signaling and ex vivo T
cell differentiation.  In Chapter 3, the fabrication and characterization of Notch
functionalized microbeads are discussed, including the effects of incubation period, bead
concentration, ligand density, incubation buffers, temperature and cellular toxicity.
Chapter 4 demonstrates the dose-dependent manner of the Notch ligand functionalized
microbeads with several qualitative and quantitative assays including myotube inhibition,
intracellular Notch receptor activation, real-time RTPCR gene expression analysis and
luciferase reporter expression.  Chapter 5 illustrates successful T cell commitment in a
dose-dependent manner using hematopoietic progenitors, supportive stroma and Notch
ligand functionalized beads and immunophenotype analysis. Lastly, Chapter 7 discusses
the project insights, conclusions, and future directions.  Appendix A includes a side study
we performed on optimization of scaffold properties for hematopoietic differentiation.
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2.1 OVERVIEW OF T CELL RELATED IMMUNODEFICIENCIES AND
TRANSPLANTATION STRATEGIES
About one in 10000 Americans is born with a maldeveloped thymus, a condition
known as Di George’s Syndrome (DGS).  Early diagnosis and bone marrow or thymic
transplantation lead to recovery and minimal discomfort in the quality of life (Bonilla and
Geha 2003; Huggins 2006).  For those unchecked, however, a lifetime of constant
monitoring, prophylactic antibiotics and preventive care rather than corrective care is
undergone. In fact, preventive care is the standard for such disorders.  Most primary T
cell immunodeficiencies such as DGS are disorders of genetic nature and have no
effective replacement therapy (Bonilla and Geha 2003; Buckley 2003; Souhami 2002).
(Table 2.1 summarizes some T cell immunodeficiencies with treatment options.)
For conditions such as these, there is a strong need of functional T lymphocytes
that can replenish and restore the afflicted’s immune system.  T cell immunodeficiencies
and conditions like cancer rely on transplantations such as bone marrow or adoptive T
cell transfer to reconstitute the compromised immune defenses.  Such transplantations
have displayed a fair amount of success.  Indeed, great strides have been made from Till
and McCullough’s seminal studies in hematopoietic reconstitution in the 1960s (Till and
McCollough 1961).  For severe combined immunodeficiency patients, for example, bone
marrow transplantation success rates have ranged from 50 to 100% (Bertrand et al., 1999;
Sinha 2006).  Moreover, according to a recent survey conducted by Buckley, 79% of
primary immunodeficiency patients transplanted with HLA-identical marrow have lived
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(Buckley 2003).  Donor type, age at transplantation and severity of condition often
dictate the success rate of the procedure; the earlier a condition is diagnosed and treated,
the greater the chances of survival (Bonilla and Geha 2003).
Stem cell transplantations have laid much of the groundwork for adoptive T cell
transfer, a procedure that has become more common during the last 20 years (Yee 2006).
In adoptive transfer, healthy T effector cells are expanded, trained and infused into the
patient where they combat and in effect eradicate the preexisting tumor.  Effector T cells
are particularly well-suited in such in vivo applications due to their specificity, long
lifespan and ability to be genetically manipulated (June 2007).  Adoptive transfer has
been beneficial for patients with cytomegalovirus and Epstein-Barr virus-associated post-
transplant lymphoproliferative disease resulting in CMV-specific cytotoxic T lymphocyte
response restoration and antiviral activity, respectively (Leen et al., 2007).  In a recent
study by Yee et al, melanoma antigen specific T cell clones were administered with
encouraging results in ten patients in a phase 1 trial.  T cell clones persisted in vivo with
little toxicity, homed to tumor site, and removed tumor cells positive for melanoma
antigen for almost a two-year period (Yee 2002).  The emerging trend, however, is the
difficulty in treating immunocompromised patients with malignancies and highly
immunosuppressed individuals (Leen et al., 2007).  Also, despite, the attractive nature
and success of effector T cell transfer, the translation from in vitro to in vivo clinical trials
has been difficult and the procedure is still suboptimal.  In the in vivo, tumor
microenvironment, T cells are short-lived, fail to proliferate and function.  Additionally,
the process itself can be time, labor and cost intensive and take up to 4-16 weeks, a very
long period for individuals with progressive diseases (June 2007; Yee 2005).  The need
for a robust large-scale production of antigen specific T cells remains (June 2007).
Future studies in T cell training, expansion and differentiation have the potential to
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significantly benefit cancer and immunodeficiency patients and have a lasting impact on
cancer treatment and therapy.
2.2 T CELL DEVELOPMENT AND DIFFERENTIATION
T cell development is comprised of a series of complex interactions that take
place both in the bone marrow and thymus and ultimately result in the formation of
CD4+ and CD8+ T cells that are capable of recognizing MHC class II or class I
molecules, respectively, and informing the immune system of extracellular or
intracellular infections.  Hematopoiesis, the generation of all blood cells, normally occurs
in the bone marrow in the adult mouse (and man).  For T cell generation, however,
hematopoietic progenitors migrate via the bloodstream in response to chemokines
secreted by thymic epithelial cells and through the post-capillary venules into the thymus
for T cell development and maturation (Champion 1986; Gill et al., 2003; Goldsby 2003;
Wilkinson et al., 1999).  It remains unclear whether hematopoietic progenitors have
committed to the T cell lineage prior to thymic entry and many reports have demonstrated
limited B cell potential of immature thymocytes with in vivo, in vitro and clonal analysis
assays (Balciunaite et al., 2005; Jenkinson et al., 2006; Porritt et al., 2004; Sambandam et
al., 2005; Tan et al., 2005; Zediak et al., 2005).  Nevertheless, immature thymocytes must
undergo a strict development and selection process before they have fully matured.  This
process can be divided into the double negative stages, ! selection, TCR rearrangement,
negative and positive selection (Gill et al., 2003; Goldsby 2003).  Figure 2.1 summarizes
this process of T cell development delineating the surface marker expression, thymic
signals, cell interactions and location of thymocyte development.
Early T lineage progenitors (ETPs) can be identified through their CD44+CD25-
CD4-CD8- cell surface marker phenotype.  Because these cells are CD4-CD8-, they are
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known as double negative (DN).  Progression of the differentiation in the DN stage is
marked by the surface expression changes of CD44 and CD25 in four stages: DN1 –
CD44+CD25-, DN2 – CD44+CD25+, DN3 – CD44-CD25+, DN4 – CD44-CD25-).
Notch signaling and interleukin-7 (IL-7) play instrumental roles in driving the
differentiation from the DN1 to the DN3 stages, during which the developing thymocytes
rearrange the ! locus of T cell receptor (TCR) and if successful express TCR " chain and
the pre-TCR complex.  Selected DN3 thymocytes expand and generate a large and
diverse set of CD4+CD8+ thymocytes (known as double positive or DP cells) during !
selection that proceed to " chain loci rearrangements and assembly of the "! TCR-CD3
complex.  Next, the developing DP thymocytes interact with the cortical epithelial cells
and are positively selected based on their ability to recognize self major
histocompatibility complex (MHC) and self peptide.  Auto reactive thymocytes are
eliminated during negative selection where positively selected thymocytes associate with
macrophages and dendritic cells in the medulla and undergo apoptosis.  The few cells that
survive the selection processes downregulate the coreceptor and develop into CD4+ or
CD8+ T cells based on their ability to interact with MHCII and MHCI expressing cells,
respectively (Bhandoola and Sambandam 2006; Ciofani and Zuniga-Pflucker 2007; Gill
et al., 2003; Goldsby 2003; Guidos 2006).   T cells with #$ lineage are also produced in
the thymus but a description has been omitted in the interest of length.
2.3 THYMIC MICROENVIRONMENT
Thymocyte development takes place in a complex milieu of supportive cells and
extra-cellular matrix (ECM) that are responsible for the proliferation, adhesion,
migration, and selection processes thymocytes undergo before reaching maturity
(Anderson et al., 2000, Germain 2002; Goldsby 2003).  Several of the signals necessary
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for thymocyte development and survival which include Notch signaling and MHC-TCR
interactions have been characterized through overexpression, gain-of-function and
transfection studies (Germain 2002; Goldsby 2003).  The thymic microenvironment can
be outlined into the following components: molecules (both soluble and cell-bound),
extracellular matrix, vasculature, and cells made up of supportive stroma, hematopoietic
and non-hematopoietic alike.  In a recent paper by Petrie and Zuniga-Pflucker, seven
zones have been outlined due to histologic differences and differences in signaling
environments.  The following description describes the protein and cell-based signals and
how they are responsible in dictating the development of thymic progenitors, which is
largely coupled to the migration of progenitors from zone to zone.  One note to be added
is the omnipresent nature of Notch signaling in the thymic microenvironment.  Notch
signaling is discussed in greater detail below.
As described below, thymic development and differentiation is only possible due
to the environmental complexity and interplay of the thymic stroma and developing
progenitors.  This complex milieu directs the migration, adhesion and proliferation
events, characteristic of the T cell differentiation process.  In this process, the bone
marrow progenitors first must migrate to the perimedullary cortex (PMC) in the thymus
through venules, a zone (PMC) rich in homing and adhesion signals such as P-selectin,
fibronectin, laminin, VCAM-1, and CCL21.  Once the progenitors reach the PMC or
Zone 1, DN1 cells expand up to 1000 times with signals from IL-7, Kit ligand, and
Hedgehog signaling.  Finally, Notch signaling is necessary to prevent non-T cell
commitment and takes place due to the increased expression of Delta-like 1 ligand in
cortical stroma.  In the inner cortex, or Zone 2, upregulation of RAG gene expression in
progenitors takes place resulting in TCR# and TCR$ gene rearrangements.  IL-7, which is
known to be responsible for survival and proliferation, is present in Zone 2 and also aids
13
in TCR expression and cell adhesion.  Kit ligand is also produced by Zone 2 stroma,
aiding in progenitor proliferation.  CXCL12 is secreted in the cortex and plays a role in
the directional migration of progenitors as they develop.  Both VCAM-1 and E-cadherin,
expressed on epithelial stroma cells in Zone 2, form the adhesive substrate for migration.
Notch ligands are again present on stroma to ensure T cell commitment.   In Zone 3 or
the outer cortex, DN3 cells migrate to the capsule through the adhesive support and
polarity signals of VCAM-1 and CCL25, respectively.  Both IL-7 and Notch ligands, also
present in Zone 3, are thought to provide the signals necessary for TCR! locus
rearrangement, a key step in committing progenitors to the T cell lineage.  Expansion also
takes place in Zone 3 but the factors responsible remain unknown.  Late DN3 and pre-DP
cells undergo completion of TCR! rearrangements, pre-TCR expression, acquisition of
CD4 and CD8 markers and migrate back towards the cortex in the subcapsular zone or
Zone 4.  Unfortunately, in the area of external stimuli, little besides the large role the
preTCR plays in the developmental processes is known.  CCL25 and laminin-5 are
known to play a role in migration and adhesion, respectively.  TNF, present on medullary
stromal cells, is thought to play a role in survival, while Notch remains to be a key player
in survival and differentiation.   CD4CD8 DP cells reside and migrate back towards the
cortex in Zone 5.  Here, the cells cease proliferation - it is thought through some self-
initiated programming and further their maturation.  Also, the requirement for stromal
matrix-cell contact no longer applies.  DP cells still rely on soluble factors and cell-cell
contact from stroma to provide the MHC signals, ICAM-1 and IL-7 for positive selection,
migration and survival respectively.   The outer medulla or Zone 6 is distinguishable
from the other zones by its abundance of dendritic cells (DCs), responsible for presenting
antigens to developing T cells during negative selection.  Medullary epithelial cells, also
present in this area, are largely responsible for presenting the self-antigens to the DCs and
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thus eliminating auto-reactive T lymphocytes.  CD80, CD86, and ICAM-1 also play a
part in ensuring effective contact between stroma and T cells.  Medullary epithelial cells
also express CCL19 and CCL21 ligands which aid the migration of SP T cells toward the
medulla.  IL-7 and thymic stromal lymphopoietin (TSLP) support SP survival in Zone 6.
The final step in SP T cell maturation is a 7-10 day period in Zone 7 or central medulla
before they export out of the thymus.  MHC-TCR engagement is thought to aid in final
development of SP cells and induction of further delineation of T cell types.  Additional
signals include CD69 expression on stroma which mediate cell retention and
lymphotoxin-! receptor necessary for maturation.  Edg1, CD69 and G protein-coupled
receptors are believed to aid in thymic export but have not completely been confirmed
(Anderson et al., 1996; Anderson et al., 2000; Ciofani and Zuniga-Pflucker 2007; Ladi et
al., 2006; Petrie and Zuniga-Pflucker 2007; Postlethwaite 1997; Schuurman et al 1997).
2.4 NOTCH SIGNALING
2.4.1 Overview of Notch Signaling
The term Notch signaling was coined in the 1930s when a “notch” was observed
in a mutant Drosophila wing (Mohr 1919).  Although early studies indicated a role in
Drosophila and neurogenesis, roles in several vertebrate developmental decisions ranging
from neuronal differentiation to hematopoietic progenitor expansion were soon observed
(Artavanis-Tsakonis et al., 1995; Baron 2003; Chiba 2006; Jarriault et al., 1995).  There
are four receptors (Notch1-4) that make up the Notch family of receptors.  These
receptors are highly conserved and are made up of 29-36 epidermal growth factor repeats
in the extracellular portion, which are responsible for initiating Notch signaling by
binding to Notch ligands.  The intracellular portion of Notch transduces the Notch signal
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to the nucleus and consists of RAM domain and ankyrin repeats.  In mammals, there are
5 ligands - Jagged 1, Jagged 2, Delta 1, Delta 3, and Delta 4.  Two main cleavages take
place in the transmembrane receptor upon ligand-receptor binding.  One cleavage takes
place on the extracellular portion and depends on the presence of metalloproteases while
the other cleavage occurs in the transmembrane domain generating an intracellular Notch
domain (ICN) upon #-secretase activity.  The RAM and ankyrin repeats initiate the
binding of the ICN to the helix-loop-helix transciption factor CBF1/RBP-Jk (for
mammals), once the ICN has successfully translocated into the nucleus.  In the absence of
Notch signaling, CBF1/RBP-Jk is bound to corepressors and transcription is blocked.
Upon successful Notch signaling, the ICN kicks off the corepressors, and engages
proteins such as Mastermind-like proteins, initiating transcription.  The complex,
however, is eliminated rapidly (Maillard et al., 2005).
2.4.2 Importance in T Cell Development
Notch signaling is well known and perhaps most characterized in determining the
fate of developing T cells, evident by the extensive expression of Notch ligands in the
thymic microenvironment.  These receptors and ligands are tightly regulated in their
expression both in the bone marrow and thymus to achieve a unique balance of
lymphocyte development (Ciofani and Zuniga-Pflucker 2007; Parreira et al., 2003; Petrie
and Zuniga-Pflucker 2007).  The expression of all four receptors by the developing
thymocytes and the supportive thymic stroma has been previously characterized while
Delta ligand (1 and 4) expression has been shown in the thymic stroma (Ciofani and
Zuniga-Pflucker 2007; Parreira et al., 2003; Petrie and Zuniga-Pflucker 2007).  In situ
hybridization studies have shown a high density of Delta 4 ligand, specifically,
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throughout the subcapsular zone, cortex and cortical-medullary junction, indicating the
importance of the ligand in T cell development (Heinzel et al., 2007).
Gain-of-function, overexpression, and loss of function studies have been
instrumental in understanding the necessity of Notch signaling in thymocyte development
and survival.  In studies with constitutively active forms of the Notch ligand in HSCs, B
cell development was inhibited entirely and extrathymic T cell generation was observed
(Pui et al., 1999).  Defects of Notch1 gene also led to deficiencies in T cell development
and an increase of B cell development in the thymus (Radtke et al., 1999).  Similar results
were observed in CSL based studies.  CSL is known for controlling the signaling of
Notch receptors.  When bone marrow progenitors that were deficient in CSL were placed
in the thymus, T cells failed to form, leading to development of B cells (Han et al., 2002).
Additional gain-of-function studies demonstrated ectopic T cell development in the bone
marrow microenvironment upon Notch1-IC or Delta 4 expression in progenitors (Dorsch
et al., 2002; Yan et al., 2001).  These studies combined with what is known on the thymic
microenvironment reveal the vital role Notch ligands play in T cell fate decisions.
2.5 EX VIVO T CELL DIFFERENTIATION METHODS
2.5.1 Fetal and reaggregate thymic organ cultures
Immense progress has been made in the area of ex vivo T cell differentiation in
the last forty years, leading to a wealth of insights in T cell development and
lymphopoiesis.  Early studies relied on fetal thymic organ culture (FTOCs) system for T
cell development, largely established by Owen and Jenkinson.  This was mostly due to
the widely held belief that the thymus and its architecture particularly, were indispensable
in T cell development.  In FTOCs, the thymic lobes are stripped of thymocytes with
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chemical treatment and used to provide their unique architecture and signaling to thymic
progenitors (de Pooter and Zuniga-Pflucker 2007; Lehar and Bevan 2002; Zuniga-
Pflucker 2004).  FTOCs were the established means of studying T cell development and
elucidated the underpinnings of the field.  For example, Yeoman and colleagues
demonstrated the ability to generate CD4+ and CD8+ SP T cells from human bone
marrow and umbilical cord blood cells in FTOCs with varying differentiation capabilities
observed between progenitor populations (Yeoman et al., 1993).  Additional FTOC based
studies supplied important detail on mechanisms of T cell development including
differentiation abilities of various progenitor populations, importance of cell cycle and
effect of cytokines, to name a few (Plum et al., 1994; Res et al., 1996; Toki et al., 1991;
Weekx et al., 2000).  Reaggregate thymic organ cultures (RTOCs), which consists of
disaggregated stroma that have subsequently been recombined, were also beneficial for
such studies (Anderson et al., 1993).  FTOC and RTOC based cultures though seminal in
their contributions to T cell development and vital even today for their ability to provide
adequate environments for T cell selection, suffer from low cell differentiation
efficiencies, varied results, complicated setup, and difficulties in isolating distinct signals
(de Pooter and Zuniga-Pflucker 2007; Zuniga-Pflucker 2004).
2.5.2 Recent methods: thymic stroma, cytokine cocktails, stromal cell lines
Developments in scaffold technology led to the application of thymic stroma to
tantalum based matrices, readily used in bone repair and the efficient generation of
human T cells with up to 70% CD3+ T cells after 14 days of stroma-human CD34+ cell
coculture (Poznansky et al., 2000).  Further studies illustrated successful positive and
negative selection in these matrices with E1 and OVAp peptide addition, respectively
(Marshall et al., 2003).  Time needed to establish thymic structure in 3D cultures was still
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a potential disadvantage of the system.  Another method readily used requires the
addition of exogenous cytokines such as stem cell factor, IL-7, flt-3 ligand, IL-6, IL-7,
IL-3, and thrombopoietin and immobilization of Delta ligands at various concentrations.
This method is especially attractive due to its quantitative and cell-free nature and ability
to be scaled up.  Using this method, Bernstein and colleagues have elegantly
demonstrated the dose-dependent effects of immobilized Notch ligand Delta1 on cord
blood cell derived T cell differentiation and thymus repopulation (Delaney et al., 2005;
Ohishi et al., 2002).  Higher ligand densities resulted in an increased CD34-CD7+
differentiation efficiency and interestingly enough lower SCID reconstitution ability
(Delaney et al., 2005).  Thy1+CD25+ expression from lin-sca-1+c-kit+ murine bone
marrow hematopoitic precursors was also shown upon exposure to increasing amounts of
DLL1 with higher densities inhibiting the development of B cells (Dallas et al., 2005).
One disadvantage of the method, however, remains the expense associated with
supplementary cytokines.  One alternative to exogenous cytokines is a supportive cell
line that in turn secretes relevant cytokines.  Use of cytokine secreting stromal cell lines
has in fact been extensively utilized in lymphoid differentiation (Cho et al., 1999;
Gutierrez-Ramos and Palacios 1992; Jaleco et al., 2001; Landreth and Dorschkind 1988;
Nakano et al., 1996).  Cell lines such as RP.0.10, S17, and OP9 generate and secrete
lymphoid cytokines such as IL-7 and SCF (for OP9 for example) that aid in proliferation
and survival (Cho et al., 1999; Gutierrez-Ramos and Palacios 1992; Jaleco et al., 2001;
Landreth and Dorschkind 1988; Nakano et al., 1996).  Furthermore, OP9 cells, derived
from the OP/OP mice, fail to produce macrophage colony-stimulating factor, a factor
known to drive myeloid differentiation, thus further aiding in lymphopoiesis (Zuniga-
Pflucker 2004).  Despite the success in generating hematopoietic cell lineages including
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B cells, erythrocytes, and NK cells, the generation of T cells using these stromal cell lines
was unsuccessful (Zuniga-Pflucker 2004).
2.5.3 Current method: OP9-DL1 cell line and spinoffs
As indicated above, Notch signaling is both omnipresent and indispensable in T
cell development.  DLL1, for example, is particularly distributed in high densities in the
thymic cortex and cortical-medullary junction (Ciofani and Zuniga Pflucker, 2007).
These findings led to one of the greatest tools in T cell differentiation research today: the
creation of a DLL1 expressing OP9 cell line (de Pooter and Zuniga-Pflucker 2007; Lehar
and Bevan 2002; Pear 2005; Rolink et al., 2006; Zuniga-Pflucker 2004).  The emergence
of a Notch expressing cell line pushed the T cell differentiation field forward with a flood
of seminal studies following. The in vitro system is based on the OP9 stromal cell line
utilized for B cell differentiation (described above) but takes advantage of Notch
signaling to drive the differentiation toward the T cell lineage.
Zuniga-Pflucker and colleagues, the makers of the OP9-DL1 cell line, have
contributed significantly and continue to contribute to the field today.  Early studies with
the OP-DL1 cell line led to the induction of T cell differentiation in murine fetal liver
cells, embryonic stem cells and bone marrow derived HSCs as indicated by CD4CD8
marker expression and T cell specific gene transcripts and/or TCR rearrangements.
Functional SP CD8+ TCR"! T cells can be observed using the in vitro system after 22
days of culture. The resulting T cell population does not, however, include any CD4+ T
helper cells unless transported to a FTOC for the latter half of the differentiation process.
The absence of MHC II+ cells in the in vitro system is thought to be responsible (de
Pooter and Zuniga-Pflucker 2007; Schmitt et al., 2002; Schmitt et al., 2004).
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Significant developments were made in differentiation from human sources, as
well.  A 2004 study indicated the generation of DP "! T cells from a CD34+ bone
marrow source within 35 days of coculture (De Smedt et al., 2004).  La Motte-Mohs and
colleagues demonstrated the generation of pre-T CD7+CD1a+ cells and DP "! T cells
within 24 days of coculture with OP9-DL1 and CD34+CD38- human cord blood derived
HSCs (La Motte-Mohs et al., 2005).    More recently, Zhao et al generated p53 or ESO
tumor antigen specific T cells, the holy grail of T cell research, using the OP9-DL1
coculture system.  Human cord blood derived CD133+/CD34+ cells were transfected
with TCR expressing vectors with reactivity against tumor antigens p53 or NY-ESO-1.
GMCSF and IL-2 secretion was observed upon T cell incubation with peptide-pulsed
antigen presenting cells (Zhao et al., 2007).  Also, Lefort and colleagues demonstrated
that a short 4 day exposure to immobilized DLL4 ligand was sufficient enough to induce
CD7+cytCD3%+ phenotype, relevant T cell transcription factors and TCR rearrangements
in CD34+ cord blood cells.  Further incubation with DLL4 expressing OP9 cell line or
FTOC culture initiated DP status in developing T cell progenitors (Lefort et al., 2006).
The introduction of Notch ligands into supportive cell lines such as OP9 has
stimulated similar approaches of Notch signaling and stroma for T cell development.
Hozumi and colleagues first demonstrated the importance of intracellular Notch1 coupled
with OP9 and IL-7 to T lymphopoiesis in their 2003 study where intracellular Notch 1, 2
or 3 were transfected into hematopoietic progenitors.  Results indicated DP Thy1.2+ cells
for all three Notch receptors (Hozumi et al., 2003).  One year later, the same group
demonstrated the differentiation of cKit+ fetal liver cells into Thy1.2+ T cell progenitors
with TCR arrangements upon incubation with OP9-DLL4 stromal cells (Hozumi et al.,
2004).   Lehar and colleagues used OP9 transfected Jagged 1 and OP9 transfected Delta 1
cell lines to demonstrate the importance of Delta 1 and not Jagged 1 in the induction of
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maturation and expansion of T cell precursors (Lehar and Bevan 2005).  Finally Jaleco et
al successfully generated DP T cells using DL1 transfected S17 stromal cell line (Jaleco
et al., 2001).
2.5.4 Limitations of OP9-DL1 system
The OP9-DL1 based system of T cell differentiation has eliminated the
inconvenience associated with FTOCs and stroma based systems, the previous standard
in in vitro T cell differentiation. The far-reaching impact of the OP9-DL1 system lies in
its ease, efficiency, reproducibility and ability to be manipulated (Zuniga-Pflucker 2004).
However, some drawbacks inherent in this system have prevented the generation of
functional CD4 cells and reduced the efficiency of the system for the eventual high
throughput generation of T cells.  First, the generation of functional CD4 SP cells has yet
to be demonstrated using Notch based systems.  OP9 cells fail to express the MHC II
molecule and provide the microenvironment necessary for selection, both of which are
necessary for CD4 T cell differentiation (de Pooter and Zuniga-Pflucker 2007; Zuniga-
Pflucker 2004).  Another fundamental limitation is the dependence of OP9 based systems
on transfected cells for Notch signaling.  The transfection of stroma cells for different
Notch ligands can become cumbersome and interfere with normal genetic expression of
the OP9 cell (Lehar and Bevan 2005).  In addition, the inherent design of the current
coculture system makes large-scale T cell generation difficult, specifically for 3D studies
in biomimetic environments.  Also, a systematic quantification of ligand amount is
difficult in OP9 based studies due to cell dependent ligand presentation.
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2.5.5 Motivation for DLL4 based T cell differentiation
The high density of the Notch ligand in the thymic microenvironment, the gain-
of-function studies, and in vitro studies demonstrating successful T cell specification
upon DLL4 exposure all indicate the significance of the ligand in thymocyte
development.  Despite the insightful studies provided by Hozumi et al and Lefort et al,
studies utilizing Notch ligand DLL4 in ex vivo T cell development have been limited
(Hozumi et al., 2004; Lefort et al., 2006).  Further studies elucidating the quantitative and
temporal effects of Notch ligand DLL4 would provide immense insight into the density
dependence of Notch signaling in lymphopoiesis, specifically the T cell commitment and
maturation as implicated in recent papers by Dallas et al, Ciofani et al and Lehar et al
(Ciofani et al., 2005; Dallas et al., 2005; Lehar and Bevan 2005).  These studies would
also help understand the separate roles, if any, of the Notch ligands DLL1 and DLL4 in T
cell development.
2.6 BEADS IN CELL STUDIES
2.6.1 Overview of beads
Magnetic antibody-coated beads have been widely used for immunoseparation
applications for almost 20 years (Egeland et al., 1991; Swann et al., 1992).  More
recently, however, magnetic beads are being applied to a more diverse set of cell based
problems, due to their obvious separation applications, commercial availability, ability to
study cellular processes on a micro scale, and ability to be molecularly defined and
optimized.  Two studies, for example, have exploited the magnetic nature of the beads to
characterize the localization and trafficking of EGF based signals and vesicles with the
use of electron microscopy, respectively (Friedlander et al., 2005; Li et al., 2005).
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Glycine receptor diffusion has also been tracked microscopically using 0.5-µm beads,
though not magnetic, coated with anti-myc antibodies (Craig and Lichtman 2001).
Another study by Fass and Odde studied force dependent elongation and retraction in
embryonic chick forebrain neurons using anti-!1 integrin antibody coated magnetic beads
(Fass and Odde 2003).  The most extensive use of bead, magnetic or not, however, has
been in T cell activation and proliferation (Ito et al., 2003; June 2007; Kim et al., 2004;
Maus et al., 2002; Maus et al., 2003; Trickett et al., 2002).  In these studies, beads are
decorated with T cell relevant costimulatory molecules for the expansion of patient
derived T cell populations and the generation of antigen specific CD4 and CD8
populations.  Levine and colleagues first demonstrated up to 109 – 1011 fold expansion in
CD4+ T cells with antiCD3 and antiCD28 antibody coated 4.5µm magnetic Dynalbeads
for a more than 30 day culture (Levine et al., 1997).  Trickett et al further characterized
magnetic Dynalbeads for CD4+ expansion and cytokine production, albeit with a
different type of magnetic bead, examining culture conditions such as presence of serum,
number of beads and stable vs. dynamic culture (Trickett et al., 2002).  In another study,
indirect and direct conjugation schemes of HLA tetramer to magnetic beads were
evalulated based on amount of HLA monomer/tetramer loading and ability to activate
CD4+ T cells.  Beads using an indirect binding scheme where the tetramer was not
directly bound to the bead produced the optimal results.  Maus and colleagues’ anti-CD3
and antiCD28 beads are in fact in clinical trials for adoptive immunotherapy applications,
perhaps the greatest indicator of how much progress has been made with such beads
(Maus et al., 2003).
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2.6.2 Motivation for beads as a method for protein presentation
Historically, there have been several methods of displaying proteins on surfaces
such as liposomes and immobilization onto polystyrene (Engelhard et al., 1978; Kane et
al., 1989).  Often times, proteins cannot be recognized by its associated receptor in the
soluble form, especially when such proteins are normally presented on the surface of a
cell, thus necessitating such methods of protein immobilization.  For example, soluble
monomeric or dimeric Delta-1 fusion ligands failed to activate Notch receptors in C2C12
and U20S cells as indicated by differentiation and HES1 transactivation studies,
respectively (Varnum-Finney et al., 2000).
Beads offer several benefits in protein display.  For applications such as ours,
where scaling up the production of T cells is a goal, such bead systems are ideal.  The
ability to define and optimize a system reproducibly in a more cost-effective manner, free
of safety concerns presented in cell systems, makes the bead approach an attractive
option.  Beads may in fact be more ideal than methods such as plate immobilized protein
due to the ability to reach several cell layers and provide greater surface area.  In a study
by Ito and colleagues, bead conjugated antibodies resulted in higher levels of T ell
activation as compared to plate immobilized antibodies (Ito et al., 2003).
25
Table 2.1 Table of Summary of T Cell Related Immunodeficiencies
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Figure 2.1     T cell development in the thymic microenvironment.  Notch signals, IL-7,
SCF, chemokine gradients and preTCR signals all drive the development of
DN population to a DP developing thymocyte.  In the medulla, DP cells
undergo negative selection through interactions with dendritic and
medullary epithelial cells and emigrate out of the thymus near the cortical
medullary junction.  Thymocytes undergo death by neglect and apoptosis at
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Development and Characterization of Notch Ligand Coated Microbeads
3.1 INTRODUCTION
Current efforts in ex vivo T cell differentiation have eliminated the inconvenience
associated with fetal thymic organ cultures (FTOCs) and stroma based systems, the
previous standard in vitro T cell differentiation (Han et al., 2000; Kennedy et al., 2003;
Parreira et al., 2003; Plum et al., 1994; Poznansky et al., 2000; Res et al., 1996; Weekx et
al., 2000; Yeoman et al., 1993; Zuniga-Pflucker and Schmitt 2005).  These studies have
reported a need for Notch signaling in T cell differentiation, leading to novel ways of
introducing Notch ligands into in vitro culture.  Efforts have relied largely on Notch
ligand transfected stroma to provide signals critical to T cell development and have
successfully demonstrated effective T cell progenitor generation (Hozumi et al., 2003;
Hozumi et al., 2004; La Motte-Mohs et al., 2005; Lehar et al., 2002; Schmitt et al., 2002;
Schmitt et al., 2004; Zhao et al., 2007).  The transfection of stroma cells for different
Notch ligands, however, can become cumbersome and interfere with normal genetic
expression of the OP9 stromal cell (Lehar et al., 2005).  Recent studies have also utilized
plate adsorbed Notch ligand, supplying the signal in a quantitative and cell-free manner
(Beckstead et al., 2006; Dallas et al., 2005; Delaney et al., 2005; Lefort et al., 2006;
Ohishi et al., 2002).  This method presents significant benefits for scaling up ex vivo T
cell generation for possible therapeutic applications.  Nevertheless, plate adsorption for
ligand presentation can become expensive and unstable with extended cell culture (due to
extracellular matrix secretion from cells).
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T cell activation and cell separation applications have frequently utilized
functionalized microbeads for cell targeting and providing specific signals to these cell
targets (Connors et al., 2005; Curtsinger et al., 1997; Ito et al., 2003; Levine et al., 1997;
Maus et al., 2002; Maus et al., 2003; Patel et al., 1995; Pilling et al., 1989; Sarda et al.,
2004; Trickett et al., 2002).  Microbeads offer several benefits in applications such as
these, including ease in handling and fabrication, low cost, amenable to scaling up and
effective protein (antibody or ligand) presentation (Curtsinger et al., 1997; Maus et al.,
2003).  For example, to activate and expand CD4+ T cells for clinical applications,
protocols require immobilized anti-CD3 and anti-CD28 antibodies to effectively
recognize and bind to their respective antigens upon the T lymphocytes (Levine et al.,
1996).  Studies have functionalized these antibodies onto microbeads and demonstrated
up to 1011-fold expansion of CD4+ T cells upon incubation with microbeads in the
absence of supportive feeder layers (Levine et al., 1997; Maus et al., 2002; Trickett et al.,
2002).  A recent study has additionally demonstrated increased proliferation and tumor-
specific cytokine secretion with CD4+ cells when comparing bead-activated and plate-
activated cells (Ito et al., 2003).  The increased surface area may additionally improve the
efficacy of such an artificial cell construct.  Long-term stability of functionalized beads
has also been shown up to 60 days in long-term T cell proliferation studies (Levine et al.,
1997).
In this study, we report a synthetic Notch signaling system using ligand-
functionalized magnetic microbeads (artificial stromal cells) that can ultimately be used
to evaluate how Notch ligands, specifically DLL4, presented through a biomaterial
surface affect T cell differentiation and to eventually develop a high throughput strategy
to engineer T cells from hematopoietic progenitor populations.  We functionalized
streptavidin-coated microbeads with DLL4 using biotin-streptavidin chemistry and
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antigen-antibody coupling and demonstrated their functionality using flow cytometry and
confocal microscopy.  Further, we optimized the functionalization process in terms of key
parameters such as protein and bead concentration and incubation time.  Additional
stability studies were also carried out where effect of buffer and serum on bead
functionalization over time were evaluated.  Poor results in stability testing prompted us
to switch to another bead type, which was in turn characterized in terms of protein
concentration effects, stability testing and visualization through microscopy.
(Differences in characterization results between the two beads stemmed from the
presence of a DNA linker on the first type of bead.)  Finally, we demonstrated low
cellular toxicity with beads using MTT viability test for C2C12 myoblasts and R1
embryonic stem cells.
These results demonstrate a robust, non-toxic functionalized bead system that can
be used for signaling studies in a variety of biological applications.  Such a bead-based
artificial signaling system could allow us to quantitatively study the effects of ligand
density and signaling duration thereby providing further insights into the individual roles
of the Notch ligands in T cell differentiation and ultimately aid in the development of
efficient technologies for the production of T cells for therapeutic applications.
3.2 MATERIALS AND METHODS
3.2.1 Biotinylated polyhistidine antibody functionalization and optimization
Biotinylated antibodies specific for a histidine tag on recombinant DLL4 were
coated onto streptavidin coated superparamagnetic polystyrene microbeads and optimized
in terms of the following conditions: quantity of antibody, incubation time and incubation
concentration.  Biotin Binder Kit microbeads (Dynalbiotech, Brown Deer, WI) were
washed with 0.1% bovine serum albumin (Sigma, St. Louis, MO) in PBS and incubated
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for 30 min at room temperature on a rotator with 10, 20, 50, 100, 200, 400, 600, 800,
1000, 1500, 2000, and 2100 ng of biotinylated anti-6x HIS tag antibody (R&D Systems,
Minneapolis, MN) per 107 beads at a concentration of 80000000 beads/ml.  After
incubation, beads were washed three times and stained as described below.  Incubation
time and concentration studies were performed using the optimized biotinylated anti-6x
HIS tag antibody concentration (100 ng/107 beads) for 30 min, 60 min, and 90 min and
with concentrations of 80000000 beads/ml, 800000 beads/ml, and 8000 beads/ml.  Beads
were then washed and stained as described below.
3.2.2 DLL4 functionalization and optimization
Recombinant DLL4 (R&D Systems, Minneapolis, MN) was functionalized onto
anti-6x HIS tag antibody coated microbeads as described above and was first stained to
verify effective DLL4 functionalization.  In these preliminary studies, Biotin Binder Kit
microbeads (Dynalbiotech, Brown Deer, WI) were washed and incubated with anti-6x
HIS tag antibody (R&D Systems, Minneapolis, MN) at 1 µg/ml for 30 min at room
temperature.  After incubation, beads were again washed and further incubated with the
HIS-tagged DLL4 protein (R&D Systems, Minneapolis, MN) at 2-4 µg/ml for 30 min at
room temperature.  Beads were washed and stained as described below.  Both uncoated
and anti-6x HIS tag antibody beads served as controls.  Optimization studies were then
performed which included the following conditions: quantity of DLL4, incubation time
and incubation concentration.  DLL4 binds to the anti-6x HIS tag antibody beads through
its histidine tag at the carboxy-terminus.  Biotin Binder Kit microbeads were first washed
and coated with 100 ng of biotinylated anti-6x HIS tag antibody/107 beads for 30 min at a
concentration of 80000000 beads/ml.  After adequate washing, microbeads were then
incubated for 30 min at room temperature on a rotor with 10, 20, 50, 100, 200, 500, 1000,
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and 2000 ng of DLL4 per 107 beads at a concentration of 80000000 beads/ml.  After
incubation, beads were washed three times and stained as described below.  Incubation
time and concentration studies were performed using the optimized DLL4 concentration
(1000 ng/107 beads) for 30 min, 60 min, and 90 min and with concentrations of 80000000
beads/ml, 800000 beads/ml, and 8000 beads/ml.  Beads were then washed and stained as
described below.  Additionally, DLL4 characterization studies were conducted for
streptavidin-coated magnetic microbeads without DNA linkers.  Proactive® streptavidin
coated magnetic beads (Bangs Labs, Fishers, IN) that were 5.91 µm in diameter were
coated with biotinylated anti-6x HIS antibody based on manufacturer’s recommended
protocol.  Beads are provided with a lot specific biotin-FITC saturation capacity that was
converted based on molecular weight to a saturation capacity for biotinylated anti-6x HIS
antibody.  For DLL4 titration studies, DLL4 concentrations of 20, 40, 100, 200, 400, 600,
1000, 2000, and 4000 ng of DLL4 per million beads were coated onto biotinylated anti-
6x HIS antibody coated beads as per manufacturer’s instructions.  Beads were washed
and stained as described below.
3.2.3 Bead stability testing
To test the integrity of the DLL4 coating on the microbead surface, functionalized
microbeads were incubated for up to a week at 4ºC in 0.1% BSA in PBS at a
concentration of 400000000 beads/ml and stained for DLL4 at the time of fabrication and
6 days afterward in the manner described below.  Additional studies were performed to
characterize the integrity of the functionalized microbeads in various buffers.
Functionalized microbeads were added to 48 well plates and cultured for 1 h at both 4ºC
and 37ºC (in a humidified incubator supplemented with 5% CO2) in 0.1% BSA in PBS,
serum-free C2C12 differentiation medium and serum supplemented C2C12 medium.
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Several signaling and differentiation studies are performed with C2C12 myoblasts and
thus the media listed are used frequently.  Serum-free medium was prepared as described
in studies by Chan et al (Chan, X. C. Y. et al., 2007).  Medium consisted of 1:1 ratio of
Dulbecco’s modified eagle medium and F12 nutrient mixture (Invitrogen, Carlsbad, CA),
1mM sodium pyruvate (Invitrogen, Carlsbad, CA), 2.5 µg/ml bovine insulin (Sigma-
Aldrich, St. Louis, MO), and antibiotics.  Serum supplemented medium consisted of
Dulbecco’s modified eagle medium, 10% fetal bovine serum (Hyclone, Logan, UT) and
antibiotics.  DLL4 staining (as described below) was performed for all conditions after
incubations.  Anti-6x HIS antibody functionalized beads were used as controls.  Beads
were stained with 100ng anti-6x HIS antibody per 10 million beads and 1000 ng DLL4
per 10 million beads.  Proactive® streptavidin coated magnetic beads were also tested for
integrity of DLL4 coating.  Beads were stained with calculated anti-6x HIS antibody
concentration described above and 700 ng of DLL4 per million beads and incubated for 1
hr, 1 day and 1 week timepoints in PBS at 4ºC and 37ºC and C2 serum supplemented and
serum-free media with anti-6x HIS antibody coated beads as negative controls.  Staining
was performed for all conditions after incubations.
3.2.4 Immunofluorescence and flow cytometry analysis
Conjugation of protein immobilization onto both Dynalbiotech and Bangs Labs
microbeads was confirmed by visualization through fluorescently labeled antibody
staining for relevant protein and flow cytometry analysis.  Following anti-6x HIS tag
antibody and DLL4 binding, microbeads were blocked for !2 hr at 4ºC with 3% bovine
serum albumin (Sigma-Aldrich, St. Louis, MO) in PBS.  Microbeads were then stained
with streptavidin-PE (BDBiosciences, San Jose, CA) at 0.25 µg per 106 beads in 1%
bovine serum albumin in PBS with 0.05% sodium azide (Sigma-Aldrich, St. Louis, MO)
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for 30 min at 4ºC while rotating to detect antibody immobilization.  After staining, beads
were washed three times, resuspended in 250 µl of staining buffer and analyzed using
FACSCalibur (Becton Dickinson, San Diego, CA) and CellQuest 3.1 software (BD
Biosciences, San Jose, CA).  Uncoated microbeads served as controls for antibody
staining while anti-6x HIS tag antibody beads served as controls for DLL4 staining.
Fluorescence from microbeads was subtracted from samples to adjust for background.
Staining for antibody optimization studies was also performed using FITC conjugated
goat anti-mouse IgG (Calbiochem, San Diego, CA) at the concentration for streptavidin-
PE given above.  Results were similar to streptavidin-PE results shown below (data not
shown).  For DLL4 binding, blocked microbeads were stained with anti-mouse DLL4
antibody (R&D Systems, Minneapolis, MN) at 2 µg per 106 beads in 1% bovine serum
albumin in PBS with 0.05% sodium azide (Sigma-Aldrich, St. Louis, MO) for 30 min at
4ºC while rotating.  Beads were then washed three times and stained for an additional 30
minutes at 4ºC with 0.25 µg of FITC anti-rat IgG (eBiosciences, San Diego, CA) per 106
beads while rotating.  After incubation, beads were washed, resuspended and analyzed as
described above.  Immobilized DLL4 molecules on bead surfaces were quantified using
the anti-rat IgG Quantum Simply Cellular Kit (Bangs labs, Fishers, IN) beads.  Anti-rat
IgG Quantum Simply Cellular (QSC) Kit beads consist of 5 bead types with increasing
amounts of known goat ant-rat IgG on their surfaces, from which a linear curve can be
produced and mean fluorescence can be converted to molecules of equivalent soluble
fluorochrome (MESF) from the measuring bead population assessed.  QSC beads were
stained similarly to the DLL4 immobilized beads.
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3.2.5 Confocal microscopy
Functionalized microbeads were also examined using confocal microscopy to
ensure intact DLL4 coating around the entire surface using a similar staining scheme as
described above.  Instead of the FITC anti-rat IgG, APC anti-rat IgG (Invitrogen,
Carlsbad, CA) was used at the concentration given above.  Beads were washed with
ddH2O three times after staining to prevent crystal formations and resuspended in 100 µl
of ddH2O.  Bead-water suspensions were added to glass slides and dried over night in the
dark.  Beads were then mounted with immersion oil (Sigma Aldrich, St. Louis, MO),
covered with coverslips, sealed with clear nail polish and imaged using a Leica SP2
AOBS Confocal Microscope (Leica Microsystems, Bannockburn, IL).  Anti-6x HIS
antibody-coated beads were used as controls.  Samples were imaged using reflected light,
transmitted light and fluorescence with an excitation of 633 nm with a He-Ne laser.
Similar procedure was performed for Proactive® streptavidin coated magnetic beads with
FITC anti-rat IgG staining.
3.2.6 Quantification of DLL4 conjugation using ELISA
The amount of DLL4 adsorbed onto the Biotin Binder Kit microbeads was
quantified using an ELISA assay.  Briefly, beads were coated as described above.
Washes (in 0.1% w/v bovine serum albumin in PBS) from the bead conjugation process
were stored at -20°C for ELISA analysis.  Standard wells of 96 well EIA/RIA ELISA
plates (Corning, Corning, NY) were incubated with the wash samples and standards over
night at 4°C.  Plates were then washed 4x with 0.5% (v/v) Tween 20 in PBS (PBT) and
blocked with 1% (w/v) bovine serum albumin in PBS for 1.5 h at 37°C.  After blocking,
plates were washed 4x with PBT and incubated for 1.5 h with rat anti-mouse DLL4
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IgG2a (R&D systems, Minneapolis, MN) at a concentration of 1 µg/ml at room
temperature followed by extensive washing.  Finally, HRP conjugated goat anti-rat IgG
(1:5000, eBioscience, San Diego, CA) was added to the wells.  After 1.5 h incubation,
wells were washed with PBST and developed using tetramethylbenzidin (TMB, R&D
systems, Minneapolis, MN). Absorbance values were read at 450 nm using the Opsys
MR Microplate reader (Dynex. Technologies Inc., Chantilly, VA) and Revelation
QuickLink software (Thermo Labsystems, Chantilly, VA).  All samples and standards
were analyzed in triplicate.  Amount of DLL4 conjugated to microbeads were obtained
by subtracting the measured amount of DLL4 in the washes from the original amount of
DLL4 added to the beads.
3.2.7 MTT assay
To assess the cytotoxicity effects of the Biotin Binder Kit magnetic beads with or
without functionalized DLL4, a MTT assay was performed.  R1 or C2C12 cells were
cultured with both functionalized and uncoated Biotin Binder Kit beads for 3 days, 5 days
and 7 days at bead to cell ratios of 0.1:1, 1:1 and 5:1. Briefly, undifferentiated R1
embryonic stem cells (a gift from A. Nagy, Mount Sinai Hospital, Ontario, Canada) were
expanded on LIF (leukemia inhibiting factor)-producing irradiation-inactivated
embryonic fibroblast cells (STO cells, Shan Maika, UT Austin) for 10 days.  R1
embryonic stem cells were seeded at 10000 cells/well in complete DMEM medium
(Invitrogen, Carlsbad, CA) containing 20% fetal bovine serum (Hyclone, Logan, UT), 2
mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM non- essential amino acids, 5 x 10-5 M
2-mercaptoethanol, penicillin G (100 U/mL), and streptomycin (10 µg/mL) (all from
Invitrogen, Carlsbad, CA) while C2C12 myoblasts were seeded at 20000 cells/well in 96
well plates one day prior to bead addition in C2C12 maintenance medium, consisting of
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DMEM (Invitrogen, Carlsbad, CA), 10% characterized fetal bovine serum (Hyclone,
Logan, UT) and antibiotics. Cells were counted using a hemocytometer the day of bead
addition to confirm accurate cell number for bead to cell ratios.  Additional studies used
uncoated beads only at bead to cell ratios of 0.1:1, 1:1, 10:1, 20:1 and 40:1 with the
timepoints given above.  For each timepoint, plates were removed from incubator and
medium was aspirated.  Fresh medium (100 µl) along with 10 µl of 5 mg/ml MTT
(Sigma Aldrich, St. Louis, MO) in Hank’s Balanced Salt Solution (Invitrogen, Carlsbad,
CA) was added to each well.  A medium only condition was included as background.
Plates were incubated at 5% CO2 in 37°C for 4 hours.  After incubation, 100 µl of MTT
solubilization solution (10% Triton X-100, 0.1 N HCl in anhydrous isopropanol) was
added and pipetted several times to dissolve purple formazan crystals.  The supernatant
was removed from each well and centrifuged at 300 g for 5 minutes.  Without disturbing
the pellet, 100 µl of each sample were added to new 96 well plates and read at a
wavelength of 570 nm using the plate reader.  All values were exported and analyzed in
Microsoft EXCEL.  Medium only absorbance values were subtracted from all samples.
Cells without beads were used as 100% viability and samples were converted to
percentages and plotted.  DLL4 functionalized beads were coated with 1 µg/ml of anti-6x
HIS tag antibody and 1 µg/ml of DLL4 with optimized incubation volumes and times.
3.2.8 Statistical analysis
All experiments were performed in at least an n=3.  Standard error was calculated.
Analysis of statistical significance was performed using a one tailed Student’s t-test.
Significance was determined using a 95% probability value (p<0.05).  All experiments
were repeated twice.  Representative data is shown.
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3.3 RESULTS
In past studies, Notch ligands such as DLL1 and DLL4 have been presented as
retrovirally transfected cell-surface ligands in lymphoid differentiation applications,
making ligand quantification and scale-up difficult.  To address this quantitative hurdle
and to develop a biomaterial-based artificial Notch-signaling system, our eventual goal is
to evaluate whether the Notch ligand DLL4, immobilized on the surface of magnetic
microbeads can function in T cell differentiation similar to when presented on the surface
of stromal cells. Here, DLL4 was attached to super paramagnetic microspheres using
conventional biotin-streptavidin chemistry and antibody-antigen binding.  Our goal in the
functionalization process was to (a) present the ligand in an efficient manner and (b)
preserve the conformational structure of the ligand during the process.  We evaluated this
design for microspheres with and without a DNA linker (with the DNA linker providing
separation capacity).  Figure 3.1 shows the schematic structure of the DLL4
functionalized microbeads (a) with a DNA linker (b) without a DNA linker.
3.3.1 Optimal conditions for biotinylated polyhistidine antibody functionalization to
microbeads
Biotin Binder Kit microbeads are 4.5 µm streptavidin coated superparamagnetic
polystyrene beads that are readily used for cell-bead separation applications.  The
streptavidin coating is coupled to the polystyrene bead via a DNA linker that can be
cleaved upon DNase addition.  Due to the size, cost, convenience and ability to target and
separate distinct cell populations, the microbeads were selected for cell-bead signaling
studies.
The Notch functionalized microbead system exploits the biotin-streptavidin and
antigen-antibody binding to present the Notch ligand in a highly directional fashion.
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Streptavidin on the surface of the microbeads binds to a biotinylated mouse antibody
raised against a histidine tag.  Next, recombinant DLL4 that is histidine tagged binds to
the antibody such that the activity of the DLL4 is not affected.  To ensure consistent and
effective DLL4 signaling, it is important to saturate the surface of the beads with the
biotinylated antibody such that the concentration of DLL4 can be titrated to achieve the
desired effect and study the effect of concentration.  Although the beads were purchased
from a commercial vendor with recommended bead-protein binding conditions,
optimization was necessary due to the unique application and complex protein binding
design (consisting of antibody and protein binding onto bead) entailed.
First, increasing amounts of biotinylated anti-6x HIS antibody including 10, 20,
50, 100, 200, 400, 600, 800, 1000, 1500, 2000, and 2100 ng per 107 beads at a
concentration of 80000000 beads/ml were incubated with microbeads, stained with
streptavidin-PE and analyzed for mean fluorescence intensities (MFI) using flow
cytometry analysis.  In preliminary experiments, concentrations ranging from 100 to
2100 ng per 107 beads were being used due to company recommended concentrations of
0.2 – 2 µg per 107 beads.  When very little differences in fluorescence and lack of
saturation in MFI were observed repeatedly, as shown in Figure  3.2, lower
concentrations of protein per beads were then utilized.  An optimum MFI was
consistently found at a concentration of 100 ng per 107 beads with a homogeneous
distribution of antibodies on beads (as indicated by the narrow peak), as shown in Figure
3.3, and was used for all subsequent bead studies.  Statistical significance was found for
100 ng per 107 beads concentration after performing the Student’s t test for all
concentrations (p<0.05).
Bead concentration and incubation time were then varied and examined for
optimal antibody immobilization onto bead.  Bead concentrations of 80000000 beads/ml,
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800000 beads/ml, and 8000 beads/ml were incubated with 100 ng of antibody per 107
beads for 30 min, 60 min, and 90 min, stained and analyzed for flow cytometry analysis.
Figure 3.4 indicates optimum MFI for bead concentration of 80000000 beads/ml with no
statistical significance observed when comparing increased incubation times.  However,
increases in MFI were apparent for lower concentrations with time although statistically
significant differences were only observed for 800000 beads/ml concentration between
30 min and 60 min (p<0.05) and 8000 beads/ml concentration between 30 min and 90
min (p<0.05) conditions using a Student’s t test.  As expected, more dilute bead
concentrations resulted in lower MFIs for equivalent incubation times with 80000000
beads/ml found to be statistically significant for all three incubation times (p<0.05).
Unless otherwise noted, all subsequent studies used an anti-6x HIS antibody coating of
100 ng per 107 beads for 30 min at 80000000 beads/ml.
3.3.2 Optimal conditions for DLL4 functionalization to microbeads
To assess the efficiency of the ligand functionalization process, we performed
preliminary studies using immunofluorescent staining and flow cytometry analysis.
DLL4 functionalized beads were stained with anti-DLL4 antibody and a FITC anti-rat
IgG for ligand detection.  Streptavidin coated beads were used as controls.  As shown in
Figure 3.5, 65% ± 6.53% of the beads were functionalized with DLL4 while uncoated
control and biotinylated anti-6X HIS antibody coated beads showed 11.5% ± 0.57% and
8.67% ± 1.43% staining most likely due to nonspecific binding.
Functionalized beads were also stained and imaged through confocal microscopy
to ensure the DLL4 ligand was immobilized around the entire surface of the bead.
Functionalized beads were stained with rat anti-DLL4 antibody and an APC conjugated
goat anti-rat antibody, air-dried and mounted for confocal microscopy.  Beads were
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imaged using transmission, reflection and fluorescent light at an excitation wavelength of
633 nm.  As shown in Figure 3.6F and 3.6H, there seems to be a clear DLL4 coating
(indicated by the yellow arrows) on the surface of the functionalized beads and not the
anti-6x HIS antibody coated beads (shown in Figure 3.6B and 3.6D), despite the high
autofluorescence.  Photobleaching effects were most likely responsible for the inability to
visualize DLL4 around the entire circumference.  Confocal reflection microscopy also
revealed the dispersed nature of the magnetic particles throughout the beads as seen in
Figure 3.6A and 3.6E.  Functionalized beads without the DNA linker (Bangs Labs) were
also assessed for the integrity of DLL4 surface coating.  These beads were stained with
rat anti-DLL4 antibody and a FITC conjugated anti-rat antibody, air-dried and mounted
for confocal microscopy, similar to the Biotin Binder Kit beads.  Beads were imaged
using transmission, reflection and fluorescent light at an excitation wavelength of 633
nm.  Figure 3.7F and 3.7H show an intact coating of the complete surface on
functionalized beads and the absence of one on anti-6x HIS antibody coated beads
(shown in Figure 3.7B and 3.7D).  Reflection microscopy shows a similar distribution of
magnetic particles throughout these beads as well (Figure 3.7A and 3.7E).
Next, DLL4 was optimized similarly to anti-6x HIS antibody coating with the
additional quantification of immobilized DLL4 molecules on Biotin Kinder Kit bead
surfaces.  Here, increasing amounts of DLL4 were coated onto previously optimized anti-
6x HIS antibody beads and stained for flow cytometry analysis.  Amount of DLL4
included 10, 20, 50, 100, 200, 500, 1000, and 2000 ng of DLL4 per 107 beads at a
concentration of 80000000 beads/ml.  As shown in Figure 3.8A , at the 200 ng
concentration, the bead surface began to saturate.  The drop in fluorescence intensity at
500 ng concentration cannot be explained.  To ensure maximum saturation, 1000 ng of
DLL4 per 107 beads concentration was used for all future studies.  Concentrations of 200
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– 2000 ng of DLL4 per 107 beads were shown to be significantly significant when
compared to 10-100 ng of DLL4 per 107 beads concentrations (p<0.05).  Figure 3.8B is a
representative histogram for 1000 ng of DLL4 per 107 beads concentration.  When
quantified using the Quantum Simply Cellular (QSC) Kit, the average mean soluble
equivalent fluorophores (MSEF) values ranged from 5000 – 8500.   The average number
of MSEF at saturation was 6830.665 DLL4 molecules / bead ± 711.2455 (mean ± SEM)
from two independent experiments. Proactive® streptavidin coated beads were also
evaluated in terms of DLL4 titration levels.  These beads come with a company specific
saturation capacity given for biotin-FITC binding.  This value was converted for our
system using the molecular weights of biotin-FITC and biotinylated anti-6x HIS
antibody.  Next, the Proactive® beads were coated with the calculated amount of anti-6x
HIS antibody using the manufacturer’s recommendation.  For the DLL4 titration studies,
concentrations of DLL4 including 20, 40, 100, 200, 400, 600, 1000, 2000, and 4000 ng of
DLL4 per million beads were all incubated with beads.  Coated beads were then blocked
and stained for surface functionalized DLL4.  The QSC Kit also enabled the
quantification of the number of DLL4 molecules on the surface of beads.  Figure 3.9A
indicates the increase in MSEF with increasing DLL4 concentrations while Figure 3.9B
shows a representative histogram for the 2000 ng of DLL4 per million beads
concentration.  Although the surface of the beads does not seem to be saturated, in the
interest of cost, 2000 ng of DLL4 per million beads was used for all subsequent studies
unless otherwise noted.  The average number of MSEF for 2000 ng of DLL4 per million
beads was 90058.38 DLL4 molecules / bead ± 3408.598 (mean ± SEM) from two
independent experiments.  This value is significantly larger than the 6830.665 DLL4
molecules found for the Biotin Binder Kit but seems reasonable due to the difference in
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diameter (5.91 µm for Proactive® and 4.5  µm for Biotin Binder Kit) and the additional
steric hindrance that in the Biotin Binder Kit due to the presence of a DNA linker.
An indirect DLL4 quantification method was also performed using an ELISA-
based assay to quantify the amount of DLL4 on the Biotin Binder Kit beads by
subtracting the measured amount of DLL4 on the wash buffers from the original amount
of DLL4 added to the beads. The results indicated that approximately 130 ng of DLL4
was conjugated on 106 microbeads.  Converted to molecules, this gives an estimate of
~1400 molecules/bead.  This estimate is on the same scale as the direct estimate given
above but is most likely underestimated due to the indirect nature of the assay and loss of
protein that may have occurred due to inadequate washing.
Bead concentration and incubation time optimization studies resulted in similar
optimized conditions found for the anti-6x HIS antibody coating.  Bead concentrations of
80000000 beads/ml, 800000 beads/ml, and 8000 beads/ml were incubated with 1000 ng
of DLL4 per 107 beads for 30 min, 60 min, and 90 min, stained and analyzed for flow
cytometry analysis.  Figure 3.10 indicates a clear reduction in functionalization with
decreased concentration and increased incubation time.  A statistically significant
difference was found when comparing lower concentrations for each incubation time for
all concentrations except for the 80000000 beads/ml compared to 800000 beads/ml at 90
min.  Although a statistically significant difference was only found for 800000 beads/ml
concentration between 30 min and 60 min conditions (p<0.05) and 8000 beads/ml
concentration between both 30 min and 60 min and 30 min and 90 min (p<0.05) using a
Student’s t test, the obvious trend appeared to be increased incubation time resulting in
decreased coating efficiency. In the interest of cost and to make sure all sites were in fact
saturated, beads were coated with 1000 ng of DLL4 per 107 beads for 30 min at
concentrations of 80000000 beads/ml subsequently, unless otherwise noted.
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3.3.3 Bead stability is compromised with the presence of DNA linker
After bead characterization and optimization, we wished to characterize the
stability of the DLL4 ligand on the surface of the bead in its native storage buffer (0.1%
BSA in PBS for Biotin Binder Kit and PBS for Proactive® beads) and medium.  Initially,
we hypothesized that serum may advantageously affect the bead stability.  As a result, we
tested serum-supplemented and serum-free media.  First, immunofluorescence and flow
cytometry analysis was used to assess the stability of the Biotin Binder Kit beads in their
native storage conditions, 0.1% BSA in PBS at 4°C after 1 day and 6 days of storage
(beads were coated with 100 ng of anti-6x HIS antibody and 1000 ng of DLL4 per 10
million beads).  For the simplicity’s sake, these experiments did not utilize the QSC kit,
only differences in mean fluorescence intensity.  Preliminary studies indicated a 70%
reduction in amount of immobilized DLL4 on surface of beads, which implied an
unstable bond, as shown in Figure 3.11.  Further studies, albeit preliminary in nature,
were then carried out where the effect of serum, buffer and medium were evaluated both
at 4°C and 37°C after one hour of incubation.  These studies revealed little DLL4
functionalized on surface of beads even at native conditions (0.1% BSA in PBS, 4°C), as
shown in Figure 3.12.  Nevertheless, except for the 0.1% BSA in PBS at 37°C and
serum-supplemented medium at 4°C, no DLL4 can be detected on the surface of the
beads after the incubation.  Although no conclusive statement can be made due to the
preliminary nature of the study, it appears that the DLL4 ligand is not effectively bound
and that the PBS based buffer may be the most ideal for the preservation of the ligand on
the bead.  Also, it appears that the increased temperature interferes with the stability of
the ligand, namely one of the bonds that is involved in the ligand functionalization.
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Ligand stability was far superior for Proactive® beads.  Immunofluorescence and
flow cytometry analysis were again used to assess the stability of the beads, this time
after 1 hr, 1 day and 1 week of incubation in PBS (both at 4°C and 37°C, serum-free
medium and serum-supplemented medium (at 37°C only).  Beads were coated with a
predefined amount of anti-6x HIS antibody and 700 ng of DLL4 per million beads prior
to incubation.  Anti-6x HIS antibody beads were used as negative controls.  As shown in
Figure 3.13, even after 1 week of incubation in PBS, serum-free medium or serum-
supplemented medium, functionalized beads retained a sizable percentage of DLL4 on
the surface.  The decreases in DLL4 amounts compared to the suggested storage
conditions (4°C PBS) and as a function of time are summarized in Tables 3.1 and 3.2,
respectively with values representing amount left on surface.  In terms of best buffers for
storage, 4°C PBS appears to be the best, although after 1 week of incubation there seems
to be little difference between temperatures for the PBS buffer.  Serum-free medium
appeared to least preserve the original surface density of DLL4 after one week of culture.
Thus, the presence of serum did not appear to be a factor in preserving the surface
integrity.  Interestingly, there seems to be a 40-70% decrease in surface density of DLL4
after 23 hours of incubation.
3.3.4 Viability of C2C12 myoblasts and embryonic stem cells is not significantly
affected by the presence of beads
Polystyrene particles have been shown to display cytotoxic effects on white blood
cells at high concentrations (Olivier et al., 2003).  Thus, a cytotoxicity study of beads at
varying concentrations and multiple timepoints with relevant cells was performed.  The
MTT assay is a common in vitro cytotoxicity assay that utilizes mitochondrial
dehydrogenases to cleave the tetrazolium ring and produce visible crystals that can be
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dissolved and spectrophotometrically measured.  Due to its ease and accuracy, this assay
was selected for our purposes.  Since polystyrene beads were functionalized with DLL4,
it was important to show that DLL4, itself, was not toxic at high concentrations (as
compared to polystyrene beads).  In the primary experiment, C2C12 myoblasts were
incubated at bead to cell ratios of 0.1:1, 1:1 and 5:1 for 3 days, 7 days and 9 days.  As
shown in Figure 3.14 and Table 3.3, DLL4 functionalization of beads did not affect cell
viability, although a statistically significant difference was seen between the 0.1:1 bead to
cell ratio between both type of beads the 3 day timepoint.  A similar study was carried out
for R1 embryonic stem cells, where cells were incubated at bead to cell ratios of 0.1:1,
1:1 and 10:1 for 3 days, 5 days and 7 days.  A similar trend was observed, as shown in
Figure 3.15.  A statistically significant difference was again seen for the 0.1:1 bead to
cell ratio at the 3 day timepoint, as shown in Table 3.3.  Viability does not appear to be
affected in both cell types with the addition of beads, although a decrease in viability is
apparent in the C2C12 with increased bead to cell ratios for the 7 day and 9 day
timepoints.  Interestingly, the beads appear to have a proliferative effect on the cells as
evident by the >100% viability values in some conditions.
Once we established that DLL4 functionalization did not affect cell viability, we
performed additional studies with uncoated beads only (in the interest of cost) at higher
bead to cell ratios.  Figure 3.16 shows the reduced viability with increasing bead to cell
concentration for all three timepoints.  Although statistically significant differences were
observed when comparing all bead to cell ratios for the 3 day timepoint (except when
comparing 1:1 and 10:1), the maximum reduction in viability was a mere 10%, as shown
in Figure 3.16 and Table 3.4.  The later timepoints resulted in closer viability
percentages with statistically significant differences when comparing both 1:1 and 10:1 to
40:1 bead to cell ratio, as observed in Figure 3.16 and Table 3.4.  Even at a bead to cell
59
ratio of 40:1, the cell viability is nearly 100% at the week timepoint.  For R1 cells,
however, the results differed.  An increased cytotoxicity for higher concentrations was
observed for the 3 day timepoint only, as shown in Figure 3.17.  Both 5 day and 7 day
timepoints did not display such a trend for increasing bead to cell ratios (Figure 3.17).
Statistical analysis confirmed a difference when comparing 0.1 and 1:1 to 10:1 and 40:1
for both 3 days and 5 days (Table 3.5).  These results most likely reflect the high
proliferation rate of embryonic stem cells that may mask any bead toxicity effects and
would require repeat bead additions to truly assess the effect of high bead concentrations.
Nevertheless, the lowest viability observed (7 day, 10:1 bead to cell ratio) was still 80%
(Figure 3.17).  Although some reduction in cell viability was observed, these results
illustrate that the functionalized beads do not exhibit any serious cytotoxic effects for
short-term cell bead studies in myoblasts and embryonic stem cells.
3.4 DISCUSSION
Magnetic beads have been widely used for cell separation and flow cytometry
applications for many years (Egeland et al., 1991; Patel et al., 1995; Swann et al., 1992).
From the cytocompatibility and manufacturing standpoints, beads such as these are
especially attractive.  More recently, however, beads in general have been used for a
variety of applications including force measurement and application, ligand-receptor
binding studies, signal localization and vesicle trafficking and T cell expansion and
activation (Curtsinger et al., 1997; Fass et al., 2003; Friedlander et al., 2005; Ito et al.,
2003; Kim et al., 2004; Li et al., 2005; Maus et al., 2002; Patel et al., 1995).  In the area
of T cell activation and expansion, beads have been particularly successful.  For example,
Levine and colleagues demonstrated up to 1011-fold expansion in a 60-day culture of
CD4+ T cells with anti-CD3 antibody and anti-CD28 antibody coated beads (Levine et
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al., 1997).  In another study, Ito et al found anti-CD3 and anti-CD28 antibody bound
beads to be more effective than plate immobilized antibodies in promoting T cell
activation and IL-2 secretion (Ito et al., 2003).  These findings demonstrate the promise
and potential in such a bead platform for providing antibody or protein based signals to
cells.
Significant strides have been made in the field of T cell development due to the
generation of a Notch ligand DLL1 expressing stromal cell line, OP9-DL1, by Zuniga-
Pflucker and colleagues (Zuniga-Pflucker 2004).  Several studies have successfully
demonstrated T cell development to the DP stage from both murine and human cord
blood and bone marrow-derived hematopoietic progenitors using the stroma derived and
Notch signals from the OP9-DL1 cell line (Murine embryonic stem cells have also been
shown to differentiate to the T cell lineage) (De Smedt et al., 2004; La Motte-Mohs et al.,
2005; Schmitt et al., 2002, Schmitt et al., 2004).   Other groups have relied on plate
immobilized Notch ligands to provide the necessary Notch signaling for T cell
development (Dallas et al., 2005; Delaney et al., 2005).  (Notch ligands have been shown
to require immobilization for effective signaling (Varnum-Finney et al., 2000).)
Immobilized ligands offer the ability to quantitatively control the amount of Notch
signaling the seeded population receives, an advantage the OP9-DL1 system does not
provide.  Although this system has demonstrated promise in T cell commitment ex vivo
in a cell-free manner, the expense and stability of the plate-adsorbed ligand are legitimate
concerns for long-term culture.
Originally, we envisioned a microbead with a Notch ligand directionally
functionalized on its surface; in this way, the bead had the potential to be separated from
its target cell and provide the necessary signaling in a dose-responsive manner.  For this
reason, we first used streptavidin-coated microbeads that included a DNA linker for
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bead-cell separation (with the addition of DNase). The magnetic quality of the beads was
an added feature that could aid in specific cell populations.  Such a large diameter of the
beads ensured prevention of endocytosis.
First, Biotin Binder Kit streptavidin coated microbeads were functionalized with a
Notch ligand using a biotinylated anti-HIS antibody and a HIS tagged recombinant Delta
like ligand 4.  Such microbeads have been used in T cell culture studies, but only for
activation applications (Maus et al., 2002; Trickett et al., 2002).  Our approach utilized a
highly directional binding scheme through streptavidin-biotin binding and antigen-
antibody interactions that is performed under mild conditions which does not affect the
binding site of the ligand and should ensure appropriate confirmation for efficient Notch
signaling.  Preliminary physical characterization of these beads using flow cytometry and
confocal microscopy indicated ~65% functionalization efficiency and surface
immobilized DLL4.
Next we performed in depth optimization studies of protein functionalization to
the surface of beads, examining parameters such as protein concentration (for both anti-
6x HIS antibody and DLL4), incubation time and bead concentration.  These studies
revealed similar conditions for optimum antibody/ligand functionalization.  The extent of
functionalization reached its optimum with the highest bead concentration test, 80000000
beads/ml, and the shortest incubation time, 30 min.  This seems somewhat intuitive in
that dilute bead concentrations would hinder adequate interaction between the protein and
microbead.  For the more dilute bead concentrations, longer incubation times did result in
increased protein binding, albeit less than the optimum.  It is perhaps likely that longer
incubation periods may result in increased levels of bound protein.  Curtsinger and
colleagues demonstrated a rapid immobilization time of 20-30 min for MHC1 protein
functionalized sulfate polystyrene latex microspheres, a time period that is similar to
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ours.  Additionally, the group reported a loss in surface density for extended incubation
times, perhaps due to loss or protein from surface (Curtsinger et al., 1997).   For protein
titration studies, biotinylated anti-6x HIS antibody appeared to saturate the surface at
only 100 ng/107 beads while the DLL4 ligand saturated at a 10-fold higher concentration,
1000 ng/107 beads.  Steric hindrance and sizes of the protein (where anti-6x HIS antibody
has a molecular weight of near 150 kDa and DLL4 has a molecular weight of 55 kDa) are
speculated to play a role in these observed results.
Quantification of bound DLL4 molecules was performed using two methods, an
indirect ELISA on the washes performed during DLL4 bead fabrication and a direct
fluorescent based measurement that translated to specific molecules due to a calibration
curve from commercially available calibrated standard beads.  An estimated amount of
surface saturation can be assessed from the following equation (Bangs Labs, 1999):
S = 6/(&s*d) * C
where:
S = amount of representative protein required to achieve surface saturation (mg
protein/g microspheres)
&s = density of solid sphere (g/cm
3)
d = mean diameter (µm)
C = capacity of microsphere surface for a given protein (mg protein/m2 of sphere
surface)
Using a diameter of 4.5 µm, density of 1.05 g/cm3 for polystyrene beads, capacity of 3
mg/m2 for DLL4 and a capacity of 2.5 mg/m2 for biotinylated anti-6x HIS antibody and
bead concentration of 4x108 beads/1.6g (company communication), we found ~50000
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antibody molecules/bead and 166000 DLL4 molecules/bead.  ELISA analysis indicated
130 ng of DLL4 per one million beads which translates to ~1400 molecules per bead.
The indirect nature of assay and the high possibility of losing protein during the process
prompted us to try a more direct method of quantification namely the calibration beads.
Using this method, we observed nearly 6800 molecules per bead, an estimate that is
nearly 5 times greater than the ELISA method but on the same scale.  Both values fall
well below the calculated saturation limit.
Next, we wished to qualitatively assess the degree of functionalization on the
entire bead surface using confocal microscopy.  Due to the polystyrene nature of the
beads, autofluorescence was evident at lower excitation wavelengths and was reduced at
an excitation wavelength of 633 nm (Gorostiza et al., 2005).  Regardless, a
circumferential surface coating seemed apparent from fluorescent images on
functionalized microbeads in comparison to the uncoated microbeads, indicating
successful DLL4 functionalization.  Photobleaching most likely reduced the fluorescence
around the entire bead.  Images acquired using the reflectance mode of the confocal
microscope illustrated the dispersed placement of the magnetite particles in the beads,
which are known to be reflective (Green et al., 2001).
Finally, ligand stability on bead surface in 0.1% BSA in PBS, serum-free medium
and serum-supplemented medium at 4°C and 37°C was characterized using flow
cytometry studies.  Preliminary studies were conducted assessing the ligand density after
6 days of incubation in native storage conditions (0.1% BSA in PBS 4°C).  The 70%
reduction in surface ligand density suggested a weak bond and prompted us to conduct
further studies.  We hypothesized that the presence of serum interfered with one of the
bonds in the bead and thus performed a study where beads were incubated in PBS,
serum-free medium and serum-supplemented medium at 4°C and 37°C.  These studies,
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were non ideal in nature due to low native ligand density.  Nevertheless, studies revealed
a substantial reduction in surface density for the PBS buffer when subjected to 37°C and
the absence of surface ligand on all other conditions, with the presence of some ligand on
serum-supplemented medium at 4°C, only.  Regardless, these results disproved our serum
hypothesis.
The Biotin Binder Kit beads we used depend on three bonds for effective DLL4
functionalization.  First, the streptavidin is bound to the surface of the polystyrene beads
through a DNA linker.  The second bond consists of streptavidin-biotin binding which is
known to have a bond strength of Ka = 10
15/M (Bangs Labs 1999). The final bond is
comprised of antigen-antibody interactions Ka = 10
7-1011/M (Bangs Labs 1999).
Considering this, the DNA linker appeared to be the “weakest link.”  DNase, an enzyme
that cleaves DNA, is known to be omnipresent and have a higher biological activity at
37°C.  This led us to speculate that the DNA linker was in fact being cleaved and
releasing the ligand.
To test this hypothesis, we performed similar characterization studies on similar
magnetic streptavidin coated beads that lacked the DNA linker.  These beads were 5.91
µm in diameter with a saturation capacity for biotin-FITC given for each lot.  We
converted this saturation capacity to our biotinylated anti-6x HIS antibody based on
molecular weight differences and used this amount to coat the beads.  For the DLL4
functionalization, we tested a range of values from 20, 40, 100, 200, 400, 600, 1000,
2000, and 4000 ng of DLL4 per million beads.  Our results indicated a linear relation
without saturation for the concentrations tested.  For cost-related issues, we used 2000 ng
of DLL4 per million for subsequent studies unless otherwise noted.  This concentration
corresponded to an average 90058.38 DLL4 molecules / bead ± 3408.598 (mean ± SEM),
deduced from QSC kit calibration beads.  Using the equation given above, the saturation
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capacity for the 5.91 µm beads is 2.9 mg per gram of beads which corresponds to
virtually 3700000 DLL4 molecules per bead.  Our empirically derived number of DLL4
molecules is well below this value.  Our titration results suggest an increased capacity for
DLL4 functionalization, as well.  Confocal fluorescence and reflection microscopy
confirmed successful DLL4 functionalization on the bead surface with a dispersion of
magnetic particles throughout the inside of the bead, similar to the Biotin Binder Kit
beads.  Finally, we conducted stability studies on beads, similarly to the described
methods above with additional 1 day and 1 week timepoints and PBS usage (instead of
0.1% BSA in PBS).  These results were far more encouraging with some DLL4 present in
all conditions even after 1 week of incubation.  The nearly 50% reduction in surface
density of DLL4 under its native storage conditions (PBS 4°C) after one day of
incubation is troublesome and requires further study.  Regardless, the absence of the
DNA linker resulted in more stable DLL4 functionalization for an extended period of
time in serum supplemented and serum-free medium.
Cytotoxicity of beads was also examined in this study.  Beads have been shown to
be cytotoxic to cells at various concentrations.  For example, Olivier and colleagues
performed a study where they assessed the cytotoxic effect of polystyrene and alumina
beads with different sizes and concentrations on macrophages and fibroblasts.  Increased
size and concentrations were found to be the most detrimental to cell viability for both
types of beads and cells (Olivier et al., 2003).  To assess the cytotoxicity of our beads, we
first compared DLL4 functionalized and uncoated beads at various bead to cell ratios for
C2C12 myoblasts and R1 embryonic stem cells.  We found no statistical difference
between bead to cell ratios for multiple timepoints for both cell types (Day 3, 0.1:1 was
the sole exception).  This led us to further studies of high bead to cell concentrations with
both cell types.  Our results show a similar trend to Olivier and colleagues with reduced
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viability in myoblasts and stem cells (for early time points only) at increasing bead to cell
concentrations.  No obvious trend was apparent in the stem cell viability results at later
time points most likely due to high proliferation rate.  The maximum reduction in
viability for both cell types was a mere 10-20%, displaying minimal cytotoxic effects of
beads.  These results indicate that DLL4 functionalized beads and the magnetic beads in
general do not pose any serious cytotoxic threats for stem cells and myoblasts.
In this study, we have successfully optimized the functionalization of DLL4
ligand onto magnetic streptavidin coated microbeads using antigen-antibody and biotin-
streptavidin interactions.  Furthermore, we have demonstrated qualitatively and
quantitatively the presence of DLL4 on the beads for up to a week in serum free and
serum supplemented medium under physiologic conditons.  We have extensively
characterized the non-toxic nature of the bead in both myoblasts and embryonic stem
cells, as well.  Our studies suggest the unstable nature of a DNA linker in such a
functionalized bead and warrant further study.
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Table 3.1  Reduction in surface functionalized DLL4 microbead as compared to
original amount. (values represent percent)
_________________________________________________________________
1 hr 1 day 1 week
_________________________________________________________________
Conditions 
PBS 4ºC n/a 46.81 38.81
PBS 37ºC 66.25 43.76 22.13
Serum-free medium 37ºC 43.30 23.21 3.47
Serum-supplemented 
medium 37ºC 59.18 19.79 10.41
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Table 3.2 Reduction in surface functionalized DLL4 microbead as a function of time.
(values represent percent)
_________________________________________________________________
1 hr 1 day 1 week
_________________________________________________________________
Conditions 
PBS 4ºC n/a 46.81 38.81
PBS 37ºC n/a 66.05 33.41
Serum-free medium 37ºC n/a 53.59 8.02
Serum-supplemented 
medium 37ºC n/a 33.44 17.60
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Table 3.3 Student’s t test analysis of statistical difference between uncoated and DLL4
functionalized beads cytotoxicity in C2C12 myoblasts and R1 embryonic
stem cells: p values
_____________________________________________________________




3 Day <0.05 >0.05 >0.05
7 Day >0.05 >0.05 >0.05
9 Day >0.05 >0.05 >0.05
R1 cells
3 Day <0.05 >0.05 >0.05
5 Day >0.05 >0.05 >0.05
7 Day >0.05 >0.05 >0.05
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Table 3.4  Student’s t test analysis of cytotoxicity differences from differences in bead
to cell ratios for uncoated beads with C2C12 myoblasts: p values
________________________________________________________________________
1:1 10:1 20:1 40:1
________________________________________________________________________
3 Day
0.1:1 <0.05 0.055 <0.05 <0.05
1:1 ----- >0.05 <0.05 <0.05
10:1 ------ ----- <0.05 <0.05
20:1 ----- ----- ----- 0.055
5 Day 
0.1:1 >0.05 >0.05 >0.05 <0.05
1:1 ----- >0.05 <0.05 <0.05
10:1 ----- ----- <0.05 <0.05
20:1 ----- ----- ----- >0.05
7 Day
0.1:1 >0.05 >0.05 >0.05 >0.05
1:1 ----- >0.05 >0.05 <0.05
10:1 ----- ----- >0.05 <0.05
20:1 ----- ----- ----- >0.05
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Table 3.5 Student’s t test analysis of cytotoxicity differences from differences in bead
to cell ratios for uncoated beads in R1 cells: p values
________________________________________________________________________
1:1 10:1 20:1 40:1
________________________________________________________________________
3 Day
0.1:1 >0.05 0.054 >0.05 <0.05
1:1 ----- 0.050 >0.05 <0.05
10:1 ----- ----- >0.05 >0.05
20:1 ----- ----- ----- >0.05
5 Day 
0.1:1 >0.05 <0.05 >0.05 <0.05
1:1 ----- >0.05 >0.05 <0.05
10:1 ----- ----- >0.05 <0.05
20:1 ----- ----- ----- >0.05
7 Day
0.1:1 <0.05 >0.05 >0.05 >0.05
1:1 ----- >0.05 >0.05 >0.05
10:1 ----- ----- >0.05 >0.05
20:1 ----- ----- ----- >0.05
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Figure 3.1 Schematic of Notch functionalized microbead.  (A) with and (B) without






















Figure 3.2 Anti-6x HIS antibody saturation of magnetic beads for high concentrations
using flow cytometry analysis.    Biotin binder kit streptavidin coated beads
were coated with various concentrations of anti-6x HIS antibody and
analyzed using flow cytometry analysis.  Beads were blocked in 3% BSA in
PBS and stained with 0.25 µg of streptavidin-PE /million beads.  Average
mean fluorescence intensity values are given below with bars indicating
standard error.  Uncoated beads served as negative controls.  *denotes
statistical significance when comparing 100 ng of anti-6x HIS antibody/10
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Figure 3.3 Anti-6x HIS antibody saturation of magnetic beads using flow cytometry
analysis.    (A) Titration of antibody concentrations represented as average
mean fluorescence intensities.  (B) Representative histogram of 100 ng/10
million beads concentration.  Biotin binder kit streptavidin coated beads
were coated with various concentrations of anti-6x HIS antibody and
analyzed using flow cytometry analysis.  Beads were blocked in 3% BSA in
PBS and stained with 0.25 µg of streptavidin-PE /million beads.  Average
mean fluorescence intensity values are given below with bars indicating
standard error. Uncoated beads served as negative controls.  *denotes
statistical significance when comparing 100 ng of anti-6x HIS antibody/10
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Figure 3.4 Bead concentration and incubation period optimization for anti-6x HIS
antibody coating using flow cytometry analysis. Biotin binder kit
streptavidin coated beads were incubated in 80000000, 800000, and 8000
beads/ml concentrations for 30, 60, and 90 min incubation periods at 100 ng
of anti-6x HIS antibody/10 million beads. Beads were blocked in 3% BSA
in PBS and stained with 0.25 µg of streptavidin-PE /million beads.  Average
mean fluorescence intensity values are given below with bars indicating
standard error. Uncoated beads served as negative controls.
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Figure 3.5 Microbeads can be efficiently functionalized with Notch ligand DLL4.  To
assess the efficiency of ligand binding, functionalized beads were stained
with anti-DLL4 antibody and FITC anti-rat IgG antibody and analyzed
using flow cytometry.  Streptavidin coated beads and biotinylated anti-6x
HIS tagged antibody coated beads were used as negative controls.  A.  Solid
histogram represents uncoated beads while unfilled histogram represents
DLL4 functionalized beads.  B.  Solid histogram represents biotinylated
anti-6x HIS tagged coated antibody beads while unfilled histogram
represents DLL4 functionalized beads.  C.  Comparison of coating
efficiency for coated and uncoated beads.  All experiments were performed
in triplicate. * indicates p < 0.05 compared to both control bead populations
using a Student’s t test.
*
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Figure 3.6 Fluorescence microscopy confirmation of functionalized DLL4 on the
surface of Biotin Binder Kit beads.  Anti-6x HIS beads and DLL4
functionalized beads were blocked and stained with anti-DLL4 antibody and
APC anti-rat IgG antibody and visualized under reflection, confocal and
transmission microscopy.  Anti-6x HIS beads are shown below under
reflection (A), confocal (B), and transmission microscopy (C).  DLL4
functionalized beads are shown below under reflection (E), confocal (F),
and transmission microscopy (G).  (D) and (H) indicate overlays of
reflection and fluorescence channels for anti-6x HIS beads and DLL4
functionalized beads, respectively.  Yellow arrows indicate functionalized










Figure 3.7 Fluorescence microscopy confirmation of functionalized DLL4 on the
surface of Proactive® beads.  Anti-6x HIS beads and DLL4 functionalized
beads were blocked and stained with anti-DLL4 antibody and APC anti-rat
IgG antibody and visualized under reflection, confocal and transmission
microscopy.  Anti-6x HIS beads are shown below under reflection (A),
confocal (B), and transmission microscopy (C).  DLL4 functionalized beads
are shown below under reflection (E), confocal (F), and transmission
microscopy (G).  (D) and (H) indicate overlays of reflection and











Figure 3.8 DLL4 saturation of magnetic beads using flow cytometry analysis.  (A)
Titration of DLL4 concentrations represented as average mean fluorescence
intensities.  (B) Representative histogram of 1000 ng/10 million beads
concentration.  Biotin binder kit DLL4 coated beads were coated with
various concentrations of anti-6x HIS antibody and analyzed using flow
cytometry analysis.  Beads were blocked in 3% BSA in PBS and stained
with anti-DLL4 antibody and FITC anti-rat IgG antibody. Average mean
soluble equivalent fluorophore (MSEF) values are given below with bars
indicating standard error.  Anti-6x HIS antibody coated beads served as
negative controls. *denotes statistical significance when comparing 200-
2000 ng of DLL4/10 million beads to all other lower concentrations (10-100
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Figure 3.9 DLL4 saturation of Proactive ® magnetic beads using flow cytometry
analysis.  (A) Titration of DLL4 concentrations represented as average mean
fluorescence intensities.  (B) Representative histogram of 2000 ng/million
beads concentration. Beads were coated with a predefined amount of anti-6x
HIS antibody and varying concentrations of DLL4 and analyzed using flow
cytometry analysis.  Beads were blocked in 3% BSA in PBS and stained
with anti-DLL4 antibody and FITC anti-rat IgG antibody.  Average mean
soluble equivalent fluorophore (MSEF) values are given below with bars
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Figure 3.10 Bead concentration and incubation period optimization for DLL4 coating
using flow cytometry analysis. Biotin binder kit streptavidin coated beads
were incubated in 80000000, 800000, and 8000 beads/ml concentrations for
30, 60, and 90 min incubation periods at 100 ng of anti-6x HIS antibody/10
million beads and 1000 ng of DLL4/10 million beads. Beads were blocked
in 3% BSA in PBS and stained with anti-DLL4 antibody and FITC anti-rat
IgG antibody.  Average mean fluorescence intensity values are given below
with bars indicating standard error. Anti-6x HIS antibody coated beads
served as negative controls.
82
Figure 3.11 DLL4 functionalized Biotin Binder Kit bead stability after 6 days in native
storage conditions.  Beads were coated with 100 ng of anti-6x HIS antibody
and 1000 ng of DLL4 per 10 million beads and incubated for one day and
six days in 0.1% BSA in PBS at 4ºC.  Following incubation, beads were
stained and analyzed for surface DLL4 using flow cytometry analysis.
Beads were blocked in 3% BSA in PBS and stained with anti-DLL4
antibody and FITC anti-rat IgG antibody.  Average mean fluorescence
intensity values are given below with bars indicating standard error. Anti-6x
































Figure 3.12 Effect of temperature, serum and medium on the stability of DLL4
functionalized Biotin Binder Kit bead after 1 hr incubation.  Beads were
coated with 100 ng of anti-6x HIS antibody and 1000 ng of DLL4 per 10
million beads and incubated for one hr in 0.1% BSA in PBS, serum-free
medium and serum-supplemented medium at 4ºC and 37ºC.  Following
incubation, beads were stained and analyzed for surface DLL4 using flow
cytometry analysis. Beads were blocked in 3% BSA in PBS and stained with
anti-DLL4 antibody and FITC anti-rat IgG antibody.  Average mean
fluorescence intensity values are given below with bars indicating standard























































Figure 3.13 Effect of temperature, serum and medium on the stability of DLL4
functionalized Proactive® beads after 1 hr, 1 day and 1 week of
incubation.  Beads were coated with a predefined amount of anti-6x HIS
antibody and 700 ng of DLL4 per million beads and incubated for one hr,
one day and one week in PBS, serum-free medium and serum-
supplemented medium at 4ºC (for the PBS only) and 37ºC.  Following
incubation, beads were stained and analyzed for surface DLL4 using flow
cytometry analysis. Beads were blocked in 3% BSA in PBS and stained
with anti-DLL4 antibody and FITC anti-rat IgG antibody.  Average mean
fluorescence intensity values are given below with bars indicating





















































Figure 3.14 Cytotoxicity effects of uncoated and DLL4 functionalized Biotin Binder
Kit beads using MTT assay in C2C12 myoblasts.  DLL4 functionalized
and uncoated beads were added to seeded C2C12 myoblasts at bead to cell
ratios of 0.1:1, 1:1 and 5:1 and incubated for 3 days, 7 days and 9 days
with cells.  After each incubation, a MTT solution was added and
incubated with cells for 4 hrs.  Formazan crystals were solubilized and
solutions measured at 570 nm to assess viability of cells.  All values were
normalized to cells only condition.
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Figure 3.15 Cytotoxicity effects of uncoated and DLL4 functionalized Biotin Binder Kit
beads using MTT assay in R1 embryonic stem cells.  DLL4 functionalized
and uncoated beads were added to seeded R1 embryonic stem cells at bead
to cell ratios of 0.1:1, 1:1 and 5:1 and incubated for 3 days, 7 days and 9
days with cells.  After each incubation, a MTT solution was added and
incubated with cells for 4 hrs.  Formazan crystals were solubilized and
solutions measured at 570 nm to assess viability of cells.  All values were
normalized to cells only condition.
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Figure 3.16 Cytotoxicity effects of uncoated Biotin Binder Kit beads using MTT assay
in C2C12 myoblasts.  Uncoated beads were added to seeded C2C12
myoblasts at bead to cell ratios of 0.1:1, 1:1, 10:1, 20:1 and 40:1 and
incubated for 3 days, 5 days and 7 days with cells.  After each incubation, a
MTT solution was added and incubated with cells for 4 hrs.  Formazan
crystals were solubilized and solutions measured at 570 nm to assess
viability of cells.  All values were normalized to cells only condition.
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Figure 3.17 Cytotoxicity effects of uncoated Biotin Binder Kit beads using MTT assay
in R1 embryonic stem cells.  Uncoated beads were added to seeded R1
embryonic stem cells at bead to cell ratios of 0.1:1, 1:1, 10:1, 20:1 and 40:1
and incubated for 3 days, 5 days and 7 days with cells.  After each
incubation, a MTT solution was added and incubated with cells for 4 hrs.
Formazan crystals were solubilized and solutions measured at 570 nm to
assess viability of cells.  All values were normalized to cells only condition.
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CHAPTER FOUR
Qualitative and Quantitative Assessment of Dose-Dependent Notch
Signaling
4.1 INTRODUCTION
We have previously characterized and optimized the fabrication of Notch
functionalized microbeads, both with and without a DNA linker, as described in Chapter
3.  The use of a bead system boasts two levels of control on the final ligand density
presentation, concentration of DLL4 density on bead surface and bead to cell ratio.
Previous results have demonstrated low microbead cytotoxicity and stability in serum-
supplemented medium for up to a week in the absence of a DNA linker.  Our goal is to
utilize Notch functionalized beads for the ex vivo generation of T cells for adoptive
transfer applications.  We are also interested in studying the effects, if any, of varying
both the ligand density and bead to cell ratios with Notch signaling responsive cells.  We
hypothesize that such a quantitatively controllable system can be tailored to optimize the
amount of Notch signaling by utilizing such a system.
Recent studies have explored the effects of ligand density on T cell differentiation
utilizing two main approaches, administering varying amounts of enzyme inhibitor to
prevent Notch signaling at the receptor level and immobilizing varying densities of Notch
ligands on the surface of polystyrene (Beckstead et al., 2006; Ciofani et al., 2004; Dallas
et al., 2005; Delaney et al., 2005; De Smedt et al., 2005; Lehar et al., 2005; Schmitt et al.,
2004).  The first approach involves the use of OP9-DL1 stromal cell line, which is
transfected to express Notch ligand Delta1 or other Notch signaling supportive
microenvironments.  Previous studies and reviews have explored at length the benefits of
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utilizing a Notch ligand transfected stromal cell line in T cell differentiation (de Pooter et
al., 2007; Schmitt et al., 2004; Zuniga-Pflucker et al., 2004).  As described in Chapter 2,
upon Notch ligand-receptor binding, the receptor is cleaved three times prior to the
translocation of the intracellular Notch into the nucleus and subsequent expression of
Notch target genes.  One of the cleavages involves the activity of a presenilin-dependent
# secretase that is responsible for releasing the intracellular portion of Notch for nuclear
translocation (Saxena et al., 2001).  Two inhibitors of such enzyme activity, presenilin
inhibitor X and 7 (N-[N-(3,5-difluorophenyl)-L-alanyl]-S-phenyl-glycine t-butyl ester]
DAPT have been readily used to explore the requirements of Notch signaling for
developing thymocytes (De Smedt et al., 2005; Lehar et al., 2005; Schmitt et al., 2004).
For example, Schmitt and colleagues used varying concentrations of inhibitor X to
demonstrate lymphocyte potential in fetal liver-derived HPCs.  Lower concentrations of
the inhibitor resulted in a greater induction of NK cell development while high
concentrations resulted in B cell development and loss of T cell lineage, suggesting a
threshold for Notch signaling with T cells having the maximum requirement (Schmitt et
al., 2004).  Other studies have utilized FTOC culture and OP9 transfected Jagged 1 cell
line to explore the Notch signaling thresholds in T cell development (De Smedt et al.,
2005; Lehar et al., 2005).  De Smedt and colleagues confirmed the threshold requirement
for lymphocyte development in human precursor cells using FTOC culture, with the
order being B cells, NK cells and T cells with increasing levels of Notch required (De
Smedt et al., 2005).  Finally, Lehar and colleagues also demonstrated B cell development
with high levels of inhibitor X using OP9-DL1 and developing thymocytes.  Inhibitor
addition, however, did not affect the T cell development for OP9 cells transfected with
Notch ligand Jagged 1 (Lehar et al., 2005).
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As described above, another approach to quantitatively varying the degree of
Notch signaling involves the immobilization of varying amounts of Notch ligand on the
surface of polystyrene, therefore directly controlling the amount of Notch ligand present.
Similar dose-dependent behavior of developing T lymphocytes has been observed for
both murine and human cells using immobilized Notch ligands (Dallas et al., 2005;
Delaney et al., 2005).   Dallas et al observed marked induction of T cell development for
concentrations of 2.5 µg/ml of Delta-1 or higher with little to no B cell commitment as
evident from immunophenotype analysis (Dallas et al., 2005).  In a related study,
Delaney and colleagues observed higher CD7+ expression, an early marker of human T
cells, and greater human engraftment at lower densities of immobilized Delta1 (Delaney
et al., 2005).
These studies suggest a dose-dependent role of Notch signaling in T cell
development and warrant further investigation.  Here, we have investigated the effect of
these quantitative differences using several qualitative and quantitative assessments, as
summarized in Figure 4.1.  Myotube inhibition has been used to qualitatively
demonstrate effective Notch signaling using our bead system.  Furthermore, we found
basal levels of Notch signaling using both intracellular Notch staining and RTPCR
studies in both C2C12 myoblasts and R1 embryonic stem cells.  Despite the high
background, real-time RTPCR and luciferase results imply a threshold response of
myoblasts with increased Notch target gene expression for lower bead to cell ratios and
higher luciferase activity for increased ligand densities.  Findings such as these illustrate
the importance of ligand density, aid in our understanding of Notch signaling and can be
further applied to T cell development for the eventual production of therapeutic T cell
lymphocytes.
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4.2 MATERIALS AND METHODS
4.2.1 Bead fabrication
DLL4 functionalized beads were prepared as described in Chapter 3.  Both Biotin
Binder Kit (Dynalbiotech, Brown Deer, WI) and Proactive® (Bangs Labs, Fishers, IN)
were used for Notch signaling studies.
4.2.2 C2C12 cell and R1 cell culture
R1 embryonic stem cells and C2C12 myoblasts were cultured as described in
Chapter 3.  Additionally, medium was changed for C2C12 myoblasts after 24 hr of
seeding for all studies and differentiation medium was added.  Differentiation medium
consisted of DMEM (Invitrogen, Carlsbad, CA), 10% equine serum (Hyclone, Logan,
UT) and antibiotics.  Differentiation medium is known to promote myoblast
differentiation and myotube formation.
4.2.3 C2C12 myotube inhibition assay for Notch signaling
Notch signaling has been extensively shown to inhibit the formation of myotubes
in C2C12 cells.  Thus, myotube inhibition has been used extensively as an assay to
demonstrate efficient Notch signaling (Kopan et al., 1994; Lindsell et al., 1995; Luo et
al., 1997; Varnum-Finney et al., 2000).  Myoblast differentiation was conducted similarly
to the methods described by Varnum-Finney et al (Varnum-Finney et al., 2000).  First,
concentrations of DLL4 (R&D Systems, Minneapolis, MN) were immobilized and tested
for C2C12 differentiation.  DLL4 was immobilized at concentrations of 1 µg/ml and 1.5
µg/ml onto a 96 well plate for 2-3 hours.  After immobilization, wells were washed three
times with PBS and seeded with C2C12 (ATCC, Manassas, VA) at a concentration of
100
200000 cells/ml in C2C12 maintenance medium.  Cells without DLL4 were used as the
negative control.  Medium was changed after one day and replaced with differentiation
medium.  Qualitative analysis of myoblast differentiation and Notch activation was
conducted using visualization of myofibril formation, as described before (Varnum-
Finney et al., 2000).  Next, experiments were performed where the bioactivity of soluble
DLL4 was assessed.  In these studies, DLL4 was immobilized as described above at a
concentration of 1 µg/ml.  Soluble DLL4 was added to additional wells at 1 µg/ml and
cells without DLL4 were included as the negative control.  Medium was replaced as
described above and soluble DLL4 was replaced for relevant wells.  Imaging was
performed after 6 days of incubation using phase contrast microscopy.  To ensure
controlled orientation of DLL4, a directional binding scheme was utilized in bead
fabrication.  This binding scheme consists of streptavidin coated beads with biotinylated
anti-6x HIS antibody and histidine tagged DLL4.  Supplemental studies were conducted
where each of the components of the binding scheme were immobilized and tested in
terms of myoblast differentiation using methods as described above.  For all protein
immobilization conditions, proteins were coated for 2 hours at 2 µg/ml at 37°C.  Proteins
included neutravidin (Pierce Biotechnology, Rockford, IL), biotinylated anti-6x HIS
antibody (R&D Systems, Minneapolis, MN) and recombinant DLL4 (R&D Systems,
Minneapolis, MN).  For neutravidin-biotinylated anti-6x HIS-DLL4 condition, wells
were blocked with 1% BSA at 37°C following the antibody incubation.  Finally, DLL4
coated beads were also incubated with C2C12 cells and tested for myotube inhibition as
described above.  Cells were seeded one day prior to bead addition.  Ligand coated beads
were added to wells at bead to cell ratios of 1:1 and 5:1.  Uncoated Biotin Binder kit
beads (Dynalbiotech, Brown Deer, WI), added at the same bead to cell ratios, served as
controls.  All conditions were performed in triplicate.  Cells were visualized using the
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20x objective of the Leica fluorescent IRB inverted microscope (Meyer Instruments, San
Antonio, TX).
4.2.4 Intracellular Notch staining
To demonstrate effective Notch signaling, myoblasts and stem cells were
incubated with Notch functionalized beads and stained for activated Notch.  R1 cells and
C2C12 cells were seeded at a concentration of 20000 cells and 75000 cells, respectively,
per poly-L-lysine coated coverslips one day prior to bead incubation. Cells were then
fixed in 4% paraformaldehyde, washed with phosphate buffered saline (PBS), and then
permeabilized with 0.25% Triton X-100 for 10 minutes are room temperature and
subsequently washed one more time.  Samples were blocked in 1.5% goat serum in PBS
for 1 hour, and antibodies were diluted 1:750 with 1% BSA, 0.05% sodium azide in
PBST. Cells were incubated overnight at 4°C with primary antibody rabbit anti-
mouse/human activated Notch antibody (Abcam, Cambridge, MA), incubated 1 hour at
room temperature with Alexafluor 488 goat anti-rabbit antibody (Invitrogen, Carlsbad,
CA), washed with PBST, and stained with DAPI (Invitrogen, Carlsbad, CA) at a
concentration of 300nM for nuclear visualization.  Finally, coverslips were mounted with
Permount mounting medium (Fisher Scientific, Pittsburg, PA), sealed with clear nail
polish and stored in the dark at 4ºC.  Cells were imaged with the Zeiss Apotome Axiovert
200 microscope (Carl Zeiss Microimaging, Thornwood, NY).  Additional studies were
also conducted where the addition of Notch functionalized beads and uncoated beads
were performed.  The degree of intracellular Notch activation was assessed using staining
as described above with anti-human/mouse ICN antibody-FITC (eBioscience, San Diego,
CA).  After staining, cells were washed and resuspended in 250 µl of staining buffer and
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analyzed using FACSCalibur (Becton Dickinson, San Diego, CA) and CellQuest 3.1
software (BD Biosciences, San Jose, CA).
4.2.5 Real-time RT-PCR studies of Notch gene expression
Cytoplasmic RNA was isolated from cells using the methods described previously
(Gore and Roberts 1993).  Briefly, frozen cell pellets were first separated into nuclear and
cytoplasmic fractions using a lysis buffer.  Protein was removed from the cytoplasmic
fraction using proteinase-K (200 pg/ml final concentration; Roche Applied Science,
Indianapolis, IN) at 45ºC.   Next, a phenol-chloroform-isoamyl alcohol extraction at
ratios of 25:24:1 was performed followed by an additional chloroform extraction and
isopropanol precipitation at -20ºC.  After washing fractions with 70% ethanol, pellets
were dried and resuspended in nuclease-free water.  Quality of isolated RNA was
assessed using ND-1000 spectrophotometer (Nanodrop, Wilmington, DE).
Contaminating DNA was removed from pellets using TURBO DNA-free kit (Ambion,
Austin, TX) according to manufacturer’s instructions.  Complementary DNA was
synthesized using the Superscript First-Strand Synthesis Kit (Invitrogen, Carlsbad, CA)
using at least 500 ng of RNA.  Reaction ready SYBR® Green qPCR mix (Superarray,
Frederick, MD) was used to perform quantitative polymerase chain reaction (PCR) on
ABI Prism 7900 HT Sequence Detector (Applied Biosystems, Foster City, CA). Amount
of gene expression was deduced from threshold cycle values.  For RT-PCR studies, DNA
was amplified from mRNA with AccessQuickTM Master Mix (2X) and AMV reverse
transcriptase (Promega, Madison, WI) as per manufacturer’s instructions.  PCR consisted
of 40 cycles of 45 s at 94°C, 1 min at 60°C, and 1 min at 72°C.  PCR products were
separated by 2% agarose gel electrophoresis and were visualized with ethidium bromide
staining. Gene specific primers for HES1, Hrp2, NRARP, Beta actin and GAPDH were
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all acquired from Superarray.  Beta actin and GAPDH were used as housekeeping genes
to normalize data.
4.2.6 Luciferase reporter assay
C2C12 cells were seeded onto 24 well plates to achieve 70% confluence after 24
hours.  Cells were transfected with 4xwtCBF1Luc plasmid (gift from D. Hayward, Johns
Hopkins University, Baltimore, MD) at 1 µg/ml using Exgen 500 (Fermentas, Glen
Burnie, MD) according to manufacturer’s instructions.  Plasmid was amplified at
Aldevron (Aldevron LLC, Fargo, ND).  After 24 hours of transfection, DLL4
functionalized and uncoated beads were added to cells in serum-free differentiation
medium at designated bead to cell ratios.  Cells were washed and lysed after 24 hours
using Glo Lysis Buffer (Promega, Madison, WI).  Protein content in samples was
assessed using Micro BCA Protein Assay Kit (Pierce, Biotechnology, Rockford, IL), as
per manufacturer’s protocol.  Lysate was evaluated for luciferase expression using a
Dynex MLX Luminometer (Dynex, Chantilly, VA).  RLU values were normalized to
protein content using BCA results.  All conditions were performed with at least n=3.
4.3 RESULTS
4.3.1 Immobilization of DLL4 is necessary for Notch signaling; functionalization
scheme does not affect myotube inhibition
The inhibition of myotube formation is a classical assay performed to demonstrate
efficient signaling through Notch ligands.  It has been demonstrated that the presence of
immobilized Notch ligands inhibits the spontaneous differentiation of C2C12 myoblast
cells in myotubes (Varnum-Finney et al., 2000).  To evaluate the bioactivity of
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immobilized DLL4, we performed a C2C12 myoblast differentiation assay and monitored
the degree of myotube inhibition.  First, we immobilized various concentrations of DLL4
onto a polystyrene 96 well plate and assessed the degree of myotube inhibition after 5-6
days of incubation using phase contrast microscopy.  As shown in Figure 4.2, myotube
inhibition occurred at both concentrations of immobilized DLL4 tested, 1 µg/ml and 1.5
µg/ml, to similar degrees.  In contrast, myotube formation was observed for wells without
DLL4.  Next, we evaluated the need for immobilization by adding DLL4 at 1 µg/ml in
the immobilized and soluble forms to myoblasts and observing myotube formation.
Myotube formation was inhibited to a small extent with soluble DLL4 but nevertheless
resulted in myotube formation after the 5-6 day incubation.  The myoblast morphology is
retained only when DLL4 was immobilized, as shown in Figure 4.3.  Finally, to ensure
the functionalization scheme did not affect myotube formation or in fact have an
inhibitive effect, neutravidin, biotinylated anti-6x HIS antibody and the functionalization
scheme (neutravidin-biotinylated anti-6x HIS antibody-HIS tagged DLL4) were all
evaluated.  Proteins were immobilized at 2 µg/ml, extensively washed and seeded with
myoblasts.  Figure 4.4 shows the presence of myotubes in all conditions except those
where DLL4 was immobilized after 6 days of incubation.  The functionalization scheme
does not appear to have any additional effect, as evident by the similar morphology of
cells in Figure 4.4d and Figure 4.4e.
4.3.2 DLL4 functionalized microbeads can provide efficient Notch signaling
The degree of myotube inhibition in the presence of DLL4 functionalized
microbeads was qualitatively evaluated through phase contrast microscopy after 6 days of
culture.  Streptavidin coated beads were used as negative controls.  Figure 4.5 indicates
that the presence of Notch ligand on the microbead surface significantly inhibits myotube
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length and maturation.  (Myotubes are indicated by red arrows.)  Although the presence
of some myotube formation is suggested by the elongated morphology of the myoblasts
in Figures 4.5c and 4.5d, the mature myotube morphology is markedly reduced as
compared to Figures 4.5a and 4.5b (all images in Figure 4.5 are of 20x magnification).
Increasing the functionalized bead to cell ratio from 1:1 to 5:1 had no visible effect in
terms of increased myotube inhibition or retention of myoblast morphology, as evident in
Figures 4.5c and 4.5d indicating a saturation effect.  This data suggests a bead to cell
ratio of 1:1 is sufficient to transmit Notch signals and significantly inhibit myotube
formation in the C2C12 myoblast system.
4.3.3 Basal levels of intracellular Notch staining exist in R1 embryonic stem cells
and C2C12 myoblasts
In the previous section, we demonstrated that immobilized DLL4 (both on
polystyrene and microbeads) could provide Notch signaling to C2C12 myoblasts as
evident by the cell morphology and level of differentiation.  Here, we wished to further
investigate the level of Notch signaling on a more molecular level.  Notch signaling is
known to induce a cleavage in the ligand bound Notch receptor releasing an intracellular
Notch (ICN) portion of the Notch receptor (Maillard et al., 2005).  The ICN can be
stained in fixed and permeabilized cells and used to assess the degree of Notch signaling.
We first assessed the basal level of Notch signaling in two types of cells, myoblasts and
embryonic stem cells.  Cells were stained for the presence of intracellular Notch antibody
and imaged for a qualitative analysis.  SK-N-MC neuroepithelioma cells are known to
always express Notch and served as positive controls (Ohishi et al., 2002).  As shown in
Figure 4.6b, a significant amount of Notch signaling without any prior Notch ligand
addition existed in myoblasts.  Embryonic stem cells also displayed similar levels of
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basal Notch signaling as shown in Figure 4.7b.  In all images acquired, the ICN were
localized in the nuclei for both myoblasts and stem cells, as shown in Figure 4.6b and
Figure 4.7b.  Additional studies were conducted where Notch functionalized beads were
incubated with myoblasts and cells were assessed for Notch signaling using ICN staining
and flow cytometry analysis (data not shown).  These studies were conducted on cells
with suspension, attached and pellet culture for varying incubation periods (1hr, 1 day, 1
wk) with little to no differences between conditions with and without Notch
functionalized beads. Proactive beads® were also functionalized and tested for
intracellular Notch activation with similar results.  Differences in Notch signaling, at least
on the level of activated ICN, were most likely minimal and difficult to detect using this
assay due to the high background levels.
4.3.4 Real-time and end point RTPCR analysis indicate upregulation of Notch target
genes in myoblasts
To investigate Notch signaling at a more sensitive level, we performed RTPCR
studies using both end point and real-time quantitative analyses.  First, RNA was isolated
from R1 embryonic stem cells for a week and evaluated for inherent Notch signaling,
using a Notch target gene.  RNA was isolated on days 1, 3, 5 and 7, treated for DNA
contamination, converted to cDNA and amplified using HES1 and beta actin specific
primers.  Amplified DNA was then run on agarose gels and stained using ethidium
bromide.  Figure 4.8 shows basal levels of HES1 expression even after 1 week of culture.
Real-time RTPCR studies were also performed on R1 ESCs incubated with Notch
functionalized beads at varying bead to cell ratios.  These results revealed no difference
when comparing both uncoated and Notch functionalized beads and bead to cell ratios
(data not shown).
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Next, we examined Notch gene upregulation in myoblasts with both Notch
functionalized Biotin Binder Kit and Proactive® beads.  First, we added Notch
functionalized Biotin Binder Kit microbeads and uncoated beads at bead to cell ratios of
0.1:1 and 1:1 and studied the upregulation in HES1 gene expression.  HES1 and HERP2
genes are known to be common Notch target genes in myoblasts (Iso et al., 2001).  All
values were normalized to cells only expression levels.  Figure 4.9 shows the 5- and 4-
fold increase in gene expression for the 0.1:1 and 1:1 bead to cell ratios when comparing
DLL4 and uncoated beads, respectively, after 2 days of bead-cell incubation.  Additional
incubation where beads and cells were incubated for 6 days exhibited similar results, as
shown in Figure 4.10.  Notch functionalized Proactive® beads had a similar effect on
Notch target gene upregulation.  Here, beads were added at bead to cell ratio of 0.5 to 1
and HES1 and HERP2 target genes were studied.  Figure 4.11 shows a 3-fold and 2-fold
change in gene expression with the addition of 1200 ng of DLL4/million bead and 2000
ng of DLL4/million bead ligand densities, respectively over anti-6x HIS antibody beads.
Student’s t test indicated a p value of 0.08 when comparing the 1200 ng of DLL4/million
bead ligand density to anti-6x HIS antibody bead for the HERP2 gene.
4.3.5 Luciferase reporter assay indicates increase in Notch related CBF-1 activity in
a dose dependent manner in myoblasts with Notch functionalized beads
In mammalian systems, upon Notch ligand binding, there are a series of cleavages
in the Notch receptor one of which results in the release of the intracellular domain (ICN)
and translocation to the nucleus, as described above.  Upon entry into the nucleus, ICN
associates with the transcription factor CBF1/RBP-J and initiates activation of Notch
target genes (Maillard et al., 2005).  Here, we utilized a CBF1-Luc reporter to
demonstrate the dose-dependent effects of DLL4 functionalized beads on Notch
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signaling, directly.  The CBF1-Luc reporter has CBF1 binding elements cloned into a
GL2pro plasmid (Hayward et al., 1996) and can be used to demonstrate Notch activity
based on luciferase gene expression.  First, we tested the DLL4 functionalized Biotin
Binder Kit beads for a dose dependent response in C2C12 cells using the luciferase
reporter assay.  Transfected myoblasts were incubated with functionalized and uncoated
beads at bead to cell ratios of 1 to 1 and 5 to 1 for 24 hr and evaluated for luciferase
expression.  Results indicated an increase in luciferase expression, as shown in Figure
4.12, for both 1:1 and 5:1 bead to cell ratios, when comparing DLL4 functionalized and
uncoated beads.  Student’s t test showed a statistically significant difference for both
(p<0.05).  When comparing the luciferase expression of the DLL4 functionalized beads
to the cells only, however, no statistical difference was found for both 1:1 and 5:1 (p
values of 0.25 and 0.06, respectively).
DLL4 functionalized Proactive® beads were also incubated with transfected
myoblasts and tested for their effects on luciferase expression.  Here, however, beads
were functionalized with varying amounts of DLL4 ligand densities, to further investigate
the dose-dependent response, if any.  Beads were functionalized with low, medium and
high amounts of DLL4 (200, 600, 2000 ng of DLL4/ million beads) and incubated with
transfected myoblasts at various bead to cell ratios including 0.5:1, 1:1, 2:1 and 5:1.
Anti-6x HIS coated beads were also incubated with cells at the bead to cell ratios, given
above.  Cells were then lysed following 24 hours of incubation and tested for luciferase
activity.  As shown in Figure 4.13 and Table 4.1, no clear trend was detected for
increasing bead to cell ratios with few statistically significant differences found.  When
comparing bead to cell ratios for each density with the appropriate anti-6x HIS coated
bead to cell ratio, a statistically significant difference was found for all bead to cell ratios
for the highest ligand density except 2:1.  Comparisons with cells only values also gave
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statistically significant differences (Table 4.2).  Low and medium ligand density beads,
however, did not show an upregulation in luciferase activity in a statistically significant
manner, with the exception of 0.5:1 bead to cell ratio for the medium ligand density.
Table 4.3 summarizes the fold differences when comparing the highest ligand density
coated beads to both anti-6x HIS coated beads and cells.  The 5:1 bead to cell ratio
resulted in the greatest induction of luciferase activity with a 2.35-fold increase over
cells.  Additional studies demonstrated up to a 3-fold increase in luciferase activity for
the 5:1 bead to cell ratio (with high ligand density) over anti-6x HIS coated beads.  In
these studies, however, cells without beads had high luciferase activity resulting in only a
1.41-fold increase for the same condition (data not shown).
4.4 DISCUSSION
Notch ligands have been established as some of the key players in T cell
differentiation (Ciofani and Zuniga-Pflucker 2007; Heinzel et al., 2007; Maillard et al.,
2005; Parreira et al., 2003; Petrie and Zuniga-Pflucker 2007).  Notch ligands are known
to be present in the thymus on supportive stroma.  Recent studies have shown varying
densities of Notch ligands in the thymic microenvironment, unique to the signals required
for developing thymocytes in each niche.  For example, both Delta1 and Delta4 ligands
are expressed at a high density in the cortico-medullary junction, the site of entry for
thymic progenitors (Heinzel et al., 2007; Schmitt et al., 2004).  Although irreversible T
cell commitment does not take place here, a high density of Notch ligands ensures T
lineage specification and prevents commitment to B cell and NK cell lineages for
example (Petrie and Zuniga-Pflucker 2007).  The medulla, known as the site of positive
selection and exportation, on the other hand, boasts a very low density of Delta ligands
(Heinzel et al., 2007).   Developing thymocytes are nearly mature once they reach the
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medulla and most likely do not need Notch signals for functional maturation (Petrie and
Zuniga-Pflucker 2007).
This idea of density-dependent Notch signaling and T cell development has
recently been explored and has led to a better understanding of developmental potential
and necessary levels of Notch signaling (Beckstead et al., 2006; Ciofani et al., 2004;
Dallas et al., 2005; Delaney et al., 2005; De Smedt et al., 2005; Lehar et al., 2005;
Schmitt et al., 2004).  Use of # secretase inhibitors such as presenilin inhibitor X and
DAPT in Notch ligand supportive stroma suggest a Notch signaling threshold capable of
committing progenitors at varying levels of Notch ligand density (Ciofani et al. 2005; De
Smedt et al., 2005; Lehar et al., 2005; Schmitt et al., 2004).  The current hypothesis
suggests that T cells, NK cells and B cells require increasing levels of Notch signaling,
with T cells requiring the greatest level and B cell requiring the least.  Moreover,
providing a high degree of Notch signaling obligates T cell specification and prevention
of B cell commitment.  One disadvantage of such an indirect method of controlling levels
of Notch signaling, however, is the failure to quantitatively characterize the Notch
signaling needed.
A more direct method of “measuring” Notch signaling has recently been studied
where varying concentrations of Notch ligands are immobilized on the surface of
polystyrene (Dallas et al., 2005; Delaney et al., 2005).   Dallas and colleagues observed
significant induction of T cell commitment in murine progenitors at concentrations of 2.5
µg/ml of DLL1 or greater.  These studies also confirmed the presence of little to no B cell
commitment at such concentrations.  Similar results were observed for human
progenitors, as well (Delaney et al., 2005).
Both methods have made significant contributions to our understanding in T cell
development and represent two examples of ex vivo differentiation schemes.  Coculture
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studies with Notch ligand transfected cell stroma more closely represent the thymic
microenvironment but suffer from the inability to quantify the amount of Notch signaling
and provide a cell-free microenvironment, both of which are important for scaling up the
production of human T cells.  Immobilized Notch ligand is better suited for scaling up T
cell generation in terms of a cell-dependent system but may pose expense issues.  Also, in
both methods, the removal of Notch signaling from the culture environment for possible
optimization or developmental studies can be difficult to achieve.
We have addressed such limitations with the functionalization of Notch ligands
on commercially available microbeads.  Our design exploits the highly directional and
high strength binding of streptavidin-biotin and antigen-antibody interactions to provide
Notch ligands in a quantifiable manner.  Collectively, there are two levels of ligand
density control in this design, ligand density on each bead and bead to cell ratio.  In this
study we have, we have extensively studied the effect of bead to cell ratio using several
qualitative and quantitative assays at both the extracellular and intracellular levels.  These
assays are summarized in Figure 4.1.
We first used the myotube inhibition assay to demonstrate Notch signaling at the
level of cellular morphology.  Notch signaling has been extensively shown to inhibit
myotube formation and maintain the myoblast phenotype through primarily coculture
studies (Iso et al., 2001; Kopan et al., 1994; Kuroda et al., 1999; Lindsell et al., 1995;
Luo et al., 1997; Mizutani et al., 2000; Nofziger et al., 1999; Varnum-Finney et al.,
2000).  In these studies, myeloma, fibroblast and fibrosarcoma cell lines were transfected
to express Notch ligands such as Jagged 1 or Delta 1 and used to characterize the signal
transduction and gene expression responses to Notch signaling in C2C12 cells (Iso et al.,
2001; Kuroda et al., 1999; Mizutani et al., 2000; Nofziger et al., 1999).  These studies
also suffer from the inherent dependence on a transfected cell line to present the ligand.
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Varnum-Finney and colleagues have utilized another approach in C2C12 cells, namely
ligand immobilization (onto polystyrene), and have elegantly demonstrated Notch
signaling and myotube inhibition only when Notch ligand Delta 1 is immobilized.
Significant reduction of a selected myotube marker (myosin) could be observed in these
studies with 1 µg/ml of adsorbed Delta 1 after 2-3 days of differentiation (Varnum-
Finney et al., 2000).
DLL4 is a member of the Delta family of Notch ligands and has been extensively
studied in T cell and vasculature applications.  To demonstrate effective Notch signaling,
studies were first conducted with increasing amounts of plate adsorbed Notch ligand and
C2C12 differentiation was monitored.  These studies indicated myotube inhibition after
5-6 days with 1 µg/ml of Delta 4, which is consistent to previous plate adsorbed Delta 1
studies (Varnum-Finney et al., 2000).    Immobilization of Notch ligand Delta 1 has been
shown to be necessary for myotube inhibition while non-immobilized forms thwarted
Notch activation.  We conducted a similar assay here where Delta 4 was cultured with
C2C12 cells at a concentration of 1 µg/ml in both the immobilized and soluble forms and
myotube inhibition studied.  Our results were consistent with Delta 1 studies and
demonstrated myotube inhibition with soluble forms of Delta 4.  Additional studies were
also performed to confirm that the myotube inhibition was in fact a result of the Delta 4
ligand and not any other component of the functionalization scheme.  Myotube inhibition
was only observed in wells where DLL4 was immobilized, implying no inhibitive effect
of streptavidin or biotinylated anti-6x HIS antibody.   Finally, to verify whether DLL4
functionalized microbeads can effectively provide Notch signaling, we performed the
myotube inhibition assay described above.  DLL4 functionalized or unmodified beads at
various bead to cell ratios were used.  We demonstrated that a bead to cell ratio of 1:1
was sufficient to inhibit myotube formation.  Although some myotube-like structures
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were still evident, the tubes appear to be significantly smaller and less structured
compared to cells cultured with uncoated beads, demonstrating myotube inhibition.
These studies were performed with Notch ligand functionalized Biotin Binder Kit
microbeads, which have been established as having low stability (Chapter 3).  Thus, these
results seem counterintuitive.  We speculate the clustering or aggregation of released
DLL4 may lead to the activation of Notch receptors. These results suggest the Notch
ligand functionalized microbeads can provide Notch signaling to myoblasts as evident on
a phenotypic level.
As described earlier, Notch ligand-receptor binding induces several cleavages of
the Notch receptor, one of which results in the release and translocation of intracellular
Notch (responsible for activating Notch target genes).  Prior to bead addition,
intracellular staining revealed basal levels of Notch signaling in both myoblasts and R1
embryonic stem cells.  This result is echoed in studies by Delgado et al where the
induction of Notch1 and Notch3 were found in differentiating C2C12 myoblasts,
suggesting the induction of the Notch pathway (Delgado et al., 2003).    Other studies
have indicated the presence of Notch ligands, such as Jagged 1, Jagged 2, Delta 1 and
Delta 3 ligands in undifferentiated embryonic stem cells suggesting the induction of
Notch signaling from cell-cell contact.  Despite the basal levels of Notch signaling,
myoblasts were stained for intracellular Notch after the addition of varying levels of
Notch ligand functionalized beads.  Our results indicated no difference in fluorescence
levels when comparing conditions with and without Notch beads.  We believe that the
high background may have masked the differences, if any, in the conditions.  Also, the
Notch activation complex is degraded rapidly, further complicating the measurement of
intracellular Notch signaling (Maillard et al., 2005).  Both Biotin Binder Kit and
Proactive® beads gave similar results in ICN staining studies.
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Next, we examined the upregulation of Notch target genes using RT-PCR analysis
in R1 embryonic stem cells and C2C12 myoblasts.  HES1, HERP2 (HEY1) and NRARP
are all established Notch target genes in embryonic stem cells (Nemir et al., 2006,
Schmitt et al., 2004).  In our studies, basal levels of Notch target gene HES1 could still be
observed in undifferentiated embryonic stem cells after one week of culture
demonstrating the expression of Notch ligands and cell-cell contact.  These results
confirm the observed ICN staining results.  Nemir and colleagues found similar results
with HES1 and HERP2 expression in both 6 day and differentiated embryoid bodies
(Nemir et al., 2006).  Furthermore, no difference in Notch target gene expression between
uncoated and Notch functionalized beads was observed in studies assessing the effects of
Notch functionalized bead to cell ratio (Biotin Binder Kit), implying the high signaling
strength of cell surface Notch ligands.  In C2C12 myoblasts, however, Notch target gene
upregulation was observed.  Both Biotin Binder Kit and Proactive® beads were used for
these studies.  Both HES1 and HERP2 have been readily used as Notch target genes for
the myoblast system, although studies suggest stronger (6-fold) and longer lasting
induction for HERP2 in C2C12 cells upon coculture with Delta 1 expressing cells (Iso et
al., 2001).  Notch ligand functionalized Biotin Binder Kit microbeads were incubated
with myoblasts for two and six days before RNA isolation and subsequent gene analysis.
Both timepoints indicated a marked induction in HES1 gene expression for the low bead
to cell ratio, 0.1:1, nearly 5-fold for the real-time RTPCR analysis.  Several studies have
shown similar results.  Dallas and colleagues indicated a 1.4-fold increase in HES1
expression at 2.5 µg/ml and 2.6-fold increase in HES1 expression at 10 µg/ml of
immobilized Delta 1 ligand concentrations in murine lin-sca-1+cKit+ progenitors (Dallas
et al., 2005).  In human CD34+CD38- precursors, studies demonstrated a range of 2.5-
fold to 10-fold increase in HES1 expression for immobilized Delta 1 concentrations
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varying from 1.25 µg/ml to 5 µg/ml (Delaney et al., 2005; Ohishi et al., 2002).  In
addition, the fold difference is on the same scale as the nearly 6-fold increase in
luciferase activity for HES1 in U20S fibroblast cell line for 10 µg/ml immobilized Delta
1 (Varnum-Finney et al., 2000). Also, the 6-day timepoint results indicate a sustained
response to the Notch functionalized beads.  Addition of Notch ligand functionalized
Proactive® beads at a bead to cell ratio of 0.5:1 with medium ligand density also resulted
in a 3-fold increase of HERP2 expression for myoblasts, after 4 hr of incubation.  For
both beads, higher bead to cell ratios were used but did not result in an observable
induction of Notch target genes.  This most likely is a result of the inherent limitation of
the bead system, bead aggregation.  Notch functionalized and uncoated beads alike
aggregate at high bead to cell ratios, resulting in lower effective Notch ligand
presentation.  At low bead to cell ratios, however, aggregation does not occur, displaying
the predicted amount of Notch ligand on bead surfaces to the cells (not taking into
account any stability problems).
Finally, we conducted another assay at the molecular level where CBF1 promoter
activity was monitored using CBF1-luciferase reporter system.  Biotin Binder Kit beads
and Proactive® beads were both used for this assay.  Addition of Notch ligand
functionalized Biotin Binder Kit beads resulted in a statistically significant difference
when comparing both Notch ligand functionalized and anti-6x HIS antibody coated beads
at both 1:1 and 5:1 bead to cell ratios.  Differences between Notch beads with cells,
however, were not statistically significant, perhaps due to the stability issues of the beads.
Notch ligand functionalized Proactive® beads, however, demonstrated a marked
induction of luciferase activity when comparing coated and uncoated beads and coated
beads with cells.  For these studies, we immobilized three different densities of Notch
ligand onto the surface of beads and incubated transfected myoblasts with varying ratios
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of all three bead types (with anti-6x HIS antibody coated beads and cells).  Although no
clear trend could be observed in varying bead to cell ratio, a statistically significant
difference was found for the highest ligand density when comparing both cells and anti-
6x HIS antibody coated beads (to Notch functionalized beads).  Our results indicated a
2.35 fold increase in luciferase activity when comparing the highest ligand density with
largest bead to cell ratio to luciferase activity from cells.  These results are comparable to
CBF-1 activation studies in epithelial stem cells with immobilized Jagged 1 ligand.
Beckstead and colleagues indicated a 10-15 fold increase in luciferase activity (using a
CBF-1 reporter) when culturing epithelial cells with 1 and 10 nM concentrations of
Jagged 1 (Beckstead et al., 2006).  It is difficult to directly compare our results to other
systems due to the aggregation of beads and any differences in signaling due to the bead
design (as opposed to immobilized protein, namely differences in ability to cluster Notch
receptors).  Requirement of the high ligand density observed in our beads can be
attributed to increased ability to cluster Notch receptor and thus, result in Notch receptor
activation.
In this study, we have successfully illustrated the biological activity of a novel
Notch ligand functionalized microbead through the inhibition of C2C12 differentiation,
expression of Notch target genes, and upregulation of CBF1 activity.  Our results suggest
low bead to cell ratios and high DLL4 ligand densities to be the most effective in
inducing Notch signaling for the myoblast system most likely due to the lack of bead
aggregation and high Notch receptor clustering.  These results suggest a threshold
response for Notch signaling in myoblasts and require future studies for understanding
the ligand density dependent behavior.
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Table 4.1 Student’s t test analysis of differences among bead to cell ratios for varying




Low 200 ng DLL4/million beads
0.5:1 <0.05 >0.05 >0.05
1:1 ----- <0.05 <0.05
2:1 ----- ----- >0.05
Medium 600 ng DLL4/million beads 
0.5:1 >0.05 >0.05 >0.05
1:1 ----- >0.05 >0.05
2:1 ----- ----- >0.05
High 2000 ng DLL4/million beads
0.5:1 >0.05 >0.05 >0.05
1:1 ----- >0.05 >0.05
2:1 ----- ----- <0.05
Anti-6x HIS antibody beads
0.5:1 >0.05 >0.05 <0.05
1:1 ----- >0.05 >0.05
2:1 ----- ----- >0.05
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Table 4.2 Student’s t test analysis of differences between varying DLL4 density
coated Proactive® beads, anti-6x HIS antibody coated beads and cells for
luciferase reporter assay
________________________________________________________________________
    Anti-6x HIS antibody bead to cell ratios
0.5:1 1:1 2:1 5:1 Cells
________________________________________________________________________
Low 200 ng DLL4/
million beads
0.5:1 >0.05 ----- ----- ----- n/a
1:1 ----- 0.080 ----- ----- 0.070
2:1 ----- ----- n/a ----- n/a
5:1 ----- ----- ----- n/a n/a
Medium 600 ng DLL4/
million beads 
0.5:1 <0.05 ----- ----- ----- <0.05
1:1 ----- >0.05 ----- ----- >0.05
2:1 ----- ----- >0.05 ----- >0.05
5:1 ----- ----- ----- >0.05 >0.05
High 2000 ng DLL4/
million beads
0.5:1 <0.05 ----- ----- ----- <0.05
1:1 ----- <0.05 ----- ----- <0.05
2:1 ----- ----- 0.063 ----- <0.05
5:1 ----- ----- ----- <0.05 <0.05
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Table 4.3 Fold differences in luciferase activity between high DLL4 density coated
Proactive® beads, anti-6x HIS antibody coated beads and cells
_______________________________________________________________
     High 2000 ng DLL4/million bead to cell ratios
0.5:1 1:1 2:1 5:1
_______________________________________________________________
Anti-6x HIS beads 1.69 1.66 1.30 1.64
Cells 1.90 2.06 1.84 2.35
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Figure 4.1 Summary of Notch signaling assays utilized in the study.  (1) Image
acquisition was used to assess qualitative differences in cell morphology
using the classic myotube inhibition assay.  (2) Differences in fluorescence
representing intracellular Notch were assessed through fluorescence
microscopy and flow cytometry analysis.  (3) Notch target gene expression
levels were used to demonstrate Notch signaling in a more sensitive manner.
(4) Quantitative differences in CBF1 promoter activity as indicated by the































Figure 4.2 Surface immobilization of DLL4 inhibits myotube formation in C2C12
cells. Myotube formation is inhibited in the presence of immobilized DLL4.
10x objective phase contrast images were taken on Day 6 with (a) 0 µg/ml
DLL4 (b) 1µg/ml DLL4 (c) 1.5 µg/ml DLL4.  Polystyrene 96 well plates
were coated with ligand for 3 hours at 37°C and washed subsequently with
PBS to remove unattached ligand.  C2C12 cells were seeded and incubated





Figure 4.3 Myotube formation is inhibited in the presence of immobilized DLL4.   10x
objective phase contrast images were taken on Day 6 with (a) no DLL4 (b)
soluble 1 µg/ml DLL4 (c) immobilized 1 µg/ml DLL4.  Polystyrene 96 well
plates were coated with ligand for 2 hours at 37°C and washed subsequently
with PBS to remove unattached ligand.  C2C12 cells were seeded and
incubated for 6 days before image acquisition.





Figure 4.4 Neutravidin and biotinylated anti-6x HIS antibody immobilization do not
affect myotube inhibtion.  10x objective phase contrast images were taken
on Day 6 with (a) cells only (b) 2 µg/ml immobilized neutravidin (c) 2
µg/ml immobilized biotinylated anti-6x HIS antibody DLL4 (d) 2 µg/ml
immobilized DLL4 (e) 2 µg/ml immobilized neutravidin-biotinylated anti6x
HIS antibody-histidine tagged DLL4.  For neutravidin-biotinylated anti-6x
HIS-DLL4 condition, wells were blocked with 1% BSA at 37°C following
the antibody incubation. C2C12 cells were seeded and incubated for 6 days
before image acquisition.  Red arrows indicate myotube formation.
               




Figure 4.5 DLL4 functionalized microbeads induce Notch signaling in C2C12 cells.
Myotube formation is inhibited in the presence of DLL4 coated microbeads.
20x objective phase contrast images were taken on Day 6 with (a) 1:1
uncoated bead to cell ratio (b) 5:1 uncoated bead to cell ratio (c) 1:1 DLL4
coated bead to cell ratio (d) 5:1 DLL4 coated bead to cell ratio
(a) (b) (c) (d)
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Figure 4.6 Basal levels of Notch signaling in C2C12 myoblasts.  C2C12 myoblasts
were seeded at 75000 cells/poly-l-lysine coated coverslips one day prior to
staining.  Cells were then fixed, permeabilized and stained with anti-
human/mouse ICN antibody with a FITC conjugated secondary antibody
and DAPI to show nucleus. Myoblasts are shown below under (A) phase
contrast microscopy and (B) fluorescence microscopy.  Myoblasts stained
with secondary antibody only are also shown under (C) phase contrast
microscopy and (D) fluorescence microscopy. SK-N-MC neuroepithelioma
cells are known to always express intracellular Notch.  These cells were also
prepared as described above and are shown below under (E) phase contrast









Figure 4.7 Basal levels of Notch signaling in R1 embryonic stem cells.  R1 cells were
seeded at 20000 cells/poly-l-lysine coated coverslips two days prior to
staining.  Cells were then fixed, permeabilized and stained with anti
human/mouse ICN antibody with a FITC conjugated secondary antibody
and DAPI to show nucleus.  R1 cells are shown below under (A) phase
contrast microscopy and (B) fluorescence microscopy.  Myoblasts stained
with secondary antibody only are also shown under (C) phase contrast
microscopy and (D) fluorescence microscopy. SK-N-MC neuroepithelioma
cells are known to always express intracellular Notch.  These cells were also
prepared as described above and are shown below under (E) phase contrast







Figure 4.8    Basal levels of Notch target gene expression in R1 ES cells evident after one
week of culture.  RNA was collected from different timepoints of R1 ESCs,
treated for DNA contamination and converted to cDNA.  2 µg of RNA used
for cDNA synthesis and RTPCR.  Primers for beta actin and HES1 were
used to determine levels of Notch signaling over time.  Gels were stained




D1       D3        D5      D7
128
Figure 4.9 Low bead to cell ratios increase Notch target gene expression in C2C12
cells after 2 day incubation.  C2C12 cells were incubated with DLL4
functionalized microbeads and uncoated beads for 2 days before RNA
isolation and purification.  RNA was treated for DNA contamination,
converted to cDNA and used for real time RTPCR using gene specific
primers, HES1 and beta actin.  Values represent an average of at least an













































Figure 4.10 Low DLL4 functionalized bead to cell ratios result in HES1 gene expression
in Day 6 myoblasts.   DLL4 functionalized microbeads were added at
varying ratios to C2C12 myoblasts (seeded at 100000 cells/well).  RNA was
collected after 6 days of incubation, treated for DNA contamination and
converted to cDNA.  Primers for beta actin and HES1 were used to
determine levels of Notch signaling over time using RTPCR analysis.  Gels
were stained with ethidium bromide before imaging.   The study was










Figure 4.11 Proactive® beads functionalized with DLL4 upregulate Notch gene
expression in C2C12 cells after 4 hr of incubation.  C2C12 cells were
incubated with DLL4 functionalized microbeads and uncoated beads with
0.5 to 1 bead to cell ratio for 4 hr before RNA isolation and purification.
RNA was treated for DNA contamination, converted to cDNA and used
for real time RTPCR using gene specific primers, HERP2, HES1 and beta
actin.  Values represent an average of at least an n=3 and were
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Figure 4.12 DLL4 functionalized Biotin Binder Kit beads result in increased luciferase
gene activation in C2C12 myoblasts.  C2C12 cells were seeded one day
prior to transfection at 100000 cells/well.  Cells were then transfected with
4xwtCBF1Luc plasmid and 1 µg/ml using Exgen 500 as per manufacturer’s
instructions.  Beads were functionalized with 100 ng of anti-6x HIS
antibody and 1 µg of DLL4 per 10 million beads and added to cells after 24
hr of transfection.  Luciferase activity was assessed after 24 hr and corrected
to protein concentration using BCA assay.  Data represents averages of an
n=3 with data bars representing standard error.  Cells without beads had an





























Figure 4.13 DLL4 functionalized Proactive® beads result in increased luciferase gene
activation in C2C12 myoblasts.  C2C12 cells were seeded one day prior to
transfection at 100000 cells/well.  Cells were then transfected with
4xwtCBF1Luc plasmid and 1 µg/ml using Exgen 500 as per manufacturer’s
instructions.  Beads were functionalized with predefined amounts of anti-6x
HIS antibody and indicated values of DLL4 per 10 million beads at varying
ratios and added to cells after 24 hr of transfection.  Luciferase activity was
assessed after 24 hr and corrected to protein concentration using BCA assay.
Data represents averages of an n=3 with data bars representing standard
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T Cell Differentiation Using Notch Ligand Functionalized Beads
5.1 INTRODUCTION
T-cell development is comprised of a series of complex interactions that take
place both in the bone marrow and thymus and ultimately results in the formation of
CD4+ and CD8+ T cells that are capable of recognizing MHC class II or class I
molecules respectively, informing the immune system of extracellular or intracellular
infections. Hematopoietic progenitors migrate to the thymus, via the blood and undergo
dif-ferentiation into T cells through specific and complex microenvironmental signaling.
The expression of ligands and molecules in the thymic microenvironment are directly
responsible for the proliferation, adhesion, migration, and selection that these progenitors
undergo during T-cell maturation (Anderson et al., 2000; Germain 2002; Goldsby 2003)
Several of the signals necessary for thymocyte development and survival, including
Notch signaling and MHC-TCR interactions, have been characterized through
overexpression, gain-of-function, loss-of-function, and transfection studies (Germain
2002; Maillard et al., 2005).
Notch signaling is known to be well conserved throughout evolutionary
development in a variety of organisms. The role of Notch signaling in the regulation of
differentiation and self-renewal in systems, such as hematopoiesis and myogenesis, has
also been well characterized (Germain 2002; Han et al., 2000; Karanu et al., 2000;
Maillard et al., 2005; Parreira et al. 2003; Radtke et al. 2004; Karanu et al., 2000; Tan-
Pertel et al., 2000; Varnum-Finney et al., 2003).  Specifically in T-cell lymphopoiesis,
Notch signaling has been shown to be a necessary criterion. In the absence of Notch
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signaling, lymphopoiesis only occurs along the B cell lineage while the presence of
Notch ligands on the surface of stromal cells provide signals necessary for T-cell
generation (Parreira et al. 2003, Radtke et al. 2004).   Notch receptors and the Delta and
Jagged families of Notch ligands are tightly regulated in their expression both in the bone
marrow and thymus to achieve a unique balance of lymphocyte development (Maillard et
al. 2005; Parreira et al. 2003; Radtke et al. 2004).  The expression of all four receptors by
the developing thymocytes and the supportive thymic stroma has been previously
characterized while expression of Notch ligands, Delta-like ligands 1 and 4 (DLL1 and
DLL4), has been shown to occur in the thymic stroma (Parreira et al. 2003).  However,
studies assessing the importance of cell–ligand ratio as well as duration of ligand
presentation have not been explored in detail.
Our ultimate goal is to develop functionalized biomaterials and synthetic
microenvironments to efficiently generate T cells from hematopoietic stem cells (HSCs).
Eventually, this could lead to the production of CD4+ and CD8+ cells that could be used
for therapeutic purposes. Current systems to generate T cells in vitro have largely relied
on coculture of stem cells with either fetal thymus isolated from mouse (fetal thymic
organ culture, FTOC) or more recently with bone marrow derived stromal cells (OP9
cells) retro-virally transfected with the Delta and Jagged families of Notch ligands
(Dallas et al. 2005; Hozumi et al. 2003; Hozumi et al. 2004; La Motte-Mohs et al. 2005;
Lehar et al. 2005; Schmitt et al. 2002; Schmitt et al. 2004a). These systems, although
effective, are complex, require genetic manipulation of stromal cells and most
importantly do not allow quantitative analysis of the effects of ligand to stem cell ratio or
the duration of Notch signaling on T-cell differentiation. Tissue engineering of T cells
from progenitor populations in a high-throughput and efficient manner could benefit from
synthetic approaches involving biomaterial-directed Notch ligand presentation.
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Here, we report a synthetic Notch signaling system using ligand-functionalized
magnetic microbeads (artificial stromal cells) that can be used to evaluate how Notch
ligands, specifically DLL4, presented through a biomaterial surface affect T-cell
differentiation and to eventually develop a high throughput strategy to engineer T cells
from hematopoietic progenitor populations. We functionalized microbeads with DLL4
using biotin-streptavidin chemistry and antigen–antibody coupling and demonstrated
their functionality through T-cell commitment studies. Flow cytometry analysis showed
that Notch ligand functionalized beads are sufficient to commit bone marrow
hematopoietic stem cells (BMHSCs) to the T-cell lineage using the OP9 coculture
system. We additionally found that stem cell–stromal cell contact is not a necessary event
for T-cell commitment with DLL4 based Notch signaling. Such a bead-based artificial
signaling system could allow us to quantitatively study the effects of ligand density and
signaling duration thereby providing further insights into the individual roles of the Delta
and Jagged families of Notch ligands in T-cell differentiation and ultimately aid in the
development of efficient technologies for the production of T cells for therapeutic
applications.
5.2 MATERIALS AND METHODS
5.2.1 Conjugation of Notch ligand DLL4 to microbeads
The Notch ligand delta-like ligand 4 (DLL4) was conjugated to magnetic
microbeads using previously published methods for microbead functionalization (Maus et
al., 2003; Trickett et al., 2002; Trickett et al., 2003).  Briefly, biotinylated antibodies
specific for a histidine tag on recombinant DLL4 were bound to streptavidin-coated
superparamagnetic polystyrene microbeads. Biotin Binder Kit microbeads (Dynalbiotech,
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Brown Deer, WI) were washed and incubated with anti-6x HIS tag antibody (R&D
Systems, Minneapolis, MN) at 1 µg/mL for 30 min at room temperature. After
incubation, beads were again washed and further incubated with the HIS-tagged DLL4
protein (R&D Systems, Minneapolis, MN) at 2–4 µg/mL for 30 min at room temperature.
Beads were washed and stored at 4-8ºC for future use.
5.2.2 Bone marrow hematopoietic stem cell isolation and culture for in vitro T-cell
development
Stem cells were cultured with DLL4 functionalized microbeads, unmodified OP9
cells and exogenously added growth factors similar to methods described by Hozumi et al
(Hozumi et al., 2003). OP9 cells (kind gift from Tammy Reid, Toronto, Canada) were
maintained in 20% FBS (Hyclone, Logan, UT), 2.2 g/L sodium bicarbonate (Invitrogen,
Carlsbad, CA) and "MEM (Invitrogen, Carlsbad, CA). They were seeded at the
appropriate cell density in 24-well plates 1 day before stem cell seeding to achieve 60%
confluency.  BMHSCs were isolated from 5-week-old female C57BL/6 mice (Jackson
Laboratory, Bar Harbor, Maine), using standard femur removal protocols. Lin-ckit+sca-
1+ HSCs were isolated using magnetic separation (Miltenyi Biotec, Auburn, CA and
Dynal-biotech Brown Deer, WI) and seeded at a density of 2000 cells per well either
directly on top of the OP9 cell layer (mixed coculture) or in Transwell™ permeable
inserts (Corning, Acton, MA) (insert coculture) to assess if stem cell–stromal cell
physical contact is absolutely necessary for T-cell generation or whether paracrine
signaling is sufficient. Stem-cell factor (SCF) (Peprotech, Rocky Hill, NJ) and
interleukin-7 (IL-7) (Peprotech, Rocky Hill, NJ) were added to the culture at 50 and 10
ng/mL, respectively. DLL4 functionalized or nonfunctionalized Biotin Binder Kit beads
(Dynalbiotech, Brown Deer, WI) were added at defined concentrations to sample and
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control wells, respectively. For the mixed coculture condition, cells were disrupted on
Day 4 and single cell suspensions were filtered through a 40µm filter to remove OP9
cells, which generally form aggregates. Cell suspensions were again seeded on fresh
monolayers of OP9 cells for continued culture.  Beads, growth factors, and medium were
replenished. For insert culture, Transwell™ inserts were removed on Day 4 and placed in
wells containing fresh OP9 monolayers and replenished with beads, growth factors, and
medium. On Day 8, cells were trypsinized and separated from beads using DNAse (the
streptavidin on these beads are conjugated using a DNA linker) as per manufacturer’s
protocol (Dynalbiotech, Brown Deer, WI).
5.2.3 Flow cytometry
Flow cytometry was performed similar to methods described in Liu et al (Liu and
Roy 2005). Cells were washed in FACS buffer (1% bovine serum albumin (Sigma-
Aldrich, St. Louis, MO) and 0.05% sodium azide (Sigma-Aldrich, St. Louis, MO)) in
PBS twice before staining and blocked for nonspecific binding using anti-mouse
CD16/CD32 Fc Block (BD Pharmingen, San Diego, CA) for 10 min at 4-8°C. Staining
with antibodies against stage specific T-cell markers was performed at concentrations of
1 µg/100mL of FACS buffer and washed before staining with secondary fluorescently
labeled antibodies, if necessary. Isotype controls (eBioscience, San Diego, CA) were
used as negative controls. All cells were washed in FACS buffer twice and suspended in
fresh buffer for analysis. FACSCalibur (Becton Dickinson, San Diego, CA) and
CellQuest 3.1 software (BD Biosciences, San Jose, CA) were used for data acquisition
and analysis. The following antibodies and fluorochromes were used to assess stage-
specific T-cell development from BMHSCs: biotinylated CD19 (Sigma-Aldrich, St.
Louis, MO), Thy1.2-FITC, and streptavidin-PE. CD19 is a B-cell specific surface marker
143
while Thy1.2 has been extensively used as an early T-cell marker in differentiation
studies (Hozumi et al., 2003; Hozumi et al., 2004; Schmitt et al., 2002; Schmitt et al.,
2004a). All antibodies were obtained from BD Pharmingen (San Diego, CA) or
eBioscience (San Diego, CA) unless otherwise noted.
5.3 RESULTS
5.3.1 DLL4 functionalized microbeads direct BMHSCs to T-cell lineage in OP9 co-
culture systems
To demonstrate the functionality of the DLL4 functionalized microbeads, we
added these beads to the well-established OP9 coculture system and examined the effect
on T-cell differentiation. The OP9 coculture system has been widely used for lymphoid
differentiation applications due to the secretion of lymphoid specific growth factors from
OP9 stromal cells (Ciofani et al., 2004; De Smedt et al., 2004; Hozumi et al., 2003;
Hozumi et al., 2004; Lehar et al., 2005; Nakano et al., 1994; Nakano 1995; Schmitt et al.,
2002; Schmitt et al., 2004a; Schmitt et al., 2004b). However coculture of stem cells with
OP9 cells without the presence of any notch signaling exclusively generates B cells.
Recently, several groups have transfected both the original stem cell source and
supportive OP9 cells with various Notch ligands and observed the emergence of cells of
the T-cell lineage (De Smedt et al., 2004; Hozumi et al., 2003; Hozumi et al., 2004; Lehar
et al., 2005; Schmitt et al., 2002; Schmitt et al., 2004a; Schmitt et al., 2004b). We added
the DLL4 functionalized microbeads to the OP9 coculture system and analyzed the
cultures for the expression of B and T-cell specific surface markers, CD19 and Thy1.2,
respectively. We also examined the effect of cell–cell contact on T-cell differentiation
using the microbead and OP9 system. Transwell™ permeable inserts were used to
prevent cell–cell contact with the supportive OP9 layer on the culture well and BMHSCs
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on insert. Insert culture was compared to conditions where the BMHSCs were seeded
directly on the OP9 monolayer. Bead-to-cell ratio of 1:1 was used for both conditions and
streptavidin-coated beads were used as negative controls. Cultures with DLL4
functionalized beads gave rise to both Thy1.2+ cells and CD19+ cells while streptavidin-
coated bead culture resulted in CD19+ cells only. This held true for both insert and
coculture conditions. In comparison to coculture conditions, there was a larger percentage
of Thy1.2+ cells in insert culture conditions, 59.7% vs. 33.4% (Figure 5.1).  In both
insert and coculture systems, functionalized bead conditions resulted in the commitment
of both T and B cells. The sizable B-cell population is most likely due to the nonuniform
distribution of the functionalized beads and the inability of some BMHSCs to “see” the
Notch signal. B-cell differentiation efficiencies using streptavidin-coated control beads
(no DLL4 on surface) was comparable for both insert and coculture conditions, 79.9% vs.
73.8%, respectively. During the 1 week differentiation process, the original stem-cell
population underwent a proliferation of at least 2.0-fold for all conditions (data not
shown).
5.3.2 Defined ratios of DLL4 functionalized microbeads can be used for T-cell
differentiation
To further investigate the quantitative effects of the DLL4 Notch ligand on T-cell
commitment, we added the DLL4 functionalized microbeads at various concentrations
(1:1 and 5:1 bead-to-cell ratio) and observed the lymphocyte specific marker expression
after 1 week of culture, similar to the procedure outlined earlier. DLL4 functionalized
beads, at a 1:1 bead-to-cell ratio, resulted in a significant amount of Thy1.2 expression
while a bead-to-cell ratio of 5:1 gave rise to little if any Thy1.2 expression (Figure 5.2).
Low T-cell differentiation efficiencies observed in the 5:1 functionalized bead-to-cell
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ratio condition may be a result of the high bead concentration in culture. It is likely that
the beads have an inhibitory effect on proliferation of progenitors at high densities.
5.4 DISCUSSION
Recent studies have indicated a significant role for the Notch ligand DLL4 in T-
cell commitment and development. Hozumi et al. demonstrated the presence of Thy1.2+
cells from fetal liver hematopoietic progenitors using OP9 cells stably transfected to
express DLL4 (Hozumi et al., 2004). These differentiated cells were also shown to
undergo VDJ recombination and express CD25 and/or CD44, indicating the maturation to
the double negative 3 (DN3) stage of T-cell development.  Freitas et al. conducted a
recent study where the overexpression of DLL1 or DLL4 in hematopoietic cells was
shown to result in the induction of mature single positive (SP) T cells in athymic mice (de
La Coste et al., 2005; de La Coste et al., 2006; Hozumi et al., 2004). These studies,
however, involve mixed coculture with genetically modified cells and hence suffer from
two fundamental drawbacks: (a) it is difficult to quantitatively study the effects of
ligand–cell ratio and ligand interaction duration and (b) ultimately high throughput scale
up of such mixed coculture process for large scale production of therapeutic cells from
stem cells would be challenging.
The efficient generation of T cells has been achieved through several stem cell-
stroma based coculture systems (La Motte-Mohs et al., 2005; Lehar et al., 2005;
Poznansky et al., 2000; Schmitt et al., 2004). However, limited studies have been
reported in generating T cells using biomaterial-based concepts. Poznansky et al. utilized
tantalum-coated matrices seeded with mouse thymic stroma to provide the necessary
molecular cues to commit human hematopoietic stem cells to the T-cell lineage
(Poznansky et al., 2000). Despite the high efficiency of CD3+ T-cell generation, the
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inherent design of this system hinders the isolation of a pure population of T cells,
making the large scale generation of T cells difficult.
The OP9-DLL1 Notch signaling, first reported by Zuniga-Pflucker and colleagues
also utilizes a mixed coculture based design to provide direct cell–cell signaling
necessary to commit stem cells to the T-cell lineage (Zuniga-Pflucker 2004). One
fundamental limitation of this system, however, is the dependence of OP9 based systems
on transfected cells for Notch signaling. The transfection of stroma cells for different
Notch ligands can become cumbersome and interfere with normal genetic expression of
the OP9 cell (Lehar et al., 2005).  In addition, the inherent design of the current coculture
system makes large-scale T-cell generation difficult, specifically for 3D studies in
biomimetic environments. Our design addresses the abovementioned limitations by (a)
providing Notch signals through immobilization of DLL4 on microbeads (artificial
stromal cells) thereby creating a highly controllable, predesigned thymic
microenvironment and (b) by physically separating the OP9 cells from the stem-cell
population during differentiation, which enable us to obtain a purer population of T cells.
The magnetic nature of the bead also facilitates the retrieval of T cells eliminating the
difficulties involved with obtaining a pure population.
In this study, we have shown that microbeads functionalized with the Notch
ligand DLL4 can be used as artificial stromal cells to trigger Notch signaling in
myoblasts and commit BMHSCs to the T-cell lineage in both coculture and insert culture
systems in a quantitative manner. This study is one of the first to investigate the role of
DLL4 in T-cell differentiation using a synthetic, biomaterial-based signaling system. The
results demonstrate the promise of a bead-based system in studying the roles of Notch
ligands in lymphocyte development and efficiently generating T cells from progenitor
cell population using functionalized biomaterials.
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 To demonstrate the functionality of the microbeads in lymphocyte development,
BMHSCs were cultured in the presence of functionalized beads and either physically
separated OP9 stromal cells (insert cultures) or mixed coculture conditions. Our results
indicate that functionalized beads induced a significant percentage of Thy1.2+ cells in
both cultures.  However, insert cultures appeared to generate a higher percentage of cells.
The reduced surface area in the Transwell™ inserts leads to higher stem cell–stem cell
interactions (for the same number of cells plated), which could be responsible for the
increased differentiation efficiency. CD19+ B cell differentiation efficiency was similar
among both insert and coculture conditions with or without functionalized beads. The
presence of some B cells in the Notch functionalized bead culture again indicates
nonuniform localization of the DLL4 beads in the wells. Still, the differentiation
efficiency of Thy1.2+ cells for at least the insert condition is comparable to the results
described by Hozumi et al., where the Notch ligand was provided by OP9 cells
transfected for DLL4 (Hozumi et al., 2004).
Finally, to investigate the quantitative effects of DLL4 on lymphocyte
development, bead-to-cell ratios of both 1:1 and 5:1 were added in the culture conditions.
We found that functionalized bead-to-cell ratios of 1:1 resulted in a significantly higher
Thy1.2+ cell differentiation efficiency than the 5:1 bead-to-cell ratio. The reduced
differentiation efficiency in the 5:1 functionalized bead-to-cell ratio may be attributed to
an inhibitory effect on progenitor proliferation, similar to what has been observed in T-
cell activation studies with anti-CD3/anti-CD28 microbeads (Ito et al., 2003). Future
studies are needed to elucidate the dose effects of the functionalized microbeads on
progenitor proliferation. The aggregation or uneven distribution of the functionalized
beads will also need to be prevented through studies where beads and cells are
preincubated for an optimal period of time, enabling beads to be prebound to cells before
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they are placed in culture. Finally, a more extensive immunophenotype analysis
examining the expression of T-cell markers such as CD25, CD44, CD3, CD4, CD8, and a
genetic analysis assessing the expression of T-cell specific genes such as CD3% and pre-
T" are necessary to confirm the emergence of T cells and demonstrate the level of
development.
In conclusion, we have established a synthetic biomaterial-based system that can
effectively trigger Notch signaling during lymphocyte development from bone marrow-
derived stem cells. The system offers the possibility of being quantitative and tunable,
enabling the optimization of T-cell generation. This system could further progress our
understanding of ex vivo T-cell generation and might allow us to eventually generate
functional T cells from stem cells using biomaterial-based approaches.
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Figure 5.1 Notch ligand-coated microbeads direct efficient commitment of ES cells to
T  cells in both insert and mixed coculture systems. Lin-cKit+sca-1+ HSCs
were cultured with DLL4 coated or uncoated beads in insert cultures and
mixed coculture conditions in the presence of IL-7 and SCF. Cells were
harvested and analyzed for CD19 and Thy1.2 expression using flow
cytometry.  Numbers in quadrants correspond to relative percentages of
cells. A) Comparison of Day 8 T-cell differentiation in insert culture from
lin-cKit+sca-1+ BMHSC with 1:1 bead-to-cell ratio using uncoated and
DLL4 coated beads. B) Representative flow cytometry dot plots of Day 8 T-
cell differentiation profiles in insert culture from lin-cKit+sca-1+ BMHSC
with 1:1 bead-to-cell ratio. C) Comparison of Day 8 T-cell differentiation in
mixed coculture from lin-cKit+sca-1+ BMHSC with 1:1 bead-to-cell ratio
using uncoated and DLL4 coated beads. D) Representative flow cytometry
dot plots of Day 8 T-cell differentiation profiles in mixed coculture from lin-
cKit+sca1+BMHSC with 1:1 bead-to-cell ratio from flow cytometry
analysis. All experiments were repeated twice. *indicates p < 0.05 compared
to DLL4 coated beads using a Student’s t test.
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Figure 5.2 Defined ratios of notch ligand-microbead can be used for T-cell
commitment. Lin-cKit+sca-1+ HSCs were cultured with DLL4 coated or
uncoated beads in insert cultures and mixed coculture conditions in the
presence of IL-7 and SCF. Cells were harvested and analyzed for CD19 and
Thy1.2 expression using flow cytometry. A) Comparison of Day 8 T-cell
differentiation in insert culture from lin- cKit+sca-1+ BMHSC with 1:1 and
5:1 bead-to-cell ratios. B) Representative flow cytometry dot plots of Day 8
T-cell differentiation profiles in insert culture from lin- cKit+sca-1+
BMHSC with 1:1 and 5:1 bead-to-cell ratio. Numbers in quadrants
correspond to relative percentages of cells. All experiments were repeated
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Conclusions and Future Directions
6.1 SUMMARY
In this study, we have designed and demonstrated a novel approach to ex vivo T
cell differentiation, the use of a Notch ligand functionalized microbead.  The process of
ligand functionalization onto the bead surface has been extensively characterized in terms
of bead concentration, incubation time and ligand concentration.  Additional studies have
demonstrated stability in buffers and serum-supplemented medium for beads without
DNA linkers.  Low cytotoxicity and ability to quantify ligand density on bead surface are
additional benefits of such a bead system.  We further demonstrated a dose-dependent
response in Notch signaling using qualitative and quantitative assays.  Finally, the Notch
ligand functionalized microbeads were successfully shown to differentiate hematopoietic
progenitors into committed T cell precursors.  These results demonstrate the immense
promise of such a biocompatible and quantifiable system that can be readily scaled up
and tailored to optimize Notch signaling and T cell differentiation efficiency.  Efforts in
optimizing scaffold parameters for hematopoietic differentiation also illustrate the ability
to tailor a microenvironment for high throughput production of hematopoietic
progenitors.
6.1.1 Conclusions and future directions on bead fabrication, characterization and
optimization studies
Chapter 3 results illustrate successful Notch ligand functionalization on magnetic
microbeads using an in depth optimization process.  Our goal in microbead design was to
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utilize a highly directional and robust binding scheme that could be both quantified and
tailored (in terms of surface ligand density) for Notch signaling applications and scaled
up for T cell differentiation studies. For these reasons, we chose commercially available
4.5 µm streptavidin coated super paramagnetic microbeads that were designed for bead-
cell separation.  Use of biotinylated anti-6x HIS antibody and histidine tagged DLL4
exploited the well-characterized and high strength streptavidin-biotin and antibody-
antigen interactions.  The original microbead design also included bead-cell separation
capability, namely the presence of a DNA linker that could be subsequently cleaved and
thus result in the removal of beads from cells with the addition of DNase.  Bead
characterization using immunofluorescence and flow cytometry analysis indicated a
saturation of bead surface well below theoretical values with optimum protein binding at
high bead concentration and low incubation times for both anti-6x HIS antibody and
histidine tagged DLL4.   Surface ligand density was also quantified and shown to be
modifiable for a wide range of protein concentrations.  Studies indicate rapid
immobilization of proteins for similar bead systems (Curtsinger et al., 1997).  Further
characterization studies involving stability in varying buffers at different temperatures,
however, revealed a severe constraint of the original design.  Little to no DLL4 could be
observed on the surface of the beads after only one hour at 37°C in serum-supplemented
or serum-free medium, despite the high binding strength of the streptavidin-biotin and
antibody-antigen bonds.  We hypothesized that the presence of the DNA linker enabled
rapid ligand removal at 37°C with the omnipresent nature of DNase.  Thus, our bead
design was refined to a simple streptavidin coated magnetic bead.  These beads gave far
superior stability in all buffers tested at both 4 and 37°C with no effect of the presence of
serum.  One concern, however, remains the nearly 50% reduction of the surface ligand
density in PBS at 4°C after just one day of incubation.  Future studies that characterize
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the stability of both the DLL4 ligand and the biotinylated antibody will enable a better
understanding of the total strength of the combined bonds.  Although the functionalized
beads are stored at conditions suggested by the manufacturer, it is also possible that the
PBS buffer is not ideal for storage of protein functionalized microbeads.  Additional
studies where various concentrations of BSA protein in PBS can be used for microbead
storage and tested for any improvement in bead stability.
Cytotoxicity results from week long bead-cell studies at various bead to cell ratios
indicated low cytotoxicity with some proliferative effects.  Cytotoxicity has been
observed for bead-cell studies in cells such as T cells and fibroblasts, however, seems to
be unique to cell type tested.  Also, length of incubation time has an effect on
cytotoxicity.  Longer incubation times for the cells tested may result in similar
observations.  Future studies should include high bead to cell ratios in different cell types
with longer incubation periods.  Incubation period is a particularly sensitive aspect for the
bead system due to the longer incubation times necessary for human T cell differentiation
applications.
Perhaps the most interesting and least characterized aspect of the system is the
intrinsic nature of magnetic beads and how it affects protein presentation.   During cell-
bead studies, bead aggregation at high densities and thus, lower effective ligand
presentation was observed for both uncoated and Notch functionalized beads alike
(presence of ligand did not affect aggregation degree).  Such aggregation might be
prevented with the addition of detergents such as Tween20 that prevent protein-protein
interactions.  Vortexing may decrease aggregation, as well.  Future studies exploring the
effects of Tween20 and vortexing on bead aggregation (and at the same time preserving
protein structure and function and not affecting cell viability) should be performed.
Aggregation may also be a result of the magnetic nature of the bead.  It may be likely that
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beads without magnetic particles aggregate to a lower degree.  Future studies with
nonmagnetic beads should be conducted to study the effect if any of magnetic particles in
bead aggregation.
Finally, how successful the presentation method, two proteins immobilized on
beads, is in being recognized and resulting in a signal deserves future studies and will be
a key player in determining the effectiveness of the system.  Several studies have alluded
to the importance of chain mobility in protein binding, most likely since this more closely
resembles the surface of a cell (Curtsinger et al., 1997; Maus et al., 2003).  Future studies
where a more direct scheme (directly conjugated DLL4 on bead surface) is used would
aid in the understanding of the beneficial effects, if any, of having a more mobile binding
scheme.  Also, chain length may play a role in cell-bead binding.  Further studies where
only DLL4 is functionalized on the bead surface can better explain the importance of
chain length.
6.1.2 Conclusions and future directions on qualitative and quantitative
characterization of dose-dependent Notch signaling
In Chapter 4, we performed a series of assays directed at characterizing the dose-
dependent effect, if any, of Notch functionalized microbeads.  We hypothesized that the
degree of Notch signaling could be adjusted by varying the amount of ligand density on
bead surfaces and/or amount of beads added to cells.  Several studies have reported a
dose-dependent effect of Notch signaling in terms of Notch target gene expression,
luciferase reporter activity, and immunophenotype analysis (Dallas et al., 2005; Delaney
et al., 2005; Ohishi et al., 2002; Schmitt et al., 2004).  More importantly, the degree of
Notch signaling has been shown to be instrumental in deciding the fate of developing
lymphocyte progenitors.  Studies have shown a Notch signaling threshold where lower
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amounts of Notch signaling enable B cell differentiation, medium amounts allow NK
cells, and high concentrations permit T cell differentiation (Dallas et al., 2005; Delaney et
al., 2005; Lehar and Bevan 2005; Ohishi et al., 2002; Schmitt et al., 2004).  The dose-
dependent quality of Notch signaling is thus, directly pertinent in differentiation
efficiency.  The myoblast system was used primarily due to ease and extensive
characterization in literature.  Qualitative studies where morphology was assessed (Notch
signaling inhibits myotube formation) confirmed Notch signaling due to bead.  Next,
more quantitative approaches, intracellular Notch signaling, RTPCR analysis and
luciferase reporter assay were all used to quantitatively characterize Notch signaling
efficiency at a more molecular level.  (Both beads were used for all assays except the
qualitative assay where only DNA linker beads were used.  Beads showed similar results
in all assays.) Intracellular Notch signaling studies showed basal levels of activated
Notch in both myoblasts and embryonic stem cells (which is confirmed in literature) and
did not seem to be sensitive enough to detect differences, if any, in the addition of Notch
functionalized beads (Iso et al., 2001, Nemir et al., 2006).  Gene expression analysis,
however, indicated some promising results for both bead types at early and late
timepoints in myoblasts.   The two day timepoint exhibited a 5 fold increase in HES1
gene expression for the DNA linker beads and a 3 fold increase in HERP2 gene
expression for Proactive® beads at bead to cell ratios of 0.1:1 and 0.5:1, respectively.
These results are on the same scale as similar studies monitoring Notch target gene
expression but with immobilized Notch ligands (Dallas et al., 2005; Delaney et al., 2005;
Varnum-Finney et al., 2000).  In these studies, high bead to cell ratios failed to increase
Notch target gene expression for both bead types.  CBF1 luciferase reporter assay showed
similar results for both bead types.  Only the Proactive® bead, however, produced
statistically significant differences at very high ligand densities between both Notch
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functionalized beads and anti-6x HIS antibody coated beads and Notch functionalized
beads and cells.
Several issues need to be further studied to better understand the RTPCR and
luciferase reporter results.  These results do indeed illustrate dose responsive behavior for
myoblasts.  Whether the ligand density or a quality of the bead system is activating the
Notch receptor needs to be further studied.  We have previously demonstrated the low
stability of the DNA linker beads from flow cytometry analysis.  If the DLL4 has been
cleaved from the surface of the beads but Notch activation has resulted, two scenarios
may have occurred.  In the first scenario, the cleaved DLL4 could have associated with
more DLL4, formed an aggregate and resulted in the clustering of Notch receptors and
Notch signaling.  Another possible option is that for the limited amount of time the ligand
remains functionalized, cells receive a signal which is sufficient to produce the results
shown using the quantitative assays.  Further studies testing the medium for the presence
of DLL4 and DLL4 aggregates and studies assessing the effect of incubation time on
gene expression and luciferase assays are necessary to better understand how the DNA
linker beads produced Notch signaling.  In addition, it is possible that the DLL4 is being
released from the Proactive® beads.  Another observation from the studies was the effect
of bead to cell ratio.  Results were generally poor in terms of gene expression and
luciferase expression for high bead to cell ratios.  Luciferase results, in fact, indicated
little to no statistical difference between bead to cell ratios for all densities tested.  These
results can be explained by the aggregation effect described in the previous section.
When aggregation takes place, the effective ligand density delivered is far less.  Future
studies preventing aggregation of beads and possibly distributing beads evenly on well
surfaces need to be performed to increase effective Notch ligand density that is in fact
being seen by cells.  Finally, if observed closely, intracellular Notch staining, gene
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expression analysis and luciferase reporter assay all indicate high basal levels of Notch
activity for myoblasts.  Other studies have similarly shown inherent Notch signaling in
myoblasts (Iso et al., 2005).  The myoblast system was chosen based on its ease and well-
established nature.  The system, however, does not seem ideal for our purposes.  An
available or transfected cell line where Notch receptors are present and Notch ligands are
not present, must be utilized to accurately assess the effect of the functionalized Notch
ligand beads.  This will eliminate any basal levels of Notch signaling due to cell-cell
contact.  Also, unless the functionalized beads can be evenly distributed to cover the
entire well surface, bead-cell contact cannot be guaranteed.
6.1.3 Conclusions and future directions on T cell differentiation using Notch
functionalized microbeads
In Chapter 5, we demonstrated successful T cell differentiation using the Notch
ligand functionalized microbeads in both insert and coculture conditions with optimal
results at a 1:1 bead to cell ratio.  The Delta 1 transfected OP9 stromal cell system of T
cell differentiation has been extensively used to demonstrate T cell commitment and
development using human and murine progenitors from sources such as cord blood and
bone marrow (de Pooter and Zuniga-Pflucker 2007; La Motte-Mohs et al., 2005; Schmitt
et al., 2004).  Immobilization of Notch ligand onto polystyrene coupled with supportive
stroma is another method that has demonstrated effective T cell commitment and
development in both murine and human progenitors (Dallas et al., 2005; Delaney et al.,
2005; Ohishi et al., 2002).  Our results perhaps most directly compare to studies
performed by Hozumi and colleagues where fetal liver progenitors were transfected with
intracellular Notch and incubated with supportive stroma (OP9) in both coculture and
insert conditions (Hozumi et al., 2003).  The differentiation efficiency for the insert
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culture is comparable to Hozumi and colleagues results.  The coculture differentiation
efficiency may be lower due to the aggregation of beads, decreased cell to surface area
ratio, decreased probability of bead-cell binding (with the addition of stroma present), as
compared to insert culture.  Further studies where higher cell numbers are utilized will
most likely result in greater differentiation efficiencies for coculture conditions.  When
bead to cell ratio was increased to 5 to 1, a lower differentiation efficiency resulted.  The
aggregation of beads could have decreased effective ligand presentation but the increased
bead number could have potentially become cytotoxic for cells.  Cytotoxicity assays
where effects of bead number on hematopoietic progenitors should be studied in the
future.  Something to note here is the fact that these studies were performed with DNA
linker beads which have been shown to have low stability.  Possible clustering of
antibodies from cleaved DLL4 ligand aggregates has been mentioned in the previous
section.  Lefort and colleagues demonstrated that a very short exposure time to
immobilized DLL4 is sufficient to commit human progenitors (Lefort et al., 2006).  This
result supports our findings.  Also, although studies have found that continued Notch
signaling is necessary for T cell differentiation in the thymus using OP9-DL1 cells, it is
not necessary that these results apply to DLL4.  Also, our level of assessment here is T
cell commitment which may require a different level of Notch signaling.  Future studies
testing the effect of incubation with DLL4 functionalized microbeads will help to clarify
the effects if any of incubation time.
6.1.4 Conclusions and future directions on scaffold properties and stromal cell
coculture effects on hematopoietic differentiation of embryonic stem cells
In Chapter 6, we have successfully shown that scaffold properties can be
optimized to induce increased hematopoietic differentiation efficiency of embryonic stem
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cells.  The ability to scale up the ex vivo production of hematopoietic progenitors for
stem cell transplantation and even T cell differentiation applications (would require use
of Notch ligands) is very beneficial and could potentially impact therapeutic applications.
Low levels of hematopoietic differentiation from ESCs have plagued the field, however,
prompting several studies in creative methods of improving differentiation efficiency
(Dang et al., 2002; Dang et al., 2004; Gerecht-Nir et al., 2004; Gerecht-Nir et al., 2004b;
Levenberg et al., 2003).  Use of rotating bioreactors, scaffolds with pore sizes ranging
from 50-500 µm, and use of capsules have all demonstrated improved differentiation and
reduced agglomeration (what is thought to decrease differentiation efficency) (Dang et
al., 2004; Gerecht-Nir et al., 2004; Gerecht-Nir et al., 2004b; Levenberg et al., 2003).
We hypothesized that reduction of pore size would increase HPC differentiation.
Immunophenotype analysis, where cell surface markers cKit and sca-1 were stained,
revealed increased HPC cell numbers for the reduced pore size.  Mechanical properties of
scaffolds were also tested and shown to increase differentiation efficiency with increased
elastic moduli.  Finally, stromal cell coculture was shown to have a beneficial effect on
differentiation efficiency, most likely due to secretion of supportive growth factors such
as IL-7 and SCF.  These results demonstrate that scaffold properties can be tailored to
optimize the differentiation efficiency of stem cells.  There are several concerns to be
discussed, however.  Scaffolds utilized in these studies consisted of poly lactic acid, a
synthetic polymer that does not exist in the physiological environment but does degrade
after time.  Use of such a non-natural polymer elicits some concern for the generation of
therapeutic cells.  Future studies where biological components already existent in the
bone marrow (site of hematopoiesis) could potentially give better differentiation
efficiencies.  Also, use of the scaffold platform can be problematic in cell retrieval and
viability.  Further studies improving cell retrieval and viability with gentler methods of
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cell removal should be performed.  And perhaps the greatest concern for such ex vivo
differentiation studies is the realistic therapeutic impact the cells can make.  Future
studies where HPCs are implanted into mice and tested for reconstitution would elucidate
the clinical application of such cells.  Additional studies where HPCs are differentiated
using established methods such as the OP9-DL1 cell line can also be conducted for
ability to differentiate into various lineages.
6.1.5 Project design considerations
As evident from the discussion above, the current microbead system has not been
fully characterized especially in terms of how it activates the Notch receptor.  We have
illustrated from characterization studies that varying ligand densities can be
functionalized on the surface of the beads.  We have also shown that the ligand stability
is a serious concern with the DNA linker beads.  Some amount of ligand release is also
taking place with the beads without a DNA linker.  How then Notch signaling is
occurring when it does needs to be more fully studied.  There are largely two possible
outcomes of Notch ligand-receptor binding: successful Notch ligand-receptor binding and
activation and Notch receptor engagement, resulting in the blocking of Notch signaling.
It is very likely that the released DLL4 ligands are engaging the receptor and therefore
preventing any subsequent Notch signaling from occurring (even with the addition of
newly fabricated ligand beads.).  Future studies are necessary to more closely examine
the binding and activation events taking place.
It may be most beneficial to go back to the drawing board, so to speak, and really
assess what the important properties of Notch ligand receptor binding are and how these
properties can be applied to the microbead system.  These properties have been
summarized in Figure 6.1.  For successful Notch ligand-receptor binding and thus Notch
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receptor activation to take place, a variety of factors must be considered.  The microbead
system gives us the ability to test and study the effect of these factors in a systematic and
quantitative manner.  The binding scheme should obviously be simple and effective in
functionalizing the ligand onto the receptor but should also be characterized in terms of
how it affects the ligand-receptor binding.  If, for example, a biotinylated DLL4 molecule
was bound to streptavidin coated microbead, would the multiple DLL4 molecules on
each streptavidin prevent the binding of any?  Next, the effect of chain length on ligand-
receptor binding should be characterized and considered.  Chain length or spacer length is
different from binding scheme.  The introduction of a linear spacer imparts distance to
the ligand from the microbead and can aid in the ligand-receptor binding.  This can
theroretically be another layer of control for the microbead system in terms of controlling
ligand-receptor binding.  Chain mobility is another important attribute of effective ligand-
receptor binding.  In the thymic microenvironment, for example, Notch receptors are
expressed on developing T cell progenitors and Notch ligands are expressed on thymic
stroma.  Some level of mobility is likely for the cell surface ligands due to membrane
diffusion and lateral mobility.  This mobility most likely plays a role in receptor binding,
potentially recruiting additional ligands or other molecules to increase the binding.
Finally, additional accessory molecules may aid in the ligand receptor binding and should
be explored with the microbead system.
The microbead system can be used not only as a technology for T cell production
but as a tool for studying the receptor-ligand binding and Notch signaling cascade.  By
exploiting the ability to control the properties given above, we can better understand the
Notch signaling process and perhaps extend the insights to other receptor-ligand binding
systems, as well.
166





Presence of accessory molecules
(ligands, chemokines, growth factors)
Effect of spacer => distance
necessary for optimal receptor-
ligand binding
Ligand mobility (can compare
bead system to ligand
transfected stroma)
Binding scheme and its effect




Curtsinger, J., Deeths, M.J., Pease, P., and Mescher, M.F. (1997). Artificial cell surface
constructs for studying receptor-ligand contributions to lymphocyte activation.
Journal of Immunological Methods 209, 47-57.
Dallas, M.H., Varnum-Finney, B., Delaney, C., Kato, K., and Bernstein, I.D.  (2005).
Density of the Notch ligand Delta1 determines generation of B and T cell
precursors from hematopoietic stem cells.  Journal of Experimental Medicine 201,
1361-1366.
Dang, S.M., Gerecht-Nir, S., Chen, J., Itskovitz-Eldor, J., and Zandstra, P.W.  (2004).
Controlled, scalable embryonic stem cell differentiation culture. Stem Cells 22(3),
275–82.
Dang, S.M., Kyba, M., Perlingeiro, R., Daley, G.Q., and Zandstra, P.W.  (2002).
Efficiency of embryoid body formation and hematopoietic development from
embryonic stem cells in different culture systems. Biotechnol Bioeng 78(4),
442–53.
Delaney, C., Varnum-Finney, B., Aoyama, K., Brashem-Stein, C., and Bernstein, I.D.
(2005).  Dose-dependent effects of the Notch ligand Delta1 on ex vivo
differentiation and in vivo marrow repopulating ability of cord blood cells.  Blood
106, 2693-2699.
Gerecht-Nir, S., Cohen, S., and Itskovitz-Eldor, J.  (2004).  Bioreactor cultivation
enhances the efficiency of human embryoid body (hEB) formation and
differentiation. Biotechnol Bioeng 86(5), 493–502.
168
Gerecht-Nir, S., Cohen, S., Ziskind, A., and Itskovitz-Eldor, J.  (2004).  Three-
dimensional porous alginate scaffolds provide a conducive environment for
generation of well-vascularized embryoid bodies from human embryonic stem
cells. Biotechnol Bioeng 88(3), 313–20.
Hozumi, K., Abe, N., Chiba, S., Hirai, H., and Habu, S.  (2003).  Active Form of Notch
Members Can Enforce T Lymphopoiesis on Lymphoid Progenitors in the
Monolayer Culture Specific for B Cell Development.  Journal of Immunology
170, 4973-4979.
Iso, T., Sartorelli, V., Chung, G., Shichinohe, T., Kedes, L. and Hamamori, Y.  (2001).
HERP, a New Primary Target of Notch Regulated by Ligand Binding.  Molecular
and Cellular Biology 21(17), 6071-6079.
La Motte-Mohs, R.N., E. Herer, and J.C. Zuniga-Pflucker.  (2005).  Induction of T-cell
development from human cord blood hematopoietic stem cells by Delta-like 1 in
vitro. Blood 105(4), 1431-9.
Lefort, N., Benne, C., Lelievre, J.D., Dorival, C., Balbo, M., Sakano, S., Coulumbel, L.,
and Levy, Y.  (2006).  Short exposure to Notch ligand Delta-4 is sufficient to
induce T-cell differentiation program and to increase the T cell potential of
primary human CD34+ cells.  Experimental Hematology 34, 1720–1729.
Lehar, S.M. and Bevan, M.J.  (2005).   Notch ligands Delta1 and Jagged1 transmit
distinct signals to T-cell precursors.  Blood 105(4), 1440-1447.
Levenberg, S., Huang, N.F., Lavik, E., Rogers, A.B., Itskovitz-Eldor, J., and Langer, R.
(2003).  Differentiation of human embryonic stem cells on three-dimensional
polymer scaffolds. Proc Natl Acad Sci USA 100(22), 12741–6.
169
Maus, M.V., Riley,  J.L., Kwok, W.W., Nepom, G.T., and June, C,H.  (2003).  HLA
tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells.
Clin Immunol 106, 16–22.
Nemir, M., Croquelois, A., Pedrazzini, T., and Radtke, F. (2006). Induction of
Cardiogenesis in Embryonic Stem Cells via Downregulation of Notch1 Signaling.
Circ Res 98, 1471-1478.
Ohishi, K., Varnum-Finney, B. and Bernstein, I.D.  (2002).  Delta-1 enhances marrow
and thymus repopulating ability of human CD34+CD38- cord blood cells.  J Clin
Invest 100, 1165-1174.
Schmitt, T.M., Ciofani, M., Petrie, H.T., and Zuniga-Pflucker, J.C.  (2004).  Maintenance
of T Cell Specification and Differentiation Requires Recurrent Notch Receptor-
Ligand Interactions.  J Exp Med 200(4), 469-479.
Varnum-Finney B., Wu, L., Yu, M., Brashem-Stein, C., Staats, S., Flowers, D., Griffin,
J.D., and Bernstein, I.D.  (2000).  Immobilization of Notch ligand, Delta-1, is




Influence of scaffold physical properties and stromal cell coculture on
hematopoietic differentiation of mouse embryonic stem cells
1.1 INTRODUCTION
Embryonic stem cells (ESCs) are isolated from the inner cell mass of the
blastocyst and have the ability to differentiate into all types of cells and self-renew
indefinitely making them an attractive choice for in vitro and in vivo therapeutic
applications (O’Shea 1999). Recently, ESCs have been shown to successfully
differentiate into neural precursors, cardiomyocytes, hematopoietic cells in in vitro
systems and exhibit functionality in animals (Johkura et al., 2003; Kaufman et al., 2001;
Zhang et al., 2001).  Hematopoietic studies using ESCs, however, have been primarily
limited to 2D systems that have only limited ability to mimic the necessary cell–cell and
cell–material interactions occurring in the three-dimensional (3D) in vivo
microenvironment. As the prospect for stem cell based tissue regeneration increases, the
development and thorough characterization of 3D based stem cell differentiation systems
is becoming increasingly crucial.
The site of hematopoiesis migrates in a developing embryo from the yolk sac and
aorta-gonad-mesonephros region to the bone marrow where hematopoiesis occurs in
adults. During hematopoiesis, cell-mediated and soluble growth factors bind to cell
surface proteins to trigger or inhibit signal cascades, committing stem cells to either a
myeloid or lymphoid lineage. The meshwork of stroma, ECM, and bone that make up the
microenvironment provide not only the physical framework for cell proliferation and
differentiation, but are also intimately involved in adhesion, cytokine presentation, and
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cell growth (Goldsby 2003; Mantalaris et al., 1998; Nilsson et al., 1998; Sternberg 1997;
Vituri et al., 2000). In vitro hematopoietic differentiation systems exploit these
cell–stroma interactions to drive embryonic stem cells to hematopoietic lineages.
Scaffolds are increasingly being applied to stem cell cultures in order to more
closely resemble the 3D in vivo microenvironment (Bagley et al., 1999; Gerecht-Nir et
al., 2004; Levenberg et al., 2003; Sasaki et al., 2002; Sasaki et al., 2003).  Scaffolds offer
the physical support that enable cell–cell and cell–material interactions facilitating a more
tissue-like structure (Sasaki et al., 2002). For example, an ex vivo thymic
microenvironment in a tantalum-based scaffold was shown to result in efficient
differentiation of human stem cells into T cells while human ESCs were shown to
differentiate into vasculature-like structures in PLGA-based scaffolds (Levenberg et al.,
2003; Poznansky et al., 2000). Scaffold based studies have particularly been instrumental
in understanding embryoid body (EB) formation and hematopoiesis. Studies involving
stem cell encapsulation in alginate capsules and stem cell culture in alginate-based
scaffolds, for example, have elucidated the role of inhibiting EB agglomeration in
increasing hematopoietic differentiation efficiency (Dang et al., 2004; Gerecht-Nir et al.,
2004). However, systematic assessment of the role of scaffold physical properties and
culture microenvironment, e.g. influence of stromal cells, on the efficiency of ESC
hematopoiesis has not been reported.
We recently demonstrated the advantageous effects of 3D scaffold culture and
dynamic culture conditions on hematopoietic differentiation of mouse ESCs (Liu and
Roy 2005). The 3D porous substrate coupled with dynamic flow conditions limited EB
aggregation and increased hematopoietic progenitor frequency in differentiated ESCs in a
highly reproducible manner. Our objective for this study was to systematically investigate
the microenvironmental effects of 3D scaffold culture on ESC differentiation into
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hematopoietic progenitors. Previous studies have demonstrated the significance of EB
confinement as a way of optimizing hematopoietic progenitor cells (HPCs) generation
(Dang et al., 2004; Gerecht-Nir et al., 2004).  Mechanical properties have also been
shown to affect ESC differentiation in 3D structures (Battista et al., 2005; Levenberg et
al., 2003).
Poly(L-lactic acid) (PLLA) based scaffolds offer the advantage of highly tunable
mechanical and physical properties that can be tailored for individual applications
(Ishaug-Riley et al., 1998). In this study, we varied the pore size and polymer
composition of the scaffolds and explored their effect on hematopoietic differentiation of
ESCs. Stromal cells such as OP9 have been widely used in hematopoietic applications
due to their ability to secrete relevant growth factors (Cho et al., 1999; Nakano et al.,
1994; Nakano 1996; Vodyanik et al., 2005).  Here we evaluated (a) how coculture of
ESCs with bone marrow derived stromal cells (OP9) enhances the efficacy of HPC
generation and (b) whether direct cell–cell contact between ESC and OP9 cells is
necessary for this enhanced differentiation. Our results indicate that paracrine signaling
from OP9 cells can increase ESC hematopoiesis in scaffold cultures. Such a systematic
study could provide critical insights in optimizing culture conditions and ultimately offer
the potential to produce hematopoietic progenitors from ESCs in a scalable manner for
therapeutic applications.
1.2 MATERIALS AND METHODS
1.2.1 Scaffold fabrication
PLLA scaffolds were synthesized using the standard salt leaching procedures, as
described by Ishaug-Riley et al. (Ishaug-Riley et al., 1998).  Briefly, PLLA (Medisorb,
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Low IV, Alkermes, Cambridge, MA) was dissolved in dichloromethane (7.5%, 10% and
20% w/v) and 4.5 g of varying sizes of NaCl particles (sieved to <150, 150–425 or 425<
mm) was added. The PLLA/NaCl mixture was poured into a 6 cm glass Petri dish,
followed by solvent evaporation and extensive salt leaching in dH2O. Scaffolds were cut
into 8 mm diameter constructs using a biopsy punch following solvent evaporation.
Scaffolds were then freeze-dried for 48 h and stored under vacuum in the desiccator until
further use.
1.2.2 ESC culture, maintenance and differentiation
Undifferentiated mouse R1 ESCs (a gift from A. Nagy, Mount Sinai Hospital,
Ontario, Canada) were expanded on leukemia inhibiting factor (LIF)-producing
irradiation-inactivated embryonic fibroblast cells (STO cells, Shan Maika, Austin, UT)
for 10 days in complete DMEM medium (Invitrogen, Carlsbad, CA) containing 20% fetal
bovine serum (Hyclone, Logan, UT), 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1
mM non- essential amino acids, 5 x 10-5 M 2-mercaptoethanol, penicillin G (100 U/mL),
and streptomycin (10 µg/mL) (all from Invitrogen, Carlsbad, CA). This expansion
process on LIF maintains the cells in their undifferentiated state (Williams et al., 1988).
At this stage, 1 x 105 cells (unless otherwise stated) were seeded dropwise on sterilized
PLLA scaffolds (7.5%, 10%, and 20% w/v, 150–425 µm pore size or <150, 150–425 or
425< µm, 10% w/v PLLA) for 7 h at a density of 2 x 106 cells/mL. The scaffolds were
sterilized in 70% ethanol for 1 h prior to seeding. Trapped air in scaffolds was removed
as described by Ma et al. (Ma et al., 2003).  After 7 hr incubation at 37ºC, unseeded cells
in supernatant from each scaffold were quantified to measure seeding efficiency. A
seeding efficiency of 75–90% was consistently achieved using this process.
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For cell seeding studies, 104, 5 x 104, 105, 2 x 105, and 5 x 105 undifferentiated
ESCs were seeded in scaffolds (10% w/v PLLA, 150–425 µm pore size) as described
above. Seeded cells were cultured in 24 well tissue culture plates in static culture for 7 or
14 days. The differentiation medium, consisting of "MEM (Invitrogen, Carlsbad, CA),
20% FBS (Hyclone, Logan, UT), 2.2 g/L sodium bicarbonate (Invitrogen, Carlsbad, CA),
penicillin G (100 U/mL), and streptomycin (10 µg/mL) (Invitrogen, Carlsbad, CA) was
replaced every 4–5 days. For cell removal, scaffolds were first rinsed in Dulbecco’s
phosphate-buffered saline (D-PBS) (Invitrogen, Carlsbad, CA), followed by incubation
with either trypsin or Accumax (Innovative Cell Technologies, San Diego, CA) in a 37°C
water bath for 10 min, and finally vortexed and washed gently using serum- containing
medium to detach the cells.
1.2.3 OP9 cell coculture
OP9 cells, a mouse bone marrow derived stromal cell line, were used to study the
effect of stromal cell coculture on hematopoietic differentiation from ESCs. These cells
(generous gift from Tammy Reid, Stanford Lab, University of Toronto, Toronto, Canada)
were maintained in differentiating medium described above. Unless otherwise stated,
scaffolds fabricated using a 10% w/v PLLA solution with pore sizes of 150–425 µm were
used for this study. All coculture conditions were designed to study the paracrine effects
of the stromal cells, thus avoiding direct ESC–stromal cell contact. For cocultures with
R1 cells in 3D scaffolds and OP9 cells in 2D plates (3DR1/2DOP9), 3 x 104 OP9 cells
were seeded onto wells in 24 well tissue culture-treated polystyrene plates while R1 cells
were separately seeded on 8 mm diameter scaffolds. After cell attachment, scaffolds were
placed on OP9 cell layers. It is conceivable that this design could result in some limited
contact between the OP9 cells on the plate and few ESCs at the very bottom of the
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scaffolds. However, for majority of the ESCs in the scaffold would not have any stromal
cell contact. For cocultures with both R1 and OP9 cells in 3D scaffolds (3DR1/3DOP9),
3 x 104 OP9 cells were seeded onto PLLA scaffolds of 3 mm diameter. R1 cells were
seeded on separate 8 mm diameter scaffolds as described above. Both scaffolds were
placed together in 24 well plates. Care was taken to avoid physical contact between the
scaffolds. Difference in scaffold size was used to distinguish the ESC scaffolds from the
stromal cell scaffolds. For 3DR1 controls, R1 cells were seeded onto scaffolds without a
stromal cell layer. For the 3DR1/3DOP9 condition, new scaffolds, seeded with fresh OP9
cells were added to the wells every four days along with medium change. For the
3DR1/2DOP9 condition, ESCs were re-seeded on fresh OP9 cell layers at the same time
points. Stromal coculture was performed for 2 weeks followed by flow cytometry
analysis.
1.2.4 Flow cytometry analysis
Flow cytometry was performed similar to methods described previously in Liu
and Roy (Liu and Roy 2005). Generation of HPCs was assessed through staining of HPC-
specific cell surface markers on days 7 and 14. Cells were washed twice in FACS buffer,
1% bovine serum albumin (Sigma-Aldrich, St. Louis, MO) and 0.05% sodium azide
(Sigma-Aldrich, St. Louis, MO) in PBS before staining and blocked for non-specific
binding using anti-mouse CD16/CD32 Fc Block (BD Pharmingen, San Diego, CA) for 10
min at 4°C. Staining with antibodies against specific hematopoietic markers was
performed at concentrations of 1 µg/100 µl of FACS buffer and washed prior to staining
with secondary fluorescently labeled antibodies, if necessary. Isotype controls
(eBioscience, San Diego, CA) were used as negative controls. All cells were washed
twice in FACS buffer and suspended in fresh buffer before flow cytometry analysis using
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FACSCalibur (Becton Dickinson, San Diego, CA) and CellQuest 3.1 software (BD
Biosciences, San Jose, CA). Fluorescently labeled antibodies against cKit and sca-1
(cKit-PE and sca-1-FITC, BD Pharmingen, San Diego, CA) were used for the
identification of ESC-derived HPCs. Only cells that stained for both cKit and sca-1 were
identified as HPCs. Simultaneous expression of cKit and sca-1 (dual staining) surface
markers is a common hallmark of hematopoietic stem cells in mice (Wognum et al.,
2003).
1.2.5 Compressive modulus testing
Mechanical properties of scaffolds (7.5%, 10%, and 20% w/v, 150–425 µm pore
size and 10% w/v <150, 150–425, 425< µm pore size) were characterized by testing four
specimens from each scaffold type under compression between parallel plates using an
Instron (In-Spec 2200 Benchtop Tester, Instron Corporation, Canton, MA) and In-
SpecTM 2200 PDA Emulator software (Instron Corporation, Canton, MA). A 125 N
compression static load cell and 0.2 mm/s cross-head speed were used. Young’s modulus
for each sample was calculated by performing a regression on the linear region of the
load-compression data.
1.2.6 Statistical analysis
All experiments were performed in triplicate except for pore size studies
(performed in duplicate). Analysis of statistical significance was performed using a one




Recently we reported the effects of 3D scaffold-based culture on hematopoietic
differentiation of mouse ESCs (Liu and Roy 2005). Our results indicated hematopoietic
differentiation efficiency in 3D systems over 2D tissue culture plates. Here, we further
explored the effects of specific 3D culture conditions, specifically cell seeding density,
scaffold properties and stromal cell coculture on hematopoietic differentiation. The
experimental variables studied are summarized in Table 1.1. PLLA-based scaffolds were
selected as 3D substrates due to their ease of fabrication, highly tunable physical and
mechanical properties and their widespread application in tissue engineering. In addition,
selection of PLLA ensured minimal to no degradation of the scaffold during the period
(one week) of the differentiation experiments. Representative scaffolds were routinely
evaluated by scanning electron microscopy, which indicated interconnecting pore
structure and uniform pore sizes (data not shown).
1.3.1 Higher cell seeding density results in increased HPC differentiation
Seeding density is known to affect stem cell differentiation and can be optimized
to result in higher differentiation efficiencies (Gerecht-Nir et al., 2004; Poznansky et al.,
2000; Tsai et al., 2000; Wilson et al., 2002). To study the effect of cell density on
hematopoietic differentiation, we seeded ESCs at 104, 5 x 104, 105, 2 x 105, and 5 x 105
cells per scaffold (10% w/v PLLA, 150–425 µm, 8 mm diameter) and cultured the cells
for 7 days as described above. Cells were then harvested from scaffolds, stained for both
cKit and sca-1 expression and analyzed using flow cytometry. As shown in Figure 1.1,
HPC generation appears to increase with increasing cell seeding density in the range
investigated. Statistical analysis using Student’s t-test indicated a significant difference
between 104 cells/scaffold, 105, and 5 x 105 cells/scaffold (p<0.05).
178
1.3.2. HPC generation is impaired at larger pore sizes
Porous structures such as PLLA scaffolds provide a physical framework and
enable cell ingression and nutrient diffusion for tissue engineering applications. To
evaluate how scaffold pore sizes influence ESC hematopoiesis, 10% w/v PLLA scaffolds
with three different pore size ranges were seeded with 105 ESCs and cultured for one
week followed by flow cytometry analysis for HPC generation. Pore sizes of <150 µm,
150–425 µm and >425 µm were produced using sieved salt particles during scaffold
fabrication. As shown in Figure 1.2A, HPC generation decreases with increased pore
size. The smallest pore size (<150 µm) yielded significantly more (1.68 and 2.06 fold)
HPCs when compared to the larger pore sizes.
To address any changes in mechanical properties due to pore size differences, we
measured the compressive moduli of the scaffolds. Static compressive loads of 125 N
were applied using an Instron (In-Spec 2200 Benchtop Tester) at 0.2 mm/s on 10% PLLA
scaffolds with various pore sizes until failure. Compressive modulus varied slightly
between the smaller pore sizes and decreased significantly (p<0.05) for pore size greater
than 425 µm, as indicated in Figure 1.2B. Statistical analysis indicated a significant
difference in HPC generation between all scaffolds tested.
1.3.3. HPC generation increases with scaffold polymer concentration, compressive
modulus
To investigate the effect of mechanical properties on HPC generation, we
fabricated PLLA scaffolds with three different polymer concentrations. Scaffolds
consisting of 7.5%, 10% and 20% (w/v) PLLA with pore sizes of 150–425 µm were
seeded with 105 ESCs and cultured for a week. Figure 1.3A indicates that, on average,
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HPC generation increases with increasing polymer concentration in the range
investigated. Statistical analysis using Student’s t-test showed a significant difference
between 7.5% and 20% PLLA scaffolds.
Scaffold mechanical properties have also been shown to affect cell differentiation
and can be modified by changing the polymer concentration (Battista et al., 2005;
Levenberg et al., 2003). To measure the compressive moduli of the scaffolds with
varying PLLA concentration, a 125 N static compressive load was applied using an
Instron (In-Spec 2200 Benchtop Tester) at 0.2 mm/s on 7.5%, 10% and 20% PLLA
scaffolds (with 150–425 µm pore sizes) until failure. As shown in Figure 1.3B, the
compressive moduli increases with polymer percentage and range from 20.29±2.45 to
25.72±3.86 MPa for 7.5% and 20% PLLA scaffolds, respectively.
1.3.4. Paracrine coculture with stromal cells significantly enhances HPC generation
Stromal cells such as OP9 are often used in hematopoiesis due to their inherent
ability to secrete relevant growth factors such as interleukin-7 (IL-7) and stem cell factor
(SCF) (Cho et al., 1999). However, most of these studies were performed using a mixed
coculture system.  Here, we explored the ability of paracrine signals (i.e. no cell–cell
contact) from OP9 mouse stromal cells to improve HPC generation from ESCs cultured
in polymer scaffolds.  Briefly, we seeded 3 x 104 OP9 cells on 3 mm diameter 10% PLLA
scaffolds with pore sizes of 150–425 µm or individual wells in a tissue culture-treated 24
well plate. Next, we seeded 105 ESCs on 10% (w/v) PLLA scaffolds with pore sizes of
150–425 µm and placed these scaffolds onto a OP9 layer in well (3DR1/2DOP9) o r
placed the scaffolds into a well along with OP9 cells seeded on a separate scaffold
(3DR1/3DOP9). 105 ESCs seeded on 10% (w/v) PLLA scaffolds with pore sizes of
150–425 µm without OP9 support were used as controls. After two weeks of culture,
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cells were harvested, stained, and analyzed using flow cytometry for dual expression of
cKit and sca-1. As shown in Figure 1.4, our results indicate a significant increase in
hematopoiesis in the presence of OP9 cells (p<0.05, Student’s t-test).
1.4 DISCUSSION
In our previous work, we demonstrated the beneficial effects of 3D scaffolds on
hematopoiesis using the commercially available Cytomatrix™ system. This study
prompted us to further explore the effects of physical and mechanical properties of 3D
substrates on HPC generation. Several recent studies have provided tremendous insight
into EB formation and differentiation processes both in 2D and 3D culture systems.
Dang and colleagues illustrated the importance of EB aggregation and cell attachment,
specifically, in providing cell fate decisions during hematopoiesis using liquid
suspension, methylcellulose culture, hanging drop and attached culture in the murine
system.  A low cell seeding density was found to result in most efficient EB formation
due to the maximum size limitation (Dang et al., 2002).  In a related study, Gerecht-Nir
and colleagues utilized a rotating bioreactor system with hydrophilic alginate scaffolds
with pore sizes of 50–200 µm to study human EB formation in a physically constricted
environment.  EB agglomeration was inhibited in both rotating and scaffold
microenvironments when compared to static and petri dishes, respectively. Seeding
density was not found to affect EB formation in scaffolds (Gerecht-Nir et al., 2004).
Levenberg et al. suggested the importance of mechanical properties in supporting human
ESC growth and organization in a matrigel/fibronectin coated PLGA/PLLA scaffolds
(pore sizes of 250–500 µm) culture system (Levenberg et al., 2004). Finally, semi-
interpenetrating polymer networks of collagen, fibronectin and laminin were shown to
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influence ESC differentiation into specific cell lineages.  Mechanical properties, such as
the elastic modulus was shown to inhibit EB growth and differentiation when increased
from 16 to 34 Pa (Battista et al., 2005).
Our goal was to systematically study HPC generation in 3D PLLA scaffold
structures by varying the scaffold physical and mechanical properties as well as by
changing the cell microenvironment through cell seeding density and coculture
conditions. We used flow cytometry analysis of murine HPC markers (dual expression of
cKit and sca-1) to evaluate the effect of pore size, polymer composition, compressive
moduli, seeding density and stromal cell coculture on hematopoiesis.
Although previous studies suggested no difference in EB formation and HPC
generation for various seeding densities, our results indicate that higher ESC seeding
densities in PLLA scaffolds could result in significantly higher HPC generation (Dang et
al., 2002; Gerecht-Nir et al., 2004). This could be a result of specific scaffold material
(PLLA) or a factor of the cell density range evaluated.
Larger pore sizes were found to hinder HPC generation. Recent reports have
emphasized the importance of confining EBs to prevent agglomeration. These studies
utilized scaffold pore sizes or capsule sizes of 50–200 µm and 100–150 µm to limit EB
aggregation (Dang et al., 2002; Gerecht-Nir et al., 2004). Our results indicated pore sizes
of less than 150 µm to be the most beneficial for HPC generation, which is consistent
with these studies.
Polymer percentage and mechanical properties also seem to play a role in
dictating HPC generation efficiency (Battista et al., 2005). We found that substrate
scaffolds with higher modulus were more conducive towards HPC generation. Battista
and colleagues, however, reported an inhibitory effect on EB formation and
differentiation when the elastic modulus was raised from 16 to 34 Pa in semi-
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interpenetrating network scaffolds of collagen, fibronectin and laminin (Battista et al.,
2005). Our compressive moduli, however, were on a scale of MPa. Changes in
mechanical moduli on such different scales may affect EB formation differently. It is also
possible that the substrate material itself could have an influence on how mechanical
properties affect ESC differentiation.
Finally, we observed a significant improvement in HPC generation with OP9
stromal cell coculture. Recent studies by Thomson and colleagues have demonstrated up
to 20% HPC differentiation efficiency of human ESCs under OP9 coculture conditions
(Vodyanik et al., 2005). Here, we obtained similar results using scaffold-cultured mouse
R1 ESCs and OP9 cells either seeded on scaffolds or on tissue culture plates. These
results suggest that, direct cell–cell contact may not be a necessary condition for the
increased hematopoiesis induced by OP9 cells. Soluble factors such as IL-7 and SCF
secreted by OP9 cells might provide sufficient cues for HPC generation.
In conclusion, we have demonstrated that scaffold properties and culture
conditions significantly affect hematopoiesis of mouse ESCs. Smaller scaffold pore size,
increase mechanical stiffness, coculture with stromal cells and increasing cell seeding
density were all shown to increase HPC generation. These results suggest a critical need
for microenvironment optimization for efficient differentiation of ESCs in 3D scaffold-
based cultures.
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Table 1.1 Summary of Various Culture Conditions
Culture Parameters Description
Scaffold properties
Pore size <150_m, 150-425_m, 425_m<
Polymer percentage 7.5%, 10%, 20% w/v
Seeding density 104, 5x104, 105, 2x105, 5x105 cells/scaffold
Stromal cell coculture
3D ES cells seeded on 3D scaffold
3D-2D ES cells seeded on 3D scaffold; scaffold placed on OP9
cell layer cultured on tissue culture plates
3D-3D     ES cells seeded on 3D scaffold; OP9 cells seeded on
    separate scaffold and cultured together on a single well
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Figure 1.1 Effect of cell seeding density on HPC generation from ESCs in PLLA
scaffolds. ESCs were cultured at various seeding densities on 10% w/v
PLLA scaffolds with pore sizes of 150–425 µm for 1 week before
harvesting, staining for cKit and sca-1 expression and analysis using flow
cytometry.  Dual expression of cKit and sca-1 represents HPC population.
(A) Flow cytometry data. Numbers in quadrant correspond to cell
percentages.  Upper right quadrant indicates HPCs expressing both cKit and
sca-1. (B) Bar graph showing percentage of HPC generated for different
seeding densities (n = 3).  *indicates p<0.05 compared to the lowest seeding
density using a Student’s t-test.
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Figure 1.2   Effect of pore size on HPC generation from ESCs in PLLA scaffolds. HPC
generation is impaired at larger scaffold pore sizes. 105 ESCs were cultured
on 10% w/v PLLA scaffolds with various pore sizes for 1 week followed by
harvesting, staining for cKit and sca-1 expression and analysis using flow
cytometry.  Dual expression of cKit and sca-1 represents HPC population.
(A) Flow cytometry data. Numbers in each quadrant correspond to cell
percentages. Upper right quadrant indicates HPCs expressing both cKit and
sca-1.  (B) Bar graph demonstrating HPC generation decreases with larger
scaffold pore sizes.  Percentage of cells expressing both cKit and sca-1 at
various pore sizes (closed squares) are simultaneously plotted with the
corresponding scaffold compression moduli (closed circles). Experiments
were performed in duplicate. *indicates groups with significant difference in
HPC generation as compared to pore size of <150 µm (p<0.05, Student’s t
test). ** indicates group with significant difference in HPC generation as
compared to pore size of 150–425 µm (p<0.05, Student’s t-test). #, # #
indicates significant difference in compression modulus as compared to
scaffolds with pore size < 150 µm, and 150–425 µm (p<0.05, Student’s t-
test).
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Figure 1.3 Effect of scaffold polymer concentration on HPC generation from ESCs. 105
ESCs were cultured on PLLA scaffolds fabricated using various polymer
concentrations followed by cell harvesting, staining for cKit and sca-1
expression and analysis using flow cytometry. All scaffolds had pore sizes
of 150–425 µm. Dual expression of cKit and sca-1 represents HPC
population. (A) Flow cytometry analysis. Numbers in each quadrant
correspond to cell percentages. Upper right quadrant indicates HPCs
expressing both cKit and sca-1. (B) HPC generation may correlate with
mechanical properties of scaffold. cKit and sca-1 expression at various
polymer concentrations (closed squares) are simultaneously plotted with
corresponding scaffold compression moduli (closed circles). *indicates p
value of 0.05 when compared to 7.5% w/v PLLA scaffold using Student’s t-
test. ** indicates group with significant difference in HPC generation as
compared to 7.5% w/v PLLA scaffold (p<0.05, Student’s t-test).
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Figure 1.4 Effect of stromal cell coculture on HPC generation from ESCs in
PLLAscaffolds.  Coculture with OP9 cells may enhance HPC generation
from R1 ESCs. 105 ESCs were cultured on 10% w/v PLLA scaffolds with
pore sizes of 150–425 µm for 2 weeks followed by staining for cKit and sca-
1 expression and flow cytometry analysis. Dual expression of cKit and sca-1
represents HPC population. (A) Flow cytometry analysis. Numbers in
quadrant correspond to cell percentages. Upper right quadrant indicates
HPCs expressing both cKit and sca-1. (B) Bars indicate percentage of HPC
generated under each culture conditions. All experiments were performed in
triplicate. *indicates a p<0.05 compared to the lowest polymer concentration
using a Student’s t-test.
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Immunofluorescence detection of antiHIS coating on beads (flow
cytometry)
MATERIALS
CELLection biotin binder kit (Invitrogen, 4ºC)
Biotinylated antiHIS antibody (R&D systems, -20ºC)
Washing buffer (PBS, 0.1%BSA, 0.05% sodium azide, 4ºC)
FACS staining buffer (PBS, 1% BSA, 0.05% sodium azide, 4ºC)
Blocking buffer (PBS, 3%BSA, 4ºC)
Goat anti-mouse IgG, FITC conjugate (Calbiochem, -20ºC)
Streptavidin-PE (BDBiosciences, 4ºC)
FACS tubes
Lo protein binding tubes (0.65ml, smaller sizes if available)
Dynalbiotech magnet





1. Resuspend the Dynabeads thoroughly and transfer the desired amount of beads (2
µl) to a tube suitable for the Dynal MPC.
2. Place the tube in Dynal MPC for 1 minute. Make sure the solution is clear and
pipette off the fluid without disturbing the beads.
3. Remove the tube from the Dynal MPC, add 1 - 2 ml buffer (e.g. PBS with 0.1%
BSA) and resuspend.  If using smaller sized tubes, use 0.5 ml.
4. Place the test tube in the Dynal MPC for 1 minute, remove the buffer and take the
tube out of the Dynal MPC.
5. Resuspend the washed Dynabeads back in 2 µl buffer (4x108 beads/ml).
Dynabeads Coating Procedure
1. We will be coating in a volume of 10 µl to avoid errors with low volumes.  Thus,
add the calculated amount of total buffer (subtracting 1µl for both the beads and
antiHIS antibody) and add this to the washed bead suspension.  Resuspend
washed Dynabeads well by thoroughly pipetting.
2. Prepare antiHIS antibody solutions in 0.1% BSA in PBS with varying
concentrations in low protein binding tubes.  Make at least 3-5 µl of each to avoid
running out of solution.  Calculate concentrations such that 1 µl is the volume
added to each tube.
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3. Add 1 µl of each concentration to each tube and mix well.  Pipette carefully and
only dispense liquid directly into bottom of tube.
4. Rotate the bead and antibody suspension for 30 minutes at room temperature.
5. Add 0.5/1ml PBS with 0.1% BSA to each tube and mix well.
6. Place the tube in a Dynal MPC for 1 minute. Make sure the solution is clear and
pipette off the fluid.
7. Remove the tube from the Dynal MPC and add 0.5/1ml PBS with 0.1% BSA.
8. Repeat steps 5-7 two times. Aspirate out all volume completely.
Dynabeads Staining Procedure
1. Blocking - Add 100 µl of 3% BSA in PBS and incubate for !30 min at 4ºC.
2. Place samples in Dynal MPC for 1 minute and remove supernatant.
3. Antibody incubation – In DARK.  Add FITC goat anti-mouse antibody to each
tube at a concentration of 0.25 µg/1million beads in a staining volume of 100 µl
and incubate for 30 min at 4ºC on rotator.
4. Washing - In DARK.  Wash twice with 500 µl of FACS buffer.
5. In DARK.  Aspirate off supernatant completely.  Resuspend in 250µl of FACS
buffer and add to prelabeled FACS tubes.
6. Cover FACS tubes in Styrofoam racks with paraffin and foil and proceed to
FACS.  Place racks in large foam box for convenience.  Remember to take thumb
drive, notebook with FACS settings, key and access card and of course samples.
Proceed to FACS machine.
**For studies with streptavidin-PE, a concentration of 0.25 µg/1million beads was used
as well.
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Immunofluorescence detection of DLL4 coating on beads (flow
cytometry)
MATERIALS
CELLection biotin binder kit (Invitrogen, 4ºC), concentration: 4x10^8 beads/ml
Biotinylated antiHIS antibody (R&D systems, -20ºC), concentration: 0.25 mg/ml
Recombinant DLL4 (R&D systems, -20ºC), concentration: 0.25 mg/ml
Washing buffer (PBS, 0.1% BSA, 0.05% sodium azide, 4ºC)
FACS staining buffer (PBS, 1% BSA, 0.05% sodium azide, 4ºC)
Blocking buffer (PBS, 3% BSA, 4ºC)
Rat anti-mouse monoclonal DLL4 antibody (R&D systems, -20ºC), concentration: 0.5
mg/ml
Fluorescein isothiocyanate (FITC) mouse antirat IgG (H+L) (R&D systems, -20ºC),
concentration: 0.5 mg/ml
Anti-rat quantum simply cellular kit (Bangs labs, 4ºC)
FACS tubes
Lo protein binding tubes (0.65ml, smaller sizes if available)
Dynalbiotech magnet




Dynabeads Washing Procedure (all performed sterilely)
6. Keep all reagents cold if possible.
7. Resuspend the Dynabeads thoroughly and transfer the desired amount of beads (
25 µl is the common amount made) to a tube suitable for the Dynal MPC.
8. Place the tube in Dynal MPC for 1 minute. Make sure the solution is clear and
pipette off the fluid without disturbing the beads.
9. Remove the tube from the Dynal MPC, add 1 ml buffer (e.g. PBS with 0.1%
BSA) and resuspend.  If using smaller sized tubes, use 0.5 ml.
10. Place the test tube in the Dynal MPC for 1 minute, remove the buffer entirely and
take the tube out of the Dynal MPC.
11. Resuspend the washed Dynabeads back in 25 µl buffer (4x108 beads/ml).
Dynabeads Coating Procedure (all performed sterilely)
9. Prepare antiHIS antibody solutions in 0.1% BSA in PBS with calculations of
antiHIS antibody at 100 ng/10^7 beads.  For example, for 25 µl or 10^7 beads,
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you need 100ng of antibody + beads + buffer = 25 µl total volume.  Adjust
antibody concentration so that total 25 µl is not exceeded.
10. Remove buffer from washed beads, add antibody and fresh buffer so that total
volume is 25 µl or whatever original bead volume was.
11. Rotate the bead and antibody suspension for 30 minutes at room temperature.
12. Add 0.5/1ml PBS with 0.1% BSA to each tube and mix well.
13. Place the tube in a Dynal MPC for 1 minute. Make sure the solution is clear and
pipette off the fluid.
14. Remove the tube from the Dynal MPC and add 0.5/1ml PBS with 0.1% BSA.
15. Repeat steps 5-6 two times. Aspirate out all volume completely.
16. Prepare DLL4 solutions in 0.1% BSA in PBS in low protein binding tubes.  For
25 µl and 10ng/10^7 beads, you will need 10 ng of DLL4.  Make sure the volume
does not exceed 25 µl.  Prepare all concentrations in the same way.
17. Add DLL4 to antibody coated beads and add buffer so that volume totals out to be
25 µl.
18. Rotate the antibody coated bead and DLL4 suspension for 30 minutes at room
temperature.
19. Add 0.5/1ml PBS with 0.1% BSA to each tube and mix well.
20. Place the tube in a Dynal MPC for 1 minute. Make sure the solution is clear and
pipette off the fluid.
21. Remove the tube from the Dynal MPC and add 0.5/1ml PBS with 0.1% BSA.
22. Repeat steps 5-6 two times. Aspirate out all volume completely.
23. Resuspend in 25 µl of fresh buffer and proceed with staining.
Dynabeads Staining Procedure (can be done benchtop)
7. For primary antibody solution, you want to add 2-4 µg/million beads of anti-
DLL4 antibody (concentration taken from datasheet) into FACS buffer.  For the
secondary antibody solution, you want to add 0.25 µg/million beads of FITC anti-
rat IgG (concentration taken from datasheet) into FACS buffer.  For the QC
beads, you want to add 50% of amount of antibody for 4 million cells per sample.
Also, when you make the antibody solution, you want the total staining volume to
be 100 µl.  Also label FACS tubes at this point.
8. Blocking - Remove buffer from tubes and add 100 µl of 3% BSA in PBS and
incubate for !30 min at 4ºC.
9. Place samples in Dynal MPC for 1 minute and remove supernatant.
10. Primary antibody incubation – Add 100 µl of primary antibody solution to
samples, tap several times and incubate for 30 min at 4ºC.
11. Washing - Add 500 µl of FACS buffer and pipette up and down several times.
Place in magnet, aspirate out supernatant and repeat buffer washing.  Aspirate out
supernatant completely.  For QSC kit, you will need to add 500 µl and centrifuge
at 4ºC 2500 rpm for 5 min.  Remove supernatant and repeat.
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12. IN DARK Secondary antibody incubation – Add 100 µl of secondary antibody
solution to samples, tap several times and incubate for 30 min at 4ºC in 100 µl
volume.
13. IN DARK Washing - Add 500 µl of FACS buffer and pipette up and down
several times.  Place in magnet, aspirate out supernatant and repeat buffer
washing.  Aspirate out supernatant completely.  For QSC kit, you will need to add
500 µl and centrifuge at 4ºC 2500 rpm for 5 min.  Remove supernatant and repeat.
14. IN DARK.  Add 250-400 µl of FACS buffer (depending on how dilute you want
your bead solution) to tubes.  Cover FACS tubes in Styrofoam racks with paraffin
and foil and proceed to FACS.  Place racks in large foam box for convenience.
Remember to take thumb drive, notebook with FACS settings, key and access
card and of course samples.
**NOTE:  All staining expts were performed with 1 µl of beads in 10 µl coating volumes
to avoid error.  Antibody and DLL4 amounts were scaled down accordingly.
198
Created by: Sabia Taqvi
Revised: 4/23/06
Indirect DLL4 quantification using ELISA analysis
MATERIALS
96 well high protein binding ELISA plate (Corning, NY)
DLL4 (R&D Systems, 4°C)
Anti-DLL4 antibody (R&D Systems, -20°C)
HRP Goat anti-rat antibody (eBiosciences, -20°C)
Washes from DLL4 staining (after DLL4 incubation, save 0.5-1ml washes with 0.1%
BSA in PBS in low protein binding tubes at -20°C)
Coating buffer (0.1% BSA in PBS, prepare fresh)
Washing buffer (0.5% (v/v) Tween 20 in PBS (PBT))
Blocking buffer (1% (w/v) bovine serum albumin in PBS)
Tetramethylbenzidin ((TMB), R&D systems, 4°C)
Stop solution (0.3M sulfuric acid, RT)
0.1-10 µl, 2-20 µl and 100-1000 µl pipettors with tips
Yellow and blue tips
Opsys MR Microplate reader (Dynex. Technologies Inc., VA)





1. To quantify the amount of DLL4 on beads, we will indirectly measure the DLL4
using the washes from DLL4 fabrication.  Basically, while fabricating beads, save
all three washes in low protein binding tubes.  In addition to washes from n=3
samples, save original DLL4 amounts in 0.1% BSA in PBS in low protein binding
tubes.  Store tubes in -20°C until ELISA analysis.
2. Add 100 µl of each wash sample along with original DLL4 concentrations to
wells of 96 well EIA/RIA ELISA plates and incubate over night at 4°C.  Also,
add DLL4 standards and 0.1% BSA in PBS (background) to additional wells and
incubate as well.
3. Wash plates 4x with 100 µl of 0.5% (v/v) Tween 20 in PBS (PBT).
4. Block wells with 1% (w/v) bovine serum albumin in PBS for 1.5 h at 37°C.
5. Washed 4x with 100 µl of PBT.
6. Add 100µl of rat anti-mouse DLL4 IgG2a at a concentration of 1 µg/ml to each
well and incubate for 1.5 h at room temperature (RT).
7. Wash 4x with 100 µl of PBT.
8. Add HRP conjugated goat anti-rat IgG at a dilution of 1:5000 to each well and
incubate for 1.5 h at RT.
9. Wash 4x with 100 µl of PBT.
10. Add 100µl of TMB to each well and incubate for 10 – 60 min (30 min should be
good enough) at RT.
11. Reaction can be stopped by the addition of 50µl of stop solution to wells.
12. Read absorbance values at 450 nm using the Opsys MR Microplate reader and
Revelation QuickLink software.  Turn on reader 5 minutes before ending and
press cancel 7 times (errors).  Once reader ready, only then open software or error
will occur.  Select ELISA HRP program from list of tests and read.
13. Produce standard curve and subtract the measured amount of DLL4 in the washes
from the original amount of DLL4 added to the beads to find amount of DLL4
adsorbed onto DLL4 beads.
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MTT (5mg/ml in Hank’s balanced salt solution (Invitrogen) – SigmaAldrich) Store at
-20°C, stable for 6 months at -20°C
MTT solubilization solution - 10% Triton X-100, 0.1 N HCl in anhydrous
isopropanol - Store at 4°C
1.5ml centrifuge tubes with pointed ends
Microcentrifuge
Plate reader with filter at 550nm
Relevant medium (prewarmed)
96 well ELISA plates
ASSUMPTION: preplated cells in 96 well plates




1. Remove preplated cells in 96 well plate and remove medium from each.  Use
separate pipette tip for each group.
2. Add 100µl of fresh prewarmed medium to each well.  Do NOT forget to have
wells with only medium that you use as background.
3. Add 10µl (or 10% of medium volume) of MTT solution to each well and mix
well.
4. Incubate for 2-4 hours at 37°C (we usually do 4 hour incubations).
5. Add MTT solubilization solution in a volume equal to medium volume (100µl) to
each well and pipette several times to dissolve purple formazan crystals.
6. After pipetting, remove supernatant and pipette into prelabeled microcentrifuge
tubes.
7. Spin tubes for 5 min at 300 rpm to precipitate any cell/debris.
8. Remove 100µl from each tube and place into 96 well ELISA plate.
9. Spectrophotometrically read absorbances at a wavelength of 570nm (or for us
550nm).  Shaking for 5 min is not required but is done.
10. Export absorbance values to excel and plot.
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DLL4 bioactivity assay with C2C12 cells and immobilized and soluble
DLL4
MATERIALS
DLL4 (R&D Systems, -20ºC)
Biotinylated anti-6x HIS antibody (R&D Systems, -20ºC)
Neutravidin (Pierce Biotechnology, 4ºC)
DLL4 coated beads and uncoated beads (for bead studies)
96 well tissue culture treated plates
C2C12 myoblasts
Maintenance medium
DMEM (Invitrogen, 4ºC), 10% FBS (Hyclone, -20ºC), pen/strep (Invitrogen, 4ºC)
Serum-free differentiation medium
1:1 ratio of DMEM and F12 nutrient mixture (Invitrogen, 4ºC), 1mM sodium pyruvate
(Invitrogen, 4ºC), 2.5 µg/ml bovine insulin (Sigma-Aldrich, -20ºC), and antibiotics.
** Conventional C2C12 differentiation medium
DMEM (Invitrogen, 4ºC), 10% Horse serum (Hyclone, -20ºC), pen/strep (Invitrogen,
4ºC)




Pipettors (2-20, 20-200, 1000)







Immobilized DLL4 inhibits C2C12 myoblast differentiation through Notch signaling.
Differentiation is visible through the formation of myotubes or fused myoblasts (size is
much larger).  With immobilized DLL4, myoblasts maintain their morphology while
control wells will show myotube formation within 5-6 days of incubation.
METHODS
1. Maintain C2C12 cells 1 week prior to experiment in maintenance medium.
2. Day 1: Check under microscope before use to ensure cells are not overconfluent
and there are no traces of contamination.
3. Place ethanol sprayed pipettors, stripettes, tubes, and plates under UV light in
hood at least 20 minutes prior to expt beginning.
4. Thaw out DLL4 from -20ºC before use.  For previous studies, 1 µg/ml of
immobilized DLL4 has been sufficient to inhibit C2C12 differentiation.
5. Coat 96 wells with 1 µg/ml of DLL4 in sterile PBS in 100 µl volume.  Perform
study in at least n=3.  Incubate at 37ºC for 2-3 hours.
6. Thirty min prior to incubation end, begin cell culture.  We will need at least
20000 cells/well, thus one confluent 25cm2 flask will suffice.  Ethanol

















7. Aspirate out old medium and wash with trypsin.  Add fresh trypsin and incubate
for 10-15 min at 37ºC.
8. Remove flask and check under microscope to make sure cells have detached from
flask.
9. Wash flask with 5 ml of fresh maintenance medium and transfer trypsinized cells
+ medium into centrifuge tube.  Pipette well to remove aggregates.
10. Pipette out 10 µl of cell suspension and add to hemocytometer.  Count and record
cell count.
11. Cap centrifuge tube and spin down at 300 g for 5 min.
12. After centrifugation, remove tube, ethanol tube and bring into hood.  Calculate
amount of maintenance medium necessary to add to achieve 20000 cells/.1 ml
concentration.  Remove supernatant and resuspend cells in calculated medium.
Set aside tube.
13. Remove plate from incubator and bring into hood.  Remove DLL4/PBS and wash
wells with 100 µl of PBS 3x.
14. Add 100 µl of cell suspension to wells (cells only, immob DLL4, soluble DLL4).
15. Add 0.1 µg of DLL4 to soluble wells.
16. Adjust all wells to a volume of 200 µl of maintenance medium.  Place plate into
incubator.
17. Day 2: After one day of incubation, remove medium.  Add fresh differentiation
medium to wells (remembering to add soluble DLL4 to appropriate well).
18. Check cells daily for contamination and differentiation progress.
19. Day 5/6: Cells be ready for imaging.  You should see definite myotube formation
in cells only and soluble DLL4 conditions and only myoblasts with immobilized
cells.  Image wells with microscope and save on thumb drive.  After imaging,
dispense plate into trash.
20. For bead studies, follow the protocol described above.  Seed cells one day prior to
bead addition.  Prepare bead-differentiation medium suspensions in individual
tubes (with extra medium for _-1 well), mix well, and add on Day 2 once old
medium is removed.  Continue with protocol described above.
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C2 maintenance medium (DMEM, 10% FBS, P/S)
C2 serum-free differentiation medium (1:1 DMEM/Ham’s Nutrient Mixture (Gibco),




DLL4 coated beads, uncoated beads
DLL4
4xwtCBF1Luc plasmid (1.8 mg/ml) (Gift from D Hayward, amplified by Aldevron)
Exgen 500 (Fermentas)
Glo lysis buffer (Promega)
Black luminometer plates





Yellow and blue tips
Dynalbiotech magnet














“Firefly luciferase is by far the most commonly used bioluminescent reporter. This
monomeric enzyme of 61kDa catalyzes a two-step oxidation reaction to yield light,
usually in the green to yellow region, typically 550–570nm (Figure 8.1). The first step is
activation of the luciferyl carboxylate by ATP to yield a reactive mixed anhydride. In the
second step, this activated intermediate reacts with oxygen to create a transient dioxetane
that breaks down to the oxidized products, oxyluciferin and CO2. Upon mixing with
substrates, firefly luciferase produces an initial burst of light that decays over about 15
seconds to a low level of sustained luminescence.”
METHODS
1. Cell seeding.  Maintain C2C12 cells in C2 maintenance medium.  Trypsanize and
seed cells into 24 well plate 24 hours prior to transfection time so that cells will be
60-80% confluent at the time of transfection.  Higher confluencies will result in
reduced transfection efficiency.  Seeding 40-60000 cells per well usually suffices.
If possible, seed extra well for counting.
NOTE:  Each condition will have an n=3 for the control plasmid.  If testing
concentration of beads, make sure you allot for protein coated and uncoated
beads, as well.
2. Transfection.  We will be using Exgen 500 and the manufacturer’s instructions for
transfection of reporter constructs.  DNA-exgen 500 complexes need to be made
fresh prior to transfection.
a. DNA/Exgen complex formation.  First, prepare 150mM NaCl buffer in
ddH2O.  You will need 100 µl per sample.  If you have 96 wells for
example, you will need at least 10 ml.  For our purposes, prepare 15ml of
NaCl.  (150mM NaCl x 15 ml = 2.25 mmoles; 2.25 mmoles x 58.4428
g/mole = 0.1315 g => 131.5 mg of NaCl + 15 ml of ddH2O.)
b. In Hood.  Label 15ml centrifuge tubes with plasmid and control.  Place
pipettors, syringes and tubes (ethanoled) under UV light in hood 20 min
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prior to complex formation.  You want to add your DNA (plasmid) at 1 µg
DNA/100 µl of 150mM NaCl buffer.  Since we have 5 ml (total) for
example per plasmid, we will need 50 ug of DNA.   Add plasmid and
control plasmid to 4.835 ml of buffer in labeled tubes.  Vortex gently (on
minimum speed) and spin down.
c. In Hood.  Pipette out 3.3µl of Exgen x 50 = 165 µl of Exgen and place
into sterile centrifuge tube.  Fill insulin syringe with Exgen from tube.
Holding 15 ml plasmid tube buffer on minimum speed on vortex, add
exgen drop by drop into tube until all volume has been added.  Incubate
for 10 min at room temp.
d. Complex addition.  Cell culture is all performed in hood.  Remove cell
culture plates from incubator.  Aspirate old medium.  Add 400 µl of
prewarmed DMEM + P/S.  Next, add 100 µl of Exgen/DNA mixture to
each well.  Rock plate back and forth and from side to side to achieve even
distribution.  Incubate for 4 hours at 37C.
e. After 4 hours, add 500 µl of DMEM + 20% FBS + P/S.  Incubate for
another 20 hours at 37ºC.
3. Bead addition.
a. Place pipettors, magnet, tubes, and tips under UV light 20 minutes prior to
bead addition.  Check cells under microscope to make sure NO
contamination and viability.
b. Remove old medium from well designated for counting, wash with
trypsin, and add fresh trypsin.  Incubate for 5 min and wash with medium.
Count using hemocytometer and record cell number.  You will need this
for bead calculations.
c. With cell number, make calculations of how much of bead volume you
will need for each bead to cell ratio.  For example, if the cell count is
100000 cells/well and you have an n=3 for DLL4 coated beads, you will
need at least 350000 beads (have some extra).  The beads are stored at
10^7 beads/25 µl.  This means you will need .875 µl of beads.  Also, you
need 1ml of serum-free differentiation medium per well.  Since we’re
doing a little extra, you will need 3.5 ml.
d. Wash necessary amount (1 µl) coated and uncoated beads with 0.1% BSA
in PBS (4ºC) with 500 µl and resuspend in original volume but with
differentiation medium.
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e. Add beads to tubes with medium and mix well.
f. Remove old medium from cell culture plates.  Add bead-medium
suspension to each well.
g. Check under microscope to make sure beads well suspended.  Do not
forget to add medium to immobilized DLL4 condition and cells only
condition.
h. Incubate for 24 hours at 37ºC with 5% CO2.
4. Lysis, BCA assay, and luminescence detection.  We will be using the Glo lysis
buffer to lyse cells and expose luciferase produced.  It is important to lyse cells
well (bead-cells tend to aggregate) and avoid bubbles (reduce volume).  For
normalization of cell number, we perform a BCA assay where a portion of the
lysate is tested for protein content.  The luciferase readings from the luminescence
are then divided by the protein content to get RLU/mg.  Thus, it is important to
have enough for luminescence and BCA.  We usually use 150 µl Glo lysis buffer.
a. Lysis: Check cells for contamination, cell death and note any differences
between wells.
b. Place Glo Lysis buffer (4ºC) in lukewarm water bath to equilibrate to
room temp 20 min prior to lysis.  Warm PBS in water bath (37ºC).
c. Remove old medium from cell culture wells (be sure to use different tips
for different conditions).  Wash with 500 µl of PBS and remove.
d. Add at least 150 µl of Glo Lysis buffer to each well.  Incubation of 15 min
at room temp is desired but to achieve complete lysis, a longer incubation
time is recommended.  After 15 min of incubation, pipette wells to lyse
cells.  After an additional 20-30 min, pipette several times to achieve a
homogeneous lysate (no clumps or aggregates).  Place these plates on ice
or at 4ºC while preparing BCA assay.
e. BCA:  Prepare BSA standard solutions (stock (2 mg/ml) from Pierce BCA
kit) in PBS.  Concentrations should be made in lo protein binding tubes
using serial dilutions and include 0 µg/ml, 2.5 µg/ml, 10 µg/ml, 20 µg/ml,
40 µg/ml, 200 µg/ml and 400 µg/ml.  Add 50 µl to each well in 96 well
plate (ELISA plate is fine).  Do a n=3.
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f. Prepare the BCA reagent.  The ratio is 25:24:1 for Reagent A:Reagent
B:Reagent C, respectively.  Prepare enough for standards and samples
with little extra.  Mix well.  Prepare plate-plan in lab notebook for both
BCA assay and luciferase assay plates.
g. Add 50 µl of BCA reagent to standards and wells designated for samples.
Add 50 µl of well-pipetted sample lysate to wells on ELISA plate.  Cover
plate and incubate for at least 2 hrs at 37ºC.
h.  Luminometer: Add 50 µl of well-pipetted samples to black luminometer
plates.
i. Remove luciferin from -80ºC and let equilibrate to room temp for 15-20
min.
j. Take black plate, luciferin, thumb drive to MBB (Klaus area).
Illuminometer
• Grab keys/access cards
• At ICMB make entry into the Log book and switch the instrument ON
• Chose software Mikronim 2000.
• OPEN!DESKTOP ! Bilal (*par files)
• Options !measurements   .  ! select area ! inj 3  .   ! Make area in circles
red by selecting them
                                                    RED
• Instrument ! wash ! let it run ! inj 3
• Wash again
• Instrument ! Prime ! inj 3
(Make sure you deselect all else)
• Put plate ! Read
• File Name            ! c: ! users ! Bilal ! Start
k. 
BCA: After 2 hours, remove plate from incubator and run assay for BCA assay on plate
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RNAseOUT recombinant ribonuclease inhibitor *
Superscript III RT*
RNase H *
RNA samples (stored at -20°C)
Nuclease-free 1.5ml centrifuge tubes (autoclaved)




Ice and ice bucket
Float for water bath for PCR tubes
0.1-10 µl, 20-200, 1000 pipettors
water bath (at 65ºC), thermocycler
Lab marker
Foam box for transfer
MBB card and keys
**All italicized reagents are included in the Superscript III First-strand cDNA synthesis
kit (catalog no: 18080-051)
* Starred items are given in limited quantities and will most likely run out.  Make sure
you have enough for your studies.
METHODS
The 20 _l total volume reaction can be used for 1 pg-5 µg total RNA or 1pg - 500 ng
poly(A)*RNA.
1. Before you start.  Reserve time on thermocycler (coreweb.icmb.utexas.edu) for 2
hours.  It’ll take you 1 hour or less to prepare the following.  Allow for this time
accordingly.  Spray pipettors with 20% bleach and leave pipettors to dry 10 min
before use.  Take out kit components (make sure you have enough of each) and
leave outside to thaw.  Set water bath to 65ºC and add sign saying NOT at 37ºC.
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a. Spray ice bucket with 20% bleach and fill with crushed ice.  Spray outside
with 20% bleach and bring to work area.
b. Once components have thawed, briefly centrifuge all components.  Spray
with 20% bleach and bring into work area.  Keep on ice.
c. Remove DNased samples and spray with bleach and bring into work area.
Keep on ice.
d. Label all PCR tubes for samples.  Each sample will have a corresponding
wRT and a noRT tube.  Using the numbers below, calculate how much of
each component you will need and make stock solutions.  For example,
you will need a “Step 1,” “with RT,” and “without RT.”  The Step 1 will
be for all samples during the denature step.  Also, when calculating, allow
for error.  For example, if you have 20 samples, make for 25 samples.
2. Add the following to each sample:
- 1 µl l of random hexamers
- 10pg-5ug total RNA (cannot exceed 8 µl l volume)
- 1 µl l of 10 mM dNTP mix
- nuclease free water to 10 µl l
3. Heat mixture to 65ºC for 5 minutes in water bath using float.
4. Incubate on ice for at least 1 minute.
5. Add the following to each with RT sample:
- 2 µl  10X RT buffer
- 4 µl  25 mM MgCl2
- 2 µl  0.1 M DTT
- 1 µl RNaseOUT recombinant RNase inhibitor
- 1 µl of Superscript III RT
6. Add the following to each without RT sample:
- 2 µl 10X RT buffer
- 4 µl 25 mM MgCl2
- 2 µl 0.1 M DTT
- 1 µl RNaseOUT recombinant RNase inhibitor
- 1 µl of nuclease-free water
7. Mix by pipetting gently up and down.  Place tubes in foam box and proceed to
MBB.
8. Thermocycler.  Switch on (switch on right side back).  Go to Edit and select any
program.  Using keys, insert the following program:
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- Incubate at 25ºC for 10 minutes and then 50°C for 50
minutes
- Terminate reaction at 85ºC for 5 minutes and then chill on ice
(4ºC for 99:59 (inf))
The volume is 20 µl.  This will most likely take 2 hours or so.  Reset water
bath to 37°C.
9. After 2 hours, briefly centrifuge contents.
10. Add 1 µl  of RNase H and incubate at 37°C for 20 minutes (to remove
complementary RNA).
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GORE RNA Extraction Protocol
Reference: Deena Walker, Kimberly Hillsman (Gore Lab)
MATERIALS
Cushion buffer (0.4 ml/sample)*
Lysis buffer (0.5 ml/sample)**
10X SET buffer (70 µl /sample)***
5 M NaCl (21µl /sample)
Proteinase K (Roche, -20C, 14 µl /sample)
1:1 Phenol:chloroform solution (600 µl /sample) – don’t forget to remove aqueous layer
Chloroform (600 µl /sample) – prepare fresh in 50 ml centrifuge tube
100% Isopropanol (900 µl /sample)
70% Ethanol in nuclease-free water (1 ml/sample)
RNase-DNase free 1.5ml centrifuge tubes
50ml DNase free-RNase free centrifuge tubes (Corning)
Microcentrifuge tube racks (at least 5-6)
Kimwipes (large)
RNase-zap
2-20 µl pipettors, 20-200 µl pipettors, 100-1000 µl pipettors
ART barrier pipette tips (0.1-10, 20-200, 100-1000 2 boxes should suffice), National
barrier tips (0.1-100)
Ice bucket with crushed ice
Centrifuge with small rotor at 4°C
Note: ALL solutions (except for phenol:chloroform and chloroform which should be
stored at room temperature until use) should be kept on ice.  Solutions should be prepared
fresh and used within 1 week.  All buffers should be made with nuclease-free water.
Note again: Remove RNAse from pipettors, centrifuge tubes, racks, crushed ice in ice
bucket and tips by spraying with RNase-zap and placing all in hood under UV for 30-40
minutes prior to use.  Adjust microcentrifuge temperature to 4°C.
Note: When weighing chemicals, do not dump extra chemicals back into original
container.  If using a couple of days old buffers, check pH prior to using.
*Cushion buffer recipe:
1.  Prepare in sterile 50 ml centrifuge tube.
2.  Weigh out 5.5 g of sucrose and dissolve in 35 ml of nuclease-free water.
3.  Add 400 µl of 1M Tris-HCl (pH 7.4).
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4.  Add 60 µl of 1M MgCl2.
5.  Bring up to 40 ml final volume.
6.  Mix and store at 4ºC for up to 1 week.
**Lysis buffer recipe:
1. Prepare in sterile 50 ml centrifuge tube.
2. Weigh out 4.1 g of sucrose and dissolve in 35ml of nuclease-fee water.
3. Add 100 mg of Na Deoxycholate (Dissolve completely)
4. Add 400 µl of 1M Tris-HCl (pH 7.4)
5. Add 60 µl of 1M MgCl2
6. Add 200 µl of NP-40 (Nonidet P-40, Roche, 4C) *** very viscous
7. Mix and store at 4ºC for up to 1 week.
***SET buffer recipe:
In a 50ml centrifuge tube add the DEPC water to the other components to create a total
volume of 10 ml.
- 7 ml DEPC treated water
- 1 ml of 1M Tris-HCl (pH 8.0)
- 1 ml of 0.5M EDTA (pH 8.0) heated at 56˚C to
solubilize
- 1 gram SDS
Mix and store at 4˚C or on ice for up to 1 week.
Phenol:chloroform:isoamyl alcohol (25:24:1):
Prepare this solution fresh on the day of RNA isolation.  You will need 600 µl of this per
sample, calculate total amount need and make solution accordingly.  When preparing, use
glass pipettes and avoid aqueous layer in phenol.  Remove aqueous layer after adding
both chloroform and phenol to tube using 1000 µl pipettor.
METHODS
Day 1
1. Label 4 RNase-free/DNase-free tubes (marked 1a, 1b, 1c, 1d for example) per
sample and place in centrifuge tube racks.
2. Add 400 µl of cold cushion buffer to each “a” tube of set.
3. Add 500 µl of cold lysis buffer to frozen samples and pipette up and down several
times to lyse cells completely.  Layer this over the cushion buffer so fractions do
not mix.
4. Centrifuge “a” tubes in microcentrifuge at 800 g for 6 minutes at 4ºC.  Return
samples to ice bucket after spin.
5. Transfer upper phase (550 µl) of tubes to tubes marked __b.
6. In these tubes, add 70 µl of 10X SET buffer, 21 µl of 5M NaCl, 14 µl of PK
(10mg/ml).  Vortex well (for 15 sec/tube).  Vortexing is crucial to making sure the
protein is degraded.
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7. Incubate for 45-60 at 45ºC.  Adjust microcentrifuge temperature to 21°C.
8. After incubation, add 600 µl of phenolchloroform to each tube.  Vortex hard and
mix well.
9. Centrifuge tubes at 19000g at 21°C for 4 minutes.
10. Transfer upper phase to tubes marked __c.  Add 600 µl of chloroform to tubes.
Vortex hard and mix well.
11. Centrifuge tubes at 19000g at 21°C for 4 minutes.
12. Transfer upper phase to tubes marked __d.  Do not get too close to protein layer
or organic layer.  This will lower quality of RNA.




70% Ethanol in nuclease-free water (1 ml/sample, 4°C)
Nuclease-free water (9 µl /sample, 4°C)
Kimwipes
RNase zap
0.1-10 µl pipettor, 100-1000 µl pipettor
Microcentrifuge at 4˚C, fast temp this prior to using
RNA samples
Nanodrop
Note: Remove RNAse from pipettors, centrifuge tubes, racks, kimwipes, crushed ice in
ice bucket and tips by spraying with RNase-zap and placing all in hood under UV for 30-
40 minutes prior to use.  Adjust microcentrifuge temperature to 4°C.
METHODS
1. Centrifuge the RNA tubes at 4˚C at 19,000g for 20 minutes.  Make sure all the
tubes are place with the tabs pointing out.  This makes it easier to locate each
pellet.
2. Carefully remove the RNA tubes trying not to disturb the pellet.
3. Carefully pour off the isopropanol making sure not to pour off the pellet.  Use a
sheet of colored paper if necessary to make it easier visualize the pellet.
4. Add 1ml ice cold (-20˚C) 70% EtOH (made with nuclease free water) to each
sample.  Cap and invert the tube a few times to wash the pellet.
5. Centrifuge at 4˚C at 19,000g for 10 minutes.
6. Again carefully pour off the EtOH making sure not to pour off the pellet.
Remove as much EtOH as possible.  Leave tubes open and inverted over a kim
wipe.  Allow the EtOH to evaporate for 1 hour.
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7. If after 1 hour, there is still a significant amount of EtOH not evaporated, used a
kim wipe to soak up some EtOH or pipette off small amounts to leave as little
EtOH as possible.
8. Resuspend the pellets in 9 µl of nuclease-free water.
9. Vortex and pulse in the room temperature microcentrifuge to concentrate the
contents at the bottom of the tube.
10. Proceed to MBB for nanodrop measurement.  Take 0.1-10 µl pipettor and 0.1-10
µl RNase free tips with samples and place in foam box.  Also, bring notebook to
note down absorbance values.  You will need biosci username and password.
Measure with the Nanodrop (MBB)and store at -80˚C.  Absorbance values should
be greater than 1.8 for both 230:260 and 280:260 ratios.
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Turbo DNase kit protocol (Ambion)
MATERIALS:
TURBO DNase













NOTE:  This may be the MOST crucial kit in preventing curves in your negative control
for real time RTPCR.  It is important to aliquot your DNase into low protein binding
tubes and do not expose these to repeat freeze-thaw cycles. It is also important to mix
tubes well during incubation and inactivation.  All of this will ensure proper DNase
treatment.
METHODS:
1. Add 0.1 volume 10X TURBO DNase buffer (1 µl) and 1_l TURBO DNase to
RNA (this can remove up to 2 ug of DNA) into 0.5ml tubes.
2. Incubate at 37C for 20-30 minutes.
3. Add resuspended DNase Inactivation reagent (0.1 volume = 1.1µl). Mix well.
4. Incubate for 2 min at RT, mixing occasionally.
5. Centrifuge at 10000g for 1.5 minutes and transfer to fresh tube.  This volume is
usually near 7-7.5 µl.  DO NOT aspirate inactivation reagent, may interfere
with enzymatic reactions.
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DNA Gel Electrophoresis
Materials
Comb (10 vs. 20 wells)
Agarose
1L of TBE buffer**


















1. TBE buffer preparation.  First step is to make TBE buffer for running gel.
**1x Tris-Boric Acid-EDTA Buffer (TBE) Recipe – 89mM tris (pH 7.6), 89 mM boric
acid, 2 mM EDTA
To make 10x stock ( 1 liter) – dissolve the following in 600ml of distilled water and then
fill to final volume of 1 L with distilled water:
108 g Tris base (FW: 121)
  55 g Boric acid (FW: 61.8)
40 ml 0.5 M EDTA (pH 8.0)
2. Gel preparation.  Since the genes we’re looking at are near 100 bp, we will
prepare a 2 (w/v) % agarose gel.  Consult the following chart for other gene sizes
and appropriate gel concentrations.
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a. Weigh out 2g of agarose into a weigh boat and measure 100ml of TBE
buffer in a graduated cylinder.
b. Add buffer into a small flask (able to fit into microwave) and add agarose
into the liquid.  Swirl around several times to mix.
c. Place flask into microwave and microwave on high for 2 min.  Be careful
NOT to let mixture bubble over otherwise you will have a mess.
d. Also, add appropriate comb (based on how many samples you have) into
tray prior to heating up mixture.  Tape edges well to prevent agarose from
spilling over.
e. You will need to heat up the flask several times to make sure agarose has
dissolved (turn off lights to aid in watching).  Once dissolved fully, pour
80 ml of mixture into tray and using spatula, remove any debris,
undissolved fragments (turn on the light to aid in seeing).  Leave tray
undisturbed for 20-30 minutes.
3. Sample preparation, loading and running gel.    
a. While gel is cooling, prepare samples.  You will need a long sheet of
parafilm to mix the samples on.  Paper does not need to be removed.
b. Prepare chart in lab notebook with information on what sample goes into
which well.
c. When preparing samples, prepare them in the order to be loaded.  First
well is usually DNA ladder.
d. For our tray, add 5-6µl of DNA loading buffer and 15-20µl of DNA
sample (only 10-12µl of DNA ladder should be appropriate) using
appropriate tips.
e. Once gel is cooled, remove tape and comb, carefully.
f. Place tray with gel in the appropriate position (wells at the top) into
chamber.  Add TBE buffer until “fill to this line.”  (about 700-800ml).  Do
not pour on gel.
g. Once chamber and gel are ready, mix each sample by pipetting and load
into gel using loading tips.  Position tip right above well so that sample
goes to desired well.
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h. Once samples are loaded, place lid on gel tightly, connect electrodes to
power supply (making sure samples are running from negative to positive)
and turn on supply.  Increase voltage to 110 V and press run.
i. Check on gel from time to time to make sure you see bands of loading
buffer moving.
4. Staining gel. Once bands have run 50-60% of gel length, then power supply can
be turned off.
a. Remove lid from chamber and remove casting tray with gel, being careful
not to let gel slip out.
b. Using graduated cylinder, measure 200-300ml of TBE buffer from
chamber by pouring from chamber to cylinder in sink.  Add liquid to
staining container.
c. We will need 0.5 µg/ml Ethidium bromide solution to stain the gels.
Thus, you will need 100-150 µg of Et br.  Add this to solution and mix
well before adding gel.
d. Slip in gel carefully to container to prevent splashing.  Close and place on
orbital shaker for 15-30 min.
e. Remove liquid from container and add 200-300ml of ddH20 into
container, making sure not to add it directly onto gel.  Close container.
Destain on orbital shaker for 10-30 min.
f. Remove liquid and rinse gel with ddH2O briefly.  Add fresh ddH2O to
cover gel, close container, place container with several pairs of gloves and
napkins in Et br box and proceed to MBB for imaging.  (Don’t forget
access card if after hours.)
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5. Imaging gel.  Imaging rooms are on 2nd and 3rd floor.  If they are in use, they will
be locked.  If vacant, they will be kept open with a wedge.  When finished using,
place wedge between door and wall to keep open.
a. Wear gloves, turn on regular light from illuminator and turn off light of
room.
b. Click on alpha imager (software), type in ROBERT and KRUG for
username and password.
c. Remove gel from tray carefully and place on illuminator.
d. Increase the exposing time and adjust the black, white and gamma
channels to reduce background and see bands most clearly.  Use the
camera lens for focus and zooming in.
e. Once image is ready, select freeze and print image.  Tear off image and
keep for records.
f. Close program, remove gel from illuminator and place into container.
Wipe illuminator with napkins, remove gloves and return to lab.
g. Dump water in sink, wash container and throw gel into biowaste.
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Negative control Real-time RT-PCR using SYBR green/ROX
Superarray Mastermix
Real-time must be performed on all samples without RT to confirm the absence of DNA
contamination in samples (DNase treatment should have removed all DNA, but process is
a good check to see if samples can be run using real-time).  Also, must perform no
template reaction to make sure no background, confirm the adequate linear range.
MATERIALS:




real-time optically translucent 384 well plate (can be obtained from core facility, see
Shawn)
clear tape (see Shawn)
 METHODS:
1. For each 25ul reaction, mix the following in an optically clear 384 well plate:
- 12.5 µl RT2 Real-time PCR master mix
- 10.5 µl dd H2O
- 1 µl template without RT
- 1 µl RT2 PCR primer set
2. For the no template reaction negative control, mix the following in an optically
clear 384 well plate:
- 12.5 µl RT2 Real-time PCR master mix
- 11.5 µl dd H2O
- 1 µl RT2 PCR primer set
3. Take plate to core facility and proceed with real-time methods.
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Ice cold FACS buffer (1% BSA, 0.05% Na Azide in PBS)
White rack for facs tubes
Parafilm
Zip disc/Thumb drive
Antibodies (mouse cKit-FITC, sca-1-PE, CD16/CD32 FcBlock (BD Pharmingen))
PROCEDURE:
Prepare staining scheme prior to experiment, complete with images, how each sample
will be stained for what.  Check all antibodies prior to staining and consolidate antibodies
in box.  Prepare calculations for staining protocol (how much antibody, how much FACS
buffer).  Staining volume is usually 50µl /million cells.  Recommended antibody
concentrations are listed on antibody datasheets.  Common concentration is 1µg/million
cells.  (samples, extra unstained sample, isotype controls, propidium iodide)
Staining
1. Wash pelleted cells twice with FACS buffer and spin at 300g for 5 minutes, 4 ºC.
For second wash, resuspend pellet in 1ml of buffer and transfer to 1.5ml
microcentrifuge tube and proceed as before.
2. Following centrifugation, resuspend in 30µl of FACS buffer.
3. Add calculated FcBlock amounts to each sample, resuspend cells, and incubate
for 10 minutes on crushed ice.
4. TURN OFF LIGHTS.  All remaining steps are done in DARK!!!!
5. Add calculated amounts of both antibodies to all samples (except isotype control
samples), resuspend, and stain for 30 min in dark on ice.
6. For isotype control samples, add isotype control to one sample and stain as above.
7. For extra sample, do not stain.
8. Remove from ice, tap with finger, add .5ml of facs buffer, spin for 5 min.
9. Remove supernatant from samples.
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10. Resuspend sample in 300µl of FACS buffer and transfer to FACS tubes in foam
racks.  For propidium iodide sample, add 10µl of propidium iodide when ready to
proceed to FACS and resuspend in FACS tube.  Parafilm tubes, cover with foil
and place in foam box.  Now you are ready to proceed to FACS.
FACS
1. Follow FACS procedure: Turn on pump, turn on facs machine, prime 3x, turn on
computer, enter cellquest pro, set up template or open existing template, connect
to cytometer, open up threshold, compensation, counters, setup acquisition&
storage, open inspector.
2. These next steps are VERY IMPORTANT.  Follow strictly:
a. First run positive control and adjust voltages (FSC, SSC, FL1, FL2).
VERY IMPORTANT to adjust compensation, as well.  Draw region
around positive regions in FL1FL2 plots to backgate in scatter plot and see
where lymphocyte populations are located.  This will be your reference
plot.  Record voltages and compensation.
b. Now, run sample.  Make sure speed is low and acquisition number is set to
something large.  Work fast.  Focus on FL1FL2 plot to center cells
(negative or positive, doesn’t make a difference) in center of plot.  Make
sure there are no cells not included (pushed down, etc.).  If cells are
pushed at the top, it is fine, these are most likely antibodies not cells.
Adjust compensation to make sure FL1 cells do not look like FL1FL2
positive cells (at the same time, making sure cells are not pushed to the
side).  Record settings !!
c. Once settings are set, you can continue acquiring all cells.  Settings should
not need to be changed.  Change label with each sample.  Make minor
adjustments if necessary.
d. Follow shut-down procedure.  Make a copy of data, stats onto zip, thumb
drive.  Fill in sign-in sheet.
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Cell harvesting from scaffold culture protocol
MATERIALS:
Accumax (Innovative Cell Technologies, San Diego, CA)
50ml centrifuge tubes (2 tubes/scaffold)
15ml centrifuge tubes









1. Remove scaffolds from 24 well plates and place in 50ml centrifuge tubes using
forceps (1 scaffold/tube).  Add 1ml of PBS to side of tube.
2. Rinse scaffolds and remove PBS carefully, not disturbing scaffolds.
3. Add 250ul-500ul of Accumax (enough to cover scaffolds) to each tube.  Vortex
gently and incubate in 37°C water bath for 10 min.  (Vortex gently every 3-4
minutes).
4. Detach cells by adding 1ml of serum-containing medium to each tube and gently
pipetting repeatedly for 10-20x.
5. Place mesh on top of 50ml centrifuge tube and add detached cell suspension to
remove scaffold remnants.  Rinse centrifuge tube with 1ml of medium and wash
filter to remove and remaining cells.
6. Reuse same mesh for other scaffolds of same condition.
7. Repeat above for each scaffold.
8. Resuspend cell suspension well and transfer to 15ml centrifuge tubes.  Count cells
from representative sample and note in lab notebook
9. Spin down for 300g at 4°C for 8 minutes and aspirate out supernatant.  Pellets
should be small but visible.
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Scaffold sterilization and seeding protocol
MATERIALS:
70% ethanol







2-20 µl and 20-200 µl pipettor and sterile yellow tips
60mm sterile plastic plates
60mm circles of parafilm that have been UV lighted prior to cell seeding







1. Place scaffolds in individually labeled centrifuge tubes with about 10-20ml of
70% ethanol (enough to cover the scaffolds completely while rotating on side).
Then, place tubes on rotator in ENS 621.  Rotate for at least 1-2hr.
2. After 1 hr, remove tubes from rotator and bring in hood.  Aspirate ethanol and
replace with 10-20ml of sterile PBS (or medium/FBS).  Rotate on rotator for at
least 3 hrs.  The PBS wash will remove ethanol from the scaffolds.
3. While scaffolds are washing, trypsinize and count cells.  Prepare cell suspension
so that cell seeding volume is not more than 50-100µl /scaffold for 6-8mm
diameter scaffolds and 150-200µl /scaffold for 10-15mm diameters.
4. Once suspension is ready, ethanol centrifuge tubes with scaffolds and bring inside
hood.  Using forceps, place parafilm discs in 60mm dishes.  Remove PBS wash
using glass Pasteur pipette and using forceps transfer sterile scaffolds to paraffin
films.  Use another Pasteur pipette to remove any residual liquid volume on
scaffolds (once you’ve transferred to parafilm discs).  Use different dishes for
different scaffold conditions.
5. Mix cell suspension well in centrifuge tube and seed dropwise using appropriate
pipettor onto scaffolds carefully making sure volume sits on top of scaffold.
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6. Cover dishes, label, ethanol and place in incubator carefully so that scaffolds do
not move around.  Incubate for 7 hrs.
7. Check scaffolds periodically to make sure volume has not evaporated.  If so, add
appropriate amount of medium.
8. After 7 hours, prepare 24 well plates by adding 1 ml of fresh medium into
individual wells and 1 ml of PBS on perimeter.
9. Transfer scaffolds from dishes to plates, by first immersing scaffolds in medium
in centrifuge tubes (to wash off any unattached cells) and then transferring to 24
well plates using sterile forceps.  Label, ethanol, and place in incubator.
10. Replace medium every 3-4 days.
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Susan L. Ishaug et al.  “Bone formation by three-dimensional stromal osteoblast
culture in biodegradable polymer scaffolds.”  Journal of Biomedical Materials Research,
Vol. 36, 17–28 (1997)
MATERIALS:
PLLA (Lakeshore Biomaterials)




Sieves for pore sizes (<150µm, 150-425µm, >425µm)
Teflon coated muffin pans






15 or 50ml centrifuge tubes
Tape or rubber bands
CALCULATIONS:
We use 5ml polymer solution volume / 60m diameter mold.  This gives us 2-3mm
thickness.  For a 10% (w/v), that’s 10g/100ml * 5ml = 500mg.  For 90% porosity, we use
4.5 g of NaCl.
METHODS:
1. Weigh out 4.5g of NaCl in weighboat (4.5g of salt gives 90% porosity) per mold.
Each mold gives 15 8mm diameter scaffolds.
2. Weigh out PLLA according to (w/v) percentage in weigh boat and transfer to
glass vials.
3. Add 5 ml of dichloromethane or chloroform to PLLA in vial in chemical hoods
using glass pipets and pipet aid, cap on tightly, and vortex till completely
dissolved.
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4. Add NaCl into Teflon coated pan so that salt layer is evenly dispersed within the
mold.
5. Pour polymer solution into mold and shake continuously to achieve even salt
dispersion.  Using a glass stirrod to evenly distribute salt may help.
6. Let organic solvent evaporate for 1-3hours.  Longer periods will ensure complete
evaporation but will make scaffold punching more difficult.
7. Invert mold and pop out scaffold disc.  Place on kimwipe.  Using biopsy punch or
metallic punch, punch out scaffolds and let airdry over night.  Only punch out if
scaffolds fairly dry.  Any stickiness/ strings mean you should wait.
8. For salt leaching, fill a 1L beaker with 1L of DDH2O.  Place 10-15 pre-cut
scaffolds in beaker with appropriate sized stir bar.  Turn on stir setting to 3-4 so
that scaffolds are moving but not being sheared.
9. Change water every 12 hours and let salt leach out for at least 48 hrs.
10. Remove scaffolds, dry water on kimwipe, and freeze-dry using liquid nitrogen
and lyophilizer for at least 48 hrs.  To freeze-dry, transfer scaffolds to 15 or 50ml
centrifuge tube.  Cover with small kimwipe and rubber band or tape.  Place in
liquid nitrogen for 1 minute and transfer to lyophilizer immediately.
11. After freeze-drying, transfer scaffolds as is to desiccator and store at room
temperature.
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Protocol for HSC => B/T Cell Differentiation
Steps:
1. Cell isolation (bone marrow, fetal liver)
2. Magnetic cell sorting (CD117, Sca-1, Lin depletion)
3. Flow cytometry check of cell sorting
4. Coating of plates (antibody?, antigen)
5. Cell seeding and medium change
6. Flow cytometry analysis
Starting Populations:
1. CD117+Sca-1hi 4-6 week old mice femurs
2. CD24lo/lin-/CD117+/Sca-1 hi FL cells from timed pregnant mice Swiss.NIH
mice;
HSC Sources:
1. 4-6 week old mice femurs
2. Day 15 FL cells from timed pregnant mice Swiss.NIH mice
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I.  Cell Isolation from Bone Marrow in Mice Femurs:
OBJECTIVE: To isolate cells from the bone marrow of mice femurs
** In advance, reserve room, make sure supplies are sterilized, prepare ARC box,
prepare hood for cell removal.
ARC Supplies
70% ethanol (spray bottle)
Kimwipes (11x17)
Paper towels









Lab Supplies (prepare this and store under UV light in hood before u go and kill
mice and isolate femurs)
Have a blue sheet with the following supplies
100ml Beaker with 70% ethanol
5ml Syringes
100ml Beaker for PBS
25 gauge needles (5)
sterile scissors
sterile forceps
50ml centrifuge tube for cells
Put PBS bottle in hood when ready for use (leave in water bath)
Bone Marrow from Femurs Protocol
1. Make sure room is reserved day in advance.
2. Wear lab coat and gloves
3. Spread out diapers and set up table for surgeries.  Take out supplies (ethanol,
scissors, forceps, napkins, foam box with cold PBS) out of box and place on table.
Put paper towels in one hole of killing box and paper towels on bottom of box.
4. Isolate specific mice from Rm 1.1118 and put in killing box
5. Kill using CO2 tank.  Only turn bottom gray knob and leave air on for about 5
minutes.
232
6. Do this for each mice.  Spray mouse down with 70% ethanol.  Cut off skin near
pelvis and peel down to minimize hair in flesh.  Cut below patella and put foot,
etc. in waste pile.  Near the last vertebra in the back of the mouse, make an
incision and cut entire leg off.  Make sure socket is still sealed.  Remove all
excess flesh and place femur in PBS tube.  Spray ethanol on supplies as necessary
(after all skin is removed, etc.)
7. Collect dead mice and parts in napkins/diapers and place in mice body freezer.
Clean up table/bench with ethanol and place objects back in container.
8. Wash soiled utensils with water and autoclave in fresh paper.  Store in dryer after
autoclave.
9. Throw out ice and put ethanoled PBS container with femurs in hood (first turn off
UV and turn on light).
Hood Section
10. Ethanol PBS bottle, gloves, timer.
11. Pour 40ml of PBS into 100ml beaker.  Open 5ml syringe and load 25 gauge
needle.  Load barrel with 5ml of PBS from beaker.  Lay syringe in beaker ready
for use.
12. Remove femur from centrifuge tube and clean all excess flesh not removed earlier
using scissors and forceps.  Make sure u do not expose the inside of the femur.
13. Place cleaned femur in 70% ethanol for one minute using forceps to hold femur.
14. Cut off tips of femur.
15.  Insert syringe needle into one side of femur and position bottom of femur over
50ml centrifuge tube.  Slowly flush PBS through femur and wash out so bone
appears white.  Edges may be a little tricky (cells collect here).
16. Repeat procedure for all femurs and reload syringe with fresh PBS as necessary.
17. Throw away napkin, waste, femurs, syringes, into red autoclave bag.  Throw
away needles into sharp box.  Autoclave soiled scissors and forceps.  Store tube
with cells in foam box with ice until cell separation.
18. You are now ready for magnetic cell separation.
?????Procedure Regarding FL cell isolation => UNKNOWN!
233
II.  Magnetic Cell Separation (Miltenyi Biotec – lineage depletion, Dynal Biotec –
ckit+, sca-1+ isolation)
OBJECTIVE: To isolate lin – ckit+ sca1+ cells using magnetic beads.  Will use
Miltenyi Biotec system for lin depletion and Dynal Biotec for positive selection.
**Prior to work, store antibodies on ice (make sure enough for expt and check
expiration date), prepare buffer, store columns, magnets in hood for sterilization,
count cells.
Example of required calculation:
Each mouse gives 30 x10^6 cells.  HSCs can be from 0.01% to 0.1% of original
population.  (after lineage depletion, ckit isolation, etc.)
THUS,
5 mice x ((30x10^6 cells)/mice = 150 x 10^6 or 1.5 x 10^8 cells
1.5 x 10^8 x 0.01% = 15000 HSCs
1.5 x 10^8 x 0.1% = 150000 HSCs
Range = 15000 – 150000 HSCs
Actual amount of antibodies and buffer will depend on cell count.  For example,
For 15 x 10^7 cells, we will need: (these amounts correspond to steps listed below)
40ul x 15 = 600ul of buffer to resuspend cells in
10ul x 15 = 150ul biotinylated antibody
30ul x 15 = 450ul buffer
20ul x 15 = 300ul streptavidin microbeads
10-20x labeling volume => 6 – 12 ml of buffer before spinning
500ul x 1.5 = 750ul buffer added right before magnetic separation
Components Supplied in kit:
1 mL Biotin-Antibody Cocktail:Cocktail of biotin-conjugated monoclonal antibodies
CD5, CD45R (B220), CD11b, anti- Ly-6G (Gr-1), 7-4 and Ter-119.
2 mL Anti-Biotin MicroBeads: MicroBeads conjugated to a monoclonal Anti-Biotin
antibody (clone: Bio3-18E7.2; mouse IgG1).
Reagents and instruments required:
Buffer (degassed): PBS (phosphate buffered saline without Ca2+ and Mg2+) pH 7.2,
supplemented with 0.5% BSA (bovine serum albumin). Keep
buffer cold (4-8 °C).
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MACS Columns and MACS Separators: (MS 107 max number of labeled cells 2x108
max number of total cells; LS 108 max number of labeled cells 2x109 max number of
total cells; we will need LS)
Foam box with Ice for binding
Two 50ml centrifuge tube (for waste, sample)
Four 1 ml centrifuge tubes for cell count, flow cytometry (before and after lineage
depletion)
40um nylon mesh filter
Protocol
Preparation of bone marrow cells
All steps should be performed on ice.
1. Disaggregate cells in 50ml tube by gentle pipetting them several times.
2. Pass cells through 30 µm nylon mesh to remove cell clumps.  Wet filter with buffer
before use.
3. Wash cells by adding buffer, centrifuge at 300xg for 10 minutes at 4–8 °C. Pipette off
supernatant completely.
4. Resuspend cell pellet in 5ml of buffer and take an aliquot for cell counting.
5.  Cell count: Remove 10µl of cells and place in 1ml ucentrifuge tube.  Add 10µl of
trypan blue.  Mix and add 10µl solution to each side of hemacytometer.  Count and note
cell amount (amount x 2 x number of mls x 10^4).
6.  Calculate amounts of buffers and antibodies needed.
7.  Flow: Remove 50µl of cell solution for cell staining and place in 1ml centrifuge tube.
Store on ice.
Magnetic labeling
* Fast, pre-cooled cell and antibody solutions will prevent capping of antibodies on the
cell surface and non-specific cell labeling.
* When working with less than 107 cells, use the same volumes as indicated. When
working with higher cell numbers, scale up all reagent volumes and total volumes,
accordingly.
* Working on ice may require increased incubation times. Higher temperatures and/or
longer incubation times lead to non-specific cell labeling.
1. Determine cell number.
2. Centrifuge at 300xg for 10 minutes. Pipette off supernatant completely.
3. Resuspend cell pellet in 40 µL of buffer per 107 total cells.
4. Add 10 µL of Biotin-Antibody Cocktail per 107 total cells.
5. Mix well and incubate for 10 minutes at 4-8 °C.
6. Add 30 µL of buffer per 107 total cells.
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7. Add 20 µL of Anti-Biotin MicroBeads per 107 total cells.
8. Mix well and incubate for additional 15 minutes at 4-8 °C.
9. Wash cells with buffer by adding 10-20 x labeling volume and centrifuge at 300xg for
10 minutes.  Pipette off supernatant completely.
10. Resuspend up to 108 cells in 500 µL of buffer.
11. Proceed to magnetic separation.
Magnetic separation
Note: When working with bone marrow of normal mice, the number of labeled cells is
almost equal to the number of total cells.   Do following steps in hood.  Ethanol columns,
magnets, antibody bottles before hood use.  Since we are doing lineage depletion we will
be using LS columns, large amount of cells.
1. Place LS column in the magnetic field of LS MACS Separator.
2. Prepare LS column by rinsing with appropriate amount of buffer:  LS: 3 mL.  Place
centrifuge tube under magnet ready to collect wash.  Place another tube near magnet to
get actual sample.
3. Apply cell suspension onto the column.  Allow the cells to pass through and collect
effluent as fraction
with unlabeled cells, representing the enriched lineage negative cell fraction.
4. Wash column with appropriate amount of buffer. Perform washing steps by adding
buffer three times, each time once the column reservoir is empty.  LS: 3x3 mL  Collect
the effluent in the same tube as effluent of step 3. This fraction represents the enriched
lineage negative cells.
5.  Throw away waste.  Remove magnet from inside of hood.
Evaluation of lineage negative cell purity
1.  The purity of the enriched lineage negative cells can be evaluated using flow
cytometry.  Save small aliquot (10ul) for cell count and (50ul) cell purity analysis using
flow cytometry.
2.  Keep samples on ice (sample in 50ml centrifuge tube, 1ml tube for flow, 1ml tube for
cell count).  Label tubes so no mixup occurs.
3.  Count cells using above procedure prior to positive selection part.
**At this point u will have three tubes on ice.  One 50ml centrifuge tube with samples.
Two tubes of 50ul cell suspension before and after magnetic cell separation.  Before this
upcoming part, spin down cells in buffer and resuspend in 1ml.
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**Prior to magnetic cell separation, u will need to prepare buffers (DNAase buffer and
aliquot this in 10ul portions, PBS with 0.1% Tween 5ml, PBS with 0.1% BSA 5ml,
alphaMEM with 1% heat-inactivated (for 30 min at 56C) FBS 5ml).
** Where it says RPMI substitute with alphaMEM.
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Dynal Biotech Magnetic Cell Separation (ckit+ sca-1+ cells)
 Materials supplied in kit
Component
CELLection™ Dynabeads.
Supplied as 4 x 108 beads/ml in phosphate buffered saline (PBS),
pH 7.4, containing 0.1% bovine serum albumin (BSA) and 0.02%
sodium azide (NaNH3)
Releasing Buffer. Component 1.
DNase (15,000 – 20,000 U freeze-dried per vial)
Releasing Buffer. Component 2.
Buffer
Additional materials required
Biotinylated antibodies ckit/CD117 and sca-1/Ly6AE. (Both from eBiosciences)
Magnetic particle concentrator (Dynal MPC®).
Mixing device allowing tilting and rotation of tubes (Dynal Sample Mixer).
Buffers. (releasing buffer and PBS with 0.1% tween)
Tubes, glass ware, pipettes.
2 - 8°C incubator or ice.
Use at least 25 µl Dynabeads (107 beads) and 4 µl Releasing Buffer per ml of sample. For
counted samples, to calculate number of Dynabeads to use, Dynal recommends using at
least 107 beads per ml of sample and the ratio of beads to target cells should be at least
5:1.
Example calculation of bead amount, releasing buffer necessary:
(Consistent with above numbers) We have 150000 cells or 0.15 x 10^6.  We have
resuspended the cells in 1 ml of PBS with 0.1%Tween.  Thus,
25ul of Dynabeads
4ul of Releasing Buffer
As a check step: 150000 x 5 = 750000 beads necessary.  The bead suspension comes in
4x10^8 beads/ml.  Thus, we need at least 1.875 or 2µl.
Protocol
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Perform all steps in hood.
(Do this beforehand)  Preparation of Releasing Buffer
Transfer 320 µl buffer (Component 2) to each vial of freeze-dried DNase (Component 1).
Dissolve the enzyme gently.  Aliquot the Releasing Buffer into 10µl portions and store at
-20°C for up to 6 months. Avoid freezing - thawing more than twice per aliquot.
NOTE:
Do not stir the dissolved DNase solution (Releasing Buffer) vigorously at any point in the
procedure to ensure a fully active enzyme.
B) Dynabeads washing procedure
Dynabeads should be washed before use. The washing procedure is facilitated by the use
of the magnetic device (Dynal MPC).
NOTE:
Serum or protein fractions from serum (e.g. serum albumin) may contain free biotin and
should NOT be included in buffers used before and during coupling of biotinylated
antibodies to the beads.
1. Resuspend the Dynabeads thoroughly and transfer the desired amount of beads
(25 µl) to a tube suitable for the Dynal MPC.
2. Place the tube in Dynal MPC for 1 minute. Make sure the solution is clear and
pipette off the fluid without disturbing the beads.
3. Remove the tube from the Dynal MPC, add 1 - 2 ml buffer (e.g. PBS with 0.1%
tween) and resuspend.
4. Place the test tube in the Dynal MPC for 1 minute, remove the buffer and take the
tube out of the Dynal MPC.
Resuspend the washed Dynabeads back in 25 µl buffer (4x108 beads/ml).
C) Dynabeads Coating Procedure
The amount of Ab must be titrated for optimal cell yield. The type and the amount of
antibody required for the optimal performance of the beads will vary with the Ab-affinity
and antigen density on the cell surface.
1. Resuspend washed Dynabeads well by thoroughly shaking the tube.
2. Add 0.2 - 2 µg of biotinylated antibody per 107 beads directed against an
epitope on the desired target cell. 107 beads is 25 µl at the supplied concentration.
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A concentration of beads in PBS with 0.1% tween from 1-4x108 beads/ml is
suitable for optimal coating.
3. Rotate the bead and antibody suspension for 30 minutes at room temperature.
Would orbital shaker be fine?
4. Place the tube in a Dynal MPC for 1 minute. Make sure the solution is clear and
pipette off the fluid.
5. Remove the tube from the Dynal MPC and add 1ml PBS with 0.1% tween.
6. Repeat steps 4 and 5 three times.
7. Resuspend coated beads in original volume of PBS with 0.1% bovine serum
albumin (BSA) giving a final concentration of 4 x 108 beads/ml. 0.02% sodium
azide may be added as a preservative.
The beads are now ready for direct selection of cells from a cell suspension.
D) Isolation of target cells
NOTE:
During incubation and separation procedures it is important to keep the cell suspension
and buffers cold (2 - 8°C) to prevent attachment of phagocytotic cells to Dynabeads.
NOTE:
Precoated Dynabeads stored for more than two weeks should be washed once in PBS
with 0.1% BSA before use.
1. Prepare the cell sample (e.g. resuspend total cells at 5 - 20x106 cells/ml, generally
not more than 2x106 target cells/ml) and cool it to 2 - 8°C. Cell suspensions
prepared from tissue samples can be used but cells must be washed if DNase was
used in the tissue digest. When isolating cells from whole blood or buffy coat,
wash the sample once (e.g. 10 ml sample plus 40 ml PBS with 0.1% BSA.
Centrifuge 800g for 10 minutes. Remove supernatant to the original volume, 10
ml).   All that we can ignore, already have it accurate concentration.
2. Resuspend the precoated Dynabeads thoroughly and transfer the desired amount
of beads to a tube (25 µl per ml sample).
3. ****????Remove the buffer from the beads and add 1 ml of cell suspension so
that the bead concentration is at least 107 beads/ml cell suspension and bead:target
cell ratio 5:1. Mix cells and beads by light whirlmixing.
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4. Place a cap on the tube and incubate for 15 minutes at 2 - 8°C with gentle tilting
and rotation (in shaker that’s in fridge).
5. Place the tube in the Dynal MPC and leave it to separate for at least 1 minute.
6. Discard the supernatant gently with a pipette while the rosetted cells are attached
to the tube wall by the Dynal MPC.
7. Remove the tube from the Dynal MPC and add RPMI 1640 with 1% FCS to the
rosetted cells. Use 500 µl for up to 108 beads. Increase the volume to 1 ml for up
to 2x108 beads and so on.
8. Resuspend the rosetted cells by pipetting and transfer them to a new vial. To
increase recovery the first tube can be flushed with another 500 µl medium.
9. Place the tube in the Dynal MPC for 1 minute and pipette off the fluid.
10. Remove the tube from the Dynal MPC and resuspend gently by pipetting the
rosetted cells in minimum 500 µl RPMI with 1% FCS
11. Repeat steps 9 and 10 two times.
12. After the final wash, remove the fluid and resuspend the rosetted cells gently in
RPMI with 1% FCS pre-warmed to 37°C. Use 200 µl for up to 108 beads.
Increase the volume to 400 µl for up to 2x108 beads and so on.
13. Add 4 µl of Releasing Buffer for up to 108 beads used. Increase the volume to 8 µl
for up to 2x108 beads and so on.
14. Cover tube and incubate for 15 minutes at room temperature with gentle tilting
and rotation on orbital shaker. Due to the relatively small sample volume, care
should be taken that the cells remain in the bottom of the tube during agitation.
15. Flush rosettes vigorously through a pipette 6 – 8 times, then place the tube in the
Dynal MPC, leave for 1 minute and pipette the supernatant containing the
released cells to a new test tube containing 200 µl RPMI with 10% FCS. Failure
to pipette the sample will affect cell yield.
16. Remove the tube from the Dynal MPC.
17. To obtain the residual cells, add 200 µl RPMI with 1% FCS and flush the
suspension 4 - 5 times thoroughly through a narrow tipped pipette until no lumps
are seen. Place the test tube in the Dynal MPC for 1 minute and transfer the
suspension to the same tube as in step 15.
18. The released cells will then be in a total volume of 600 µl. Count cells using
hemacytometer.  Keep sample on ice.  This sample will be used for cell culture.
19. Place 10ul of final cell suspension in a microcentrifuge tube on ice for flow
cytometry analysis.
Repeat entire procedure for sca-1 antibody.
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Flow Cytometric Analysis
Take 10µl of final cell suspension and use for flow cytometry analysis. Staining selected
cells with the same antibody as used for isolation may be performed, but must be done
before addition of Releasing Buffer.
???? Would this be us???
Indirect isolation of target cells
For some antibodies and target antigens (especially low antigen expressing target cells) it
can be more effective to perform an indirect technique.
1. Incubate cell sample with biotinylated antibody. Use excess antibody (e.g. 1 µg /
106 target cells) and incubate for 30 minutes at 2–8°C.
2. Collect pretreated cells by centrifugation at 300g for 10 minutes. Discard the
supernatant.
3. Resuspend and wash the pretreated cells once in buffer (HBSS, RPMI or PBS) to
remove all unbound antibody. Do not use buffer containing BSA or other serum
fractions. BSA with very low biotin should be used if protein is required (PBS
with 0.1% BSA).
4. Add washed CELLection™ Dynabeads to the sample (>1 x 107 beads per ml
sample) to capture the antibody coated cells. Continue from point 3 of procedure
above.
Technical Tips
To ensure the most efficient cell capture
1. Titrate the antibody concentration used for coating the CELLection™ Dynabeads.
2. Always use buffers with 0.1% tween and not BSA before the antibody is coated
onto the beads to avoid free biotin that may be contained in BSA.
3. The effectiveness of cell separation is dependent upon the effectiveness of the
primary antibody. If the biotinylated antibody does not capture the cells it may be
due to the biotin molecule affecting the antigen binding site. If this occurs, it is
recommended to try an alternative biotinylation method.
To ensure the most efficient cell release
1. Never vortex DNase when resuspending freeze-dried form in 320 µl buffer.
2. After cells are incubated with Releasing Buffer it is essential that the bead / cell
complexes are vigorously pipetted before the magnetic separation to provide
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mechanical disruption to the DNA linker. Failure to pipette the cells will affect
cell yield.
Buffers/solutions
Phosphate buffered saline (PBS) pH 7.4,
NaH2PO4 x H2O 0.16 g
Na2HPO4 x 2 H2O 0.98 g
NaCl 8.10 g
Distilled water to 1 litre
PBS with 0.1% tween
Add 0.1% (v/v) tween-20 to PBS
PBS with 0.1% BSA:
Add 0.1% (w/v) bovine serum albumin to PBS.
RPMI with 1 or 10% heat inactivated FBS for 30min at 56C:
Add 1 or 10% (v/v) fetal calf serum to RPMI 1640.
We’re going to use alpha-MEM instead.  Should give same results as long as divalent
cations are present which they are.
PRECAUTIONS
Resuspend the Dynabeads well before use to obtain a homogeneous dispersion of beads
in solution.
Precautions should be taken to prevent bacterial contamination of the product.
Preservatives should be carefully removed before use by washing.
Antibody coated Dynabeads products stored for more than two weeks should be washed
once in PBS with 0.1% BSA before use.   
243
III.  Flow cytometry check of sorted cells
OBJECTIVE: To check the efficiency of magnetic cell separation procedure of ckit+
sca-1+ cells using flow cytometry.








Isotype controls (PE, FITC)
Fc Block
FACS Buffer (PBS, 1% BSA)
FACS tubes
For each sample, do the following:
1. Fill each tube to 1ml mark with FACS buffer
2. Spin down each tube in microcentrifuge at 1000rpm for 10 min
3. Throw out supernatant and repeat steps 1 and 2.
4. Throw out supernatant and resuspend latter three tubes in 500ul of buffer.  For the
first tube, suspend in 1.5ml if possible.  Then, put 500ul of suspension in one tube
and then 500ul into another tube.  These will be for the isotype controls (FITC,
PE).
5. Add 0.5-1µl of block to each tube and incubate on ice in box for 10 min.
6. Add 0.5-1µl of PE and FITC conjugated antibodies to each tube except the
isotype controls.  For isotype controls, add 0.5µl of PE isotype control to one tube
and 0.5ul of FITC isotype control to the other.  Let tubes sit on ice in box for 1 hr.
7. Resuspend cells in tubes after an hour.
8. Spin down at 1000rpm for 10min.
9. Remove supernatant and resuspend cells in fresh buffer (500µl).  Spin again at
above rate.
10. Remove supernatant and resuspend in 250µl or less.  Put suspension in labeled
FACS tubes and keep tubes on ice.
11. Proceed to FACS machine and follow appropriate procedure.
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IV.  DLL4 Coating of Plates
OBJECTIVE: To coat 24 well tissue culture plates with DLL4 at 1.5ug/ml
**This will need to be started right after bone marrow cells have been isolated.
Magnetic separation will probably take 3 hours, thus these two tasks can be done in
parallel.
Supplies
24 well tissue culture plates
DLL4 (thaw this before use)
PBS (thaw this before use)
Microcentrifuge tube
Required Calculations:
For 3 wells of DLL4 coating –
1.5ug/ml * .1ml/well * 3 wells = .45ug
.45ug/10ug/ml = 45µl of DLL4
Total Coating liquid => 3 x 100µl = 300µl




1. Calculate as shown above for desired concentration, well amounts.
2.  Add calculated amounts of DLL4 and PBS to microcentrifuge tube.
3. Add 100µl of above prepared solution to each well.  Do this fast so protein
mixture does not coat centrifuge tube.
4. Incubate at 37C for 2-3 hours to coat the plate.
5. Wash the plate 3 times with PBS (100µl /well) and decant.  Only do washing step
RIGHT B4 you are ready to seed cells onto coating.  In other words, keep coating
wet at all times.
** Will need to eventually add in avidin, blocking and antibody steps.
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V.  Cell Seeding and Maintenance
OBJECTIVE: to seed HSCs onto DLL4 layers in tissue culture plates and
differentiate cells to B and T cell lineages with exogenously added cytokines and
environmental signals.
**If you look at Hozumi’s protocols (with inserts, FL cells), they use 10000 FLCs/
well.  If u look at Pflucker’s papers (without inserts, HSCs), they use 4000
HSCs/well.   Which are we using???
**Appropriate controls should be put in place.  Negative control: HSCs without
growth factors, without OP9.  Variants: HSCs with OP9 (insert), without growth
factors (different combinations).
Supplies




Differentiation medium (alphaMEM, pen-strep, 20%FBS, 2.2g/L NaHCO3)






1.  Prior to HSC work, OP9 cells will have to be trypsanized and counted.  Standard
procedure should be followed.  Old medium aspirated.  Cells washed with PBS.  Trypsin
added to cells and cell incubated at 37C for 10min.  Cells washed off using medium.
Cells suspended well in medium and 10µl removed for counting.  Count using
hemacytometer.  Cell suspension spun down at 1000rpm for 5 min.  Supernatant
aspirated.  Need 5000 OP9 cells in each well insert.  Remove inserts and put in other well
positions.  Resuspend cells like described below so that 300µl or less = 5000 OP9 cells.
Add medium so that there is near 350µl in each insert.
2.  HSCs will be suspended in near 600µl of alpha MEM from previous sorting step.  We
need 10000 cells in each well at 1ml or less volume that is to say, each well cannot
supercede 1ml of medium/cell suspension or it will start overflowing.  Thus, the
suspension concentration should be noted so that each volume is under 1ml.  The lowest
concentration of cells can be 10000cells/ml (which is really lo conc).  SO, if we have
100000 cells total, we should suspend them in 1ml so that 100µl is equal to 10000 cells.
The previous cell suspension from sorting step should be spun down in centrifuge at
1000rpm for 5min.
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3.  Remove supernatant and resuspend in above described way.
4.  Wash DLL4 coated wells with PBS 3x.
5.  Put appropriate amount in each well and add differentiation medium if necessary to
have 1ml volumes in each well.
6.  Add growth factors to all wells: SCF, IL-7 (these first 2 are used by Hozumi), Flt-3L
(this is consistently used by Pflucker).  The following describes the amounts chosen (on a
per well basis):
IL-7 (10ng/ml) => 10ng/ml*1ml = 10ng; 10ng/10ug/ml = 1µl
SCF (50ng/ml) => 50ng/ml*1ml = 50ng; 50ng/50ug/ml = 1µl
Flt-3L (20ng/ml) => 20ng/ml*1ml = 20ng; 20ng/5ug/ml = 4µl
7.  Replace inserts onto wells.  Be careful not to spill medium.
Done for now.  Put reagents back in appropriate locations.  Seed remaining OP9 cells at
low density on TC plate for subsequent experiments.
** After 3 days, aspirate medium.  Replace with fresh medium and fresh growth factors
in above described amounts.
VI.  Flow cytometry of differentiated cells
OBJECTIVE: To analyze the immunophenotype of differentiated cells, specifically
for B and T cell lineages after 1wk.
Supplies
CD19-Biotinylated antibody





Isotype controls (B, PE, FITC, APC)
Fc Block
FACS Buffer (PBS, 1% BSA)
FACS tubes
**Nitty gritty of isotype controls need to be added.  Need to assign appropriate controls
to PE, FITC, B, APC conjugated antibodies.
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Protocol
For each sample, do the following:
1. After 1 wk, samples from well need to be removed.  Cells will have to be
trypsanized and counted.  Standard procedure should be followed.  Old medium
aspirated.  Cells washed with PBS.  Trypsin added to cells and cell incubated at
37C for 10min.  Cells washed off using medium.  Cells suspended well in
medium and 10ul removed for counting.  Count using hemacytometer.
2. Separate samples into separate centrifuge tubes.  Each sample should be separated
into isotype controls, single positive and double positive stained cells.
3. Fill each tube to 1ml mark with FACS buffer
4. Spin down each tube in microcentrifuge at 1000rpm for 10 min
5. Throw out supernatant and repeat steps 1 and 2.
6. Throw out supernatant and resuspend tubes in 500ul of buffer.
7. Add 0.5-1µl of block to each tube and incubate on ice in box for 10 min.
8. Add 0.5-1µl of Biotinylated, PE, FITC, APC conjugated antibodies to tubes
except the isotype controls.  For isotype controls, add 0.5µl of PE isotype control,
0.5µl of FITC isotype control, 0.5µl of APC isotype control.  Let tubes sit on ice
in box for 1 hr.
9. Resuspend cells in tubes after an hour.
10. Spin down at 1000rpm for 10min.
11. Remove supernatant and resuspend cells in fresh buffer (500µl).  Add PE-
Streptavidin to biotinylated-CD19 samples.  Let tubes sit on ice in box for 1 hr.
12. Spin again at above rate.
13. Remove supernatant and resuspend cells in fresh buffer (500µl).  Spin down
again.  Resuspend in 500µl.  Put suspension in labeled FACS tubes and keep
tubes on ice.
14. Proceed to FACS machine and follow appropriate procedure.
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Important Abbreviations
APC = antigen presenting cell
BMHSC/BMHSCs = bone marrow hematopoietic stem cells
CD_ = clusters of differentiation (cell surface markers)
CMV = cytomegalovirus
DCs = dendritic cells
DGS = Di George’s Syndrome
DL1/DLL1 = Delta like ligand 1
DL4/DLL4 = Delta like ligand 4
DN = double negative
DP = double positive
EB = embryoid body
ECM = extra-cellular matrix
EGF = epidermal growth factor
ESC/ESCs = embryonic stem cell
ETPs = Early T lineage progenitors
FACS = fluorescence associated cell sorting
FTOCs = fetal thymic organ culture
HERP2 = HES1 related protein gene
HES1 = hairy enhancer of split gene
HIS = histidine
HLA = human leukocyte antigen
HPC/HPCs = hematopoietic progenitor cells
HSC/HSCs = hematopoietic stem cells
ICN = intracellular Notch
IL-7 = interleukin 7
MFI = mean fluorescence intensity
MHC = major histocompatibility complex
MSEF = mean soluble equivalent fluorophores
NK = natural killer cells
PLGA = poly lactic glycolic acid
PLLA = poly L lactic acid
PMC = perimedullary cortex
QSC = quantum simply cellular kit
RTOCs = reaggregate thymic organ culture
SCF = stem cell factor
SP = single positive
TCR = T cell receptor
249
Bibliography
Anderson, G., Harman, B.C., Hare, K.J., and Jenkinson, E.J.  (2000).  Micro-
environmental regulation of T cell development in the thymus. Semin Immunol 12,
457–464.
Anderson, G., Jenkinson, E.J., Moore, N.C., and Owen, J.J.T.  (1993).  MHC class II-
positive epithelium and mesenchyme cells are both required for T-cell
development in the thymus.  Nature 362, 70-73.
Anderson, G., Moore, N.C., Owen, J.J.T., and Jenkinson, E.J.  (1996).  Cellular
Interactions in Thymocyte Development 14, 73-99.
Artavanis-Tsakonas S., et al. (1995).   Notch signaling. Science 268, 225-232.
Bagley, J., Rosenzweig, M., Marks, D.F., and Pykett, M.J.  (1999).  Extended culture of
multipotent hematopoietic progenitors without cytokine augmentation in a novel
three-dimensional device. Exp Hematol 27(3), 496–504.
Balciunaite, G. et al.  (2005).  The earliest subpopulation of mouse thymocytes contains
potent T, significant macrophage, and natural killer cell but no B-lymphocyte
potential.  Blood 105, 1930–1936.
Baron, M.  (2003).  An overview of the Notch signaling pathway. Semin Cell Dev Bio
13, 113-119.
Battista, S., Guarnieri, D., Borselli, C., Zeppetelli, S., Borzacchiello, A., Mayol, L., et al.
(2005).  The effect of matrix composition of 3D constructs on embryonic stem
cell differentiation. Biomaterials 26(31), 6194–207.
250
Beckstead, B.L., Santosa, D.M. and Giachelli, C.M.  (2006).  Mimicking cell-cell
interactions at the biomaterial-cell interface for control of stem cell
differentiation.  J Biomed Mater Res 79A, 94-103.
Bertrand, Y., Landais, P., Friedrich, W., Gerritsen, B., Morgan, G., Fasth, A., et al.
(1999).  Influence of severe combined immunodeficiency phenotype on the
outcome of HLA non-identical, T cell-depleted bone marrow transplantation: a
retrospective European survey from the European group for bone marrow
transplantation and the European society for immunodeficiency.  J Pediatr 134,
740-8.
Bhandoola, A. and A. Sambandam.  (2006).  From stem cell to T cell: one route or many?
Nature Rev Immunol 6, 117-126.
Bonilla, F.A. and R.S. Geha.  (2003).  Primary immunodeficiency diseases.  J Allergy
Clin Immunol 111,  S571-81.
Buckley, R.H.   (2003).  Transplantation immunology: Organ and bone marrow.  J
Allergy Clin Immunol 111,  S733-44.
Cantarero, L.A. et al. (1980). The absorptive characteristics of proteins for polystyrene
and their significance in solid-phase immunoassays.  Anal Biochem 105, 375-82.
Champion, S.   (1986).   The embryonic thymus produces chemotactic peptides involved
in the homing of hemopoietic precursors.  Cell 44, 781-790.
Chiba, S.   (2006).  Concise Review: Notch Signaling in Stem Cell Systems. Stem Cells
24, 2437-2447.
251
Cho, S.K., Webber, T.D., Carlyle, J.R., Nakano, T., Lewis, S.M., and Zuniga-Pflucker,
J.C.  (1999).  Functional characterization of B lymphocytes generated in vitro
from embryonic stem cells. Proc Natl Acad Sci USA 96(17), 9797–802.
Ciofani, M. and J.C. Zuniga-Pflucker.  (2007).  The Thymus as an Inductive Site for
Lymphopoiesis.  Annu Rev Cell Dev Biol 23, 463-93.
Ciofani, M., Schmitt, T.M., Ciofani, A., Michie, A.M., Cuburu, N., et al. (2004).
Obligatory role for cooperative signaling by pre-TCR and Notch during
thymocyte differentiation. J Immunol 172(9), 5230-9.
Connors, W.L. and J. Heino. (2005). A duplexed microsphere-based cellular adhesion
assay.  Analytical Biochemistry 337, 246-255.
Craig, A.M. and J.W. Lichtman.  (2001).  Getting a bead on receptor movements. Nature
Neuroscience 4(3), 219-220.
Cumano, A., Dorshkind, K., Gillis, S., and Paige, C.J.  (1990).  The influence of S17
stromal cells and interleukin 7 on B cell development. Eur J Immunol 20, 2183-
2189.
Curtsinger, J., Deeths, M.J., Pease, P., and Mescher, M.F. (1997). Artificial cell surface
constructs for studying receptor-ligand contributions to lymphocyte activation.
Journal of Immunological Methods 209, 47-57.
Dallas, M.H., Varnum-Finney, B., Delaney, C., Kato, K., and Bernstein, I.D.  (2005).
Density of the Notch ligand Delta1 determines generation of B and T cell
precursors from hematopoietic stem cells.  Journal of Experimental Medicine 201,
1361-1366.
252
Dang, S.M., Gerecht-Nir, S., Chen, J., Itskovitz-Eldor, J., and Zandstra, P.W.  (2004).
Controlled, scalable embryonic stem cell differentiation culture. Stem Cells 22(3),
275–82.
Dang, S.M., Kyba, M., Perlingeiro, R., Daley, G.Q., and Zandstra, P.W.  (2002).
Efficiency of embryoid body formation and hematopoietic development from
embryonic stem cells in different culture systems. Biotechnol Bioeng 78(4),
442–53.
de La Coste, A. and A.A. Freitas.  (2006).  Notch signaling: Distinct ligands induce
specific signals during lymphocyte development and maturation. Immunol Lett
102, 1–9.
de La Coste, A., Six E., Fazilleau, N., Mascarell, L., Legrand, N., Mailhe, M.P., Cumano,
A., Laabi, Y., and Freitas, A.A.  (2005).  In vivo and in absence of a thymus, the
enforced expression of the Notch ligands D-1 or D-4 promotes T cell
development with specific unique effects. J Immunol 174, 2730–2737.
de Pooter, R. and J.C. Zuniga-Pflucker.   (2007).  T-cell potential and development in
vitro: the OP9-DL1 approach. Current Opinion in Immunology 19, 163-168.
De Smedt, M., Hoebeke, I., Reynvoet, K., Leclercq, G., and Plum, J.  (2005).  Different
thresholds of Notch signaling bias human precursor cells toward B-, NK-,
monocytic/dendritic-, or T-cell lineage in thymus microenvironment.  Blood 106,
3498-3506.
De Smedt, M., Hoebeke, Il, and Plum, J.  (2004).  Human bone marrow CD34+
progenitor cells mature to T cells on OP9-DL1 stromal cell line without thymus
microenvironment.  Blood Cells, Molecules, and Diseases 33, 227-232.
253
Delaney, C., Varnum-Finney, B., Aoyama, K., Brashem-Stein, C., and Bernstein, I.D.
(2005).  Dose-dependent effects of the Notch ligand Delta1 on ex vivo
differentiation and in vivo marrow repopulating ability of cord blood cells.  Blood
106, 2693-2699.
Delgado, I., Huang, X., Jones, S., Zhang, L., Hatcher, R., Gao, B., and Zhang, P.  (2003).
Dynamic gene expression during the onset of myoblast differentiation in vitro.
Genomics 82, 109-21.
Dibbern, D.A.   (2005).   Wiskott-Aldrich Syndrome.  www.emedicine.com
Dorsch, M., Zheng, G., Yowe, D., Rao, P., Wang, Y., Shen, Q., Murphy, C., Xiong, X.,
Shi, Q., Gutierrez-Ramos, J.C., Fraser, C., and Villeval, J.L.  (2002).  Ectopic
expression of Delta4 impairs hematopoietic development and leads to
lymphoproliferative disease. Blood 100, 2046-2055.
Egeland, T.  (1991).  Stem cell isolation and purification. In: J.T. Kemshead (Ed.),
Magnetic Separation Techniques Applied to Cellular and Molecular Biology.
Wordsmiths’ Conference Publications, Somerset. 135-46.
Englehard, V., Strominger, J., Mescher, M., and Burakoff, S. (1978)  Induction of
secondary cytotoxic T-lymphocytes by purified LHA-A and HLA-B antigens
reconstituted into phospholipids vesicles. PNAS USA 75, 5688.
Fass, J.N. and D.J. Odde.  (2003).  Tensile Force-Dependent Neurite Elicitation via Anti-
! Integrin Antibody-Coated Magnetic Beads. Biophysical Journal 85, 623-636.
Friedlander, E., Arndt-Jovin, D.J., Nagy, P., Jovin, T.M., Szollosi, J., and Vereb, G.
(2005).  Signal Transduction of erbB Receptors in Trastuzumab (Herceptin)
Sensitive and Resistant Cell Lines: Local Stimulation Using Magnetic
254
Microspheres As Assessed by Quantitative Digital Microscopy. Cytometry Part A
67A, 161-71.
Gerecht-Nir, S., Cohen, S., and Itskovitz-Eldor, J.  (2004).  Bioreactor cultivation
enhances the efficiency of human embryoid body (hEB) formation and
differentiation. Biotechnol Bioeng 86(5), 493–502.
Gerecht-Nir, S., Cohen, S., Ziskind, A., and Itskovitz-Eldor, J.  (2004).  Three-
dimensional porous alginate scaffolds provide a conducive environment for
generation of well-vascularized embryoid bodies from human embryonic stem
cells. Biotechnol Bioeng 88(3), 313–20.
Germain, R.N.  (2002).  T-cell development and the CD4-CD8 lineage decision. Nat Rev
Immunol,  2(5), 309-22.
Gill, J., Malin, M., Sutherland, J., Gray, D., Hollander, G., and Boyd, R.  (2003).
Thymic generation and regeneration.  Immunological Reviews 195, 28-50.
Goldsby, R.A.  (2003)  Immunology. New York: W. H. Freeman and Company.
Gore, A.C. and J.L. Roberts.  (1993).  Regulation of gonadotropin-releasing hormone
gene expression by the excitatory amino acids kainic acid and N-methyl-D,L-
aspartate in the male rat.  Endocrinology 134, 2026-2031.
Gorostiza, Pau et al.  (2005).   Molecular Handles for the Mechanical Manipulation of
Single-Membrane Proteins in Living Cells. IEEE Trans Nanobioscience 4(4),
269–276.
255
Green, C.R. et al.  (2001).  Detection of submicroscopic magnetite particles using
reflectance mode confocal laser scanning microscopy.  Cell Biology International
25(10), 985-990.
Guidos, C.  (2006).  Thymus and T-lymphocyte development: what is new in the 21st
century?  Immunological Reviews 209, 5-9.
Gutierrez-Ramos, J.C. and Ronald Palacios.  (1992).  In vitro differentiation of
embryonic stem cells into lymphocyte precursors able to generate T and B
lymphocytes in vivo.  PNAS USA 89, 9171-9175.
Han W., Ye, Q., Moore, and M.A.  (2000).  A soluble form of human $-like-1 inhibits
differentiation of hematopoietic progenitor cells. Blood 95, 1616–1625.
Han, H., Tankigaki, K., Yamatoto, N., Kuroda, K., Yoshimoto, M., et al.  (2002).
Inducible gene knockout of transcription factor recombination signal binding
protein-J reveals its essential role in T versus B lineage decision. Int Immunol 14,
637-45.
Heinzel, K., Benz, C., Martins, V.C., Haidl, I.D. and Bleul, C.C.  (2007).  Bone marrow-
derived hemopoietic precursors commit to the T cell lineage only after arrival in
the thymic microenvironment.  J Immunol 178, 858-68.
Henningson, C.T., Stanislaus, M.A., and Gewirtz, A.M.  (2003).  Embryonic and adult
stem cell therapy.  J Allergy Clin Immunol 111, S745-53.
Hozumi, K., Abe, N., Chiba, S., Hirai, H., and Habu, S.  (2003).  Active Form of Notch
Members Can Enforce T Lymphopoiesis on Lymphoid Progenitors in the
Monolayer Culture Specific for B Cell Development.  Journal of Immunology
170, 4973-4979.
256
Hozumi, K., Negishi, N., Suzuki, D., Age, N., Sotomaru, Y., Tamaoki, N., Mailhos, C.,
Ish-Horowicz, D., Habu, S., and Owen, M.J.  (2004).  Delta-like 1 is necessary for
the generation of marginal zone B cells but not T cells in vivo.  Nature
Immunology 5(6), 638-644.
Hsieh, J.J.D., Henkel, T., Salmon, P., Robey, E., Peterson, M.G. and Hayward, D. (1996).
Truncated Mammalian Notch1 Activates CBF1/RBPJk-Repressed Genes by a
Mechanism Resembling That of Epstein-Barr Virus EBNA2.  Molecular and
Cellular Biology 16(3), 952-959.
Huggins, R.H.   (2006).   T-Cell Disorders.  www.emedicine.com
Ishaug-Riley, S.L., Crane-Kruger, G.M., Yaszemski, M.J., and Mikos, A.G.  (1998).
Three-dimensional culture of rat calvarial osteoblasts in porous biodegradable
polymers. Biomaterials 19(15), 1405–12.
Iso, T., Sartorelli, V., Chung, G., Shichinohe, T., Kedes, L. and Hamamori, Y.  (2001).
HERP, a New Primary Target of Notch Regulated by Ligand Binding.  Molecular
and Cellular Biology 21(17), 6071-6079.
Ito, F., Carr, A., Svensson, H., Yu, J., Chang, A.E., and Li, Q. (2003).  Antitumor
reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells: Implications for
cell therapy in a murine model. J Immunother 26, 222–233.
Jaleco, A.C., Neves, H., Hooijberg, E., Gameiro, P., Clode, N., et al.  (2001).  Differential
effects of Notch ligands Delta-1 and Jagged-1 in human lymphoid differentiation.
J Exp Med 194, 991-1002.
257
Jarriault S., Brou, C., Logeat, F., Schroeter, E.H., Kopan, R., and Israel, A. (1995)
Signaling downstream of activated mammalian Notch. Nature 377, 355-58.
Jenkinson, E.J., Jenkinson, W.E., Rossi, S.W., and Anderson, G.  (2006).  The thymus
and T-cell commitment: the right niche for Notch?  Nature Rev Immunol 6, 551-
555.
Johkura, K., Cui, L., Suzuki, A., Teng, R., Kamiyoshi, A., Okamura, S., et al.  (2003).
Survival and function of mouse embryonic stem cell-derived cardiomyocytes in
ectopic transplants. Cardiovasc Res 58(2), 435–43.
June, C.H.  (2007) Principles of adoptive T cell cancer therapy. Journal of Clinical
Investigation. 117(5), 1204-1212.
Kane, K., Champoux, P., and Mescher, M.  (1989).  Solid-phase binding of class I and
class II MHC proteins: Immunoassay and T-cell recognition. Mol. Immunol. 26,
759-768.
Karanu, F.N., Murdoch, B., Gallacher, L., Wu, D.M., Koremoto, M., Sakano, S., and
Bhatia, M.  (2000).   The notch ligand jagged-1 represents a novel growth factor
of human hematopoietic stem cells. J Exp Med 192, 1365–1372.
Kaufman, D.S., Hanson, E.T., Lewis, R.L., Auerbach, R., and Thomson, J.A.  (2001).
Hematopoietic colony-forming cells derived from human embryonic stem cells.
Proc Natl Acad Sci USA 98(19), 10716–21.
Kennedy, M. and G.M. Keller.  (2003).  Hematopoietic commitment of ES cells in
culture. Methods Enzymol 365, 39-59.
258
Kim, J.V., Latouche, J., Riviere, I., and Sadelain, M.  (2004).  The ABCs of artificial
antigen presentation. Nature Biotechnology 22(4), 403-410.
Kopan, R., J.S. Nye, and H. Weintraub. (1994). The intracellular domain of mouse
Notch: a constitutively activated repressor of myogenesis directed at the basic
helix-loop-helix region of MyoD. Development 120(9), 2385-96.
Kuroda, K., Tani, S., Tamura, K., Minoguchi, S., Kurooka, H., and Honjo, T.  (1999).
Delta-induced Notch Signaling Mediated by RBP-J Inhibits MyoD Expression
and Myogenesis.  Journal of Biological Chemistry 274(11), 7238–7244.
La Motte-Mohs, R.N., E. Herer, and J.C. Zuniga-Pflucker.  (2005).  Induction of T-cell
development from human cord blood hematopoietic stem cells by Delta-like 1 in
vitro. Blood 105(4), 1431-9.
Ladi, E., Yin, X., Chtanova, T. and Robey, E.  (2006)  Thymic microenvironments for T
cell differentiation and selection.  Nature Immunology. 7(4), 338-343.
Landreth, K.S. and K. Dorshkind.  (1988).  Pre-B cell generation potentiated by soluble
factors from a bone marrow stromal cell line.  J Immunol 140, 845-852.
Leen, A.M., Rooney, C.M., and Foster, A.E.  (2007).  Improving T Cell Therapy for
Cancer.  Annu Rev Immunol 25, 243-65.
Lefort, N., Benne, C., Lelievre, J.D., Dorival, C., Balbo, M., Sakano, S., Coulumbel, L.,
and Levy, Y.  (2006).  Short exposure to Notch ligand Delta-4 is sufficient to
induce T-cell differentiation program and to increase the T cell potential of
primary human CD34+ cells.  Experimental Hematology 34, 1720–1729.
259
Lehar, S.M. and Bevan, M.J.  (2005).   Notch ligands Delta1 and Jagged1 transmit
distinct signals to T-cell precursors.  Blood 105(4), 1440-1447.
Lehar, S.M. and M.J. Bevan.  (2002).  T cell development in culture. Immunity 17(6),
689-92.
Levenberg, S., Huang, N.F., Lavik, E., Rogers, A.B., Itskovitz-Eldor, J., and Langer, R.
(2003).  Differentiation of human embryonic stem cells on three-dimensional
polymer scaffolds. Proc Natl Acad Sci USA 100(22), 12741–6.
Levine, B.L., Bernstein, W.B., Connors, M., Craighead, N., Lindsten, T., Thompson,
C.B., and June, C.H.  (1997).  Effects of CD28 Costimulation on Long-Term
Proliferation of CD4+ T Cells in the Absence of Exogenous Feeder Cells.  Journal
of Immunology 159, 5921-30.
Levine, B.L., Mosca, J.D., Riley, J.L., Carroll, R.G., Vahey, M.T., Jagodzinski, L.L.,
Wagner, K.F., Mayers, D.L., Burke, D.S., Weislow, O.S., St. Louis, D.C., and
June, C.H.  (1996).  Antiviral effect and ex vivo CD4+ T cell proliferation in
HIV-postitive patients as a result of CD28 costimulation.  Science 272, 1939.
Li, H., Stolz, D.B., and Romero, G.  (2005).  Characterization of Endocytic Vesicles
Using Magnetic Microbeads Coated with Signaling Ligands. Traffic 6, 324-334.
Lindsell, C.E., Shawber, C.J., Boulter, J., and Weinmaster, G.  (1995).  Jagged: a
mammalian ligand that activates Notch1. Cell 80(6), 909-17.
Liu, H., and Roy, K.  (2005).  Biomimetic three-dimensional cultures significantly
increase hematopoietic differentiation efficacy of embryonic stem cells. Tissue
Eng 11(1–2), 319–30.
260
Lowell, S., Benchoua, A., Heavey, B. and Smith, A.G.  (2006).  Notch Promotes Neural
Lineage Entry by Pluripotent Embryonic Stem Cells.  Plos Biol 4(5), 0805-0818.
Luo, B., Aster, J.C., Hasserjian, R.P., Kuo, F. and Sklar, J.  (1997).  Isolation and
functional analysis of a cDNA for human Jagged2, a gene encoding a ligand for
the Notch1 receptor. Mol Cell Biol 17(10), 6057-67.
Ma, Z., Gao, C., Gong, Y., and Shen, J.  (2003).  Paraffin spheres as porogen to fabricate
poly(L-lactic acid) scaffolds with improved cytocompatibility for cartilage tissue
engineering. J Biomed Mater Res B Appl Biomater 67(1), 610–7.
Maillard, I., Fang, T., and Pear, W.S.  (2005).  Regulation of Lymphoid Development,
Differentiation, and Function by the Notch Pathway. Annu Rev Immunol 23, 945-
74.
Mantalaris, A., Keng, P., Bourne, P., Chang, A.Y., and Wu, J.H.  (1998).  Engineering a
human bone marrow model: a case study on ex vivo erythropoiesis. Biotechnol
Prog 14(1), 126–33.
Marshall, D., Bagley, J., Le, P., Hogquist, K., Cyr, S., Von Schild, E., Pykett, M., and
Rosenzweig, M.   (2003).  T cell generation including positive and negative
selection ex vivo in a three-dimensional matrix.  Journal of Hematotherapy &
Stem Cell Research 12, 565-574.
Maus, M.V., Riley,  J.L., Kwok, W.W., Nepom, G.T., and June, C,H.  (2003).  HLA
tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells.
Clin Immunol 106, 16–22.
Maus, M.V., Thomas, A.K., Leonard, D.G.B., Allman, D., Addya, K., Schlienger, K.,
Riley, J.L., and June, C.H.  (2002).  Ex vivo expansion of polyclonal and antigen-
261
specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-
cell receptor, CD28 and 4-1BB.  Nature Biotechnology 20, 143-148.
Mizutani, K., Matsubayashi, T., Iwase, S., Doi, T.S., Kasai, K., Yazaki, M., Wada, Y.,
Takahashi, T., and Obata, Y.  (2000).  Murine Delta Homologue, mDelta1,
Expressed on Feeder Cells Controls Cellular Differentiation.  Cell Structure and
Function 25, 21–31.
Mohr, O.L.  (1919).  Character changes caused by mutation of an entire region of a
chromosome in Drosophila. Genetics 4, 275-282.
Nakano, T.  (1996).  In vitro development of hematopoietic system from mouse
embryonic stem cells: a new approach for embryonic hematopoiesis. Int J
Hematol 65(1), 1–8.
Nakano, T. (1995).  Lymphohematopoietic development from embryonic stem cells in
vitro. Semin Immunol 7, 197–203.
Nakano, T., Kodama, H., and Honjo, T.  (1994).  Generation of lymphohematopoietic
cells from embryonic stem cells in culture. Science 265(5175), 1098–101.
Nakano, T., Kodama, H., and Honjo, T.  (1996).  In vitro development of primitive and
definite erythrocytes from different precursors.  Science 272, 722-724.
Nelson, R.P. and M. Ballow.  (2003).   Immunomodulation and immunotherapy: Drugs,
cytokines, cytokine receptors, and antibodies.  J Allergy Clin Immunol 111,
S720-32.
262
Nemir, M., Croquelois, A., Pedrazzini, T., and Radtke, F. (2006). Induction of
Cardiogenesis in Embryonic Stem Cells via Downregulation of Notch1 Signaling.
Circ Res 98, 1471-1478.
Nilsson, S.K., Debatis, M.E., Dooner, M.S., Madri, J.A., Quesenberry, P.J., and Becker,
P.S.  (1998).  Immunofluorescence characterization of key extracellular matrix
proteins in murine bone marrow in situ. J Histochem Cytochem 46(3), 371–7.
Nofziger, D., Miyamoto, A., Lyons, K.M., and Weinmaster, G.  (1999).  Notch signaling
imposes two distinct blocks in the differentiation of C2C12 Myoblasts.
Development 126, 1689-1702.
O’Shea, K.S.  (1999).  Embryonic stem cell models of development. Anat Rec 257(1),
32–41.
Ohishi, K., Varnum-Finney, B. and Bernstein, I.D.  (2002).  Delta-1 enhances marrow
and thymus repopulating ability of human CD34+CD38- cord blood cells.  J Clin
Invest 100, 1165-1174.
Olivier, V. et al.  (2003).  Comparative particle-induced cytotoxicity toward macrophages
and fibroblasts.  Cell Biol Toxicol. 19(3), 145-59.
Parreira, L., Neves, H.,  and Simoes, S.  (2003).  Notch and lymphopoiesis: a view from
the microenvironment. Semin Immunol 15(2), 81-9.
Patel, D. and D. Rickwood.  (1995).  Optimization of conditions for specific binding of
antibody-coated beads to cells.  Journal of Immunological Methods 184, 71-80.
Pear, W.S.   (2005).   Cooking up T cells. Blood 105(4), 1373-1374.
263
Petrie, H.T. and J.C. Zuniga-Pflucker.  (2007).  Zoned Out: Functional Mapping of
Stromal Signaling Microenvironments in the Thymus.  Annu Rev Immunol 25,
649-79.
Pilling, D., Kitas, G.D., Salmon, M., and Bacon, P.A.  (1989).  The kinetics of interaction
between lymphocytes and magnetic polymer particles.  Journal of Immunological
Methods 122, 235-241.
Plum, J., De Smedt, M., Defresne, M-P., Leclercq, G., and Vandekerckhove, B.  (1994).
Human CD34+ fetal liver stem cells differentiate to T cells in a mouse thymic
microenvironment. Blood 84(5), 1587-93.
Porritt, H.E., Rumfelt, L.L., Tabrizifard, S., Schmitt, T.M., Zuniga-Pflucker, J.C., and
Petrie, H.T.  (2004).   Heterogeneity among DN1 prothymocytes reveals multiple
progenitors with different capacities to generate T cell and non-T cell lineages.
Immunity 20, 735-745.
Postlethwaite, A.E.  (1997).  Bidirectional interactions between T cells and the
extracellular matrix.  Transplant Immunology 5, 289-291.
Poznansky, M.C., Evans, R.H., Foxall, R.B., Olszak, I.T., Piascik, A.H., Hartman, K.E.,
Brander, C., Meyer, T.H., Pykett, M.J., Chabner, K.T., Kalams, S.A.,
Rosenzweig, M. and Scadden, D.T.  (2000).  Efficient generation of human T
cells from a tissue-engineered thymic organoid. Nature Biotechnology 18, 729-
734.
Pui, J.C.  (1999).  Notch 1 expression in early lymphopoiesis influences B versus T
lineage determination.  Immunity 11, 299-308.
264
Radtke, F., Wilson, A., Mancini, S.J., and MacDonald, H.R.  (2004).  Notch regulation of
lymphocyte development and function. Nat Immunol 5, 247–253.
Radtke, F., Wilson, A., Stark, G., Bauer, M., van Meerwijk, J., MacDonald, H.R., and
Aguet, M.  (1999).  Deficient T cell fate specification in mice with an induced
inactivation of Notch1.  Immunity 10, 547-58.
Res, P., Martinez-Caceres, E., Jaleco, A.C., Staal, F., Noteboom, E., Weijer, K., and
Spits, H.  (1996).  CD34+CD38dim cells in the human thymus can differentiate
into T, natural killer, and dendritic cells but are distinct from pluripotent stem
cells. Blood 87(12), 5196-206.
Robles, D.T.  (2006).   Candidiasis, Chronic Mucocutaneous.  www.emedicine.com
Rolink, A.G., Massa, S., Balciunaite, G., and Ceredig, R.  (2006).  Early lymphocyte
development in bone marrow and thymus.  Swiss Med Wkly 136, 679-683.
Sambandam, A., Maillard, I., Zediak, V.P., Xu, L., Gerstein, R.M., Aster, J.C., Pear,
W.S., and Bhandoola, A.  (2005).  Notch signaling controls the generation and
differentiation of early T lineage progenitors. Nature Immunol 6, 663–670.
Sarda, S., Pointu, D., Pincet, F., and Henry, N.  (2004).  Specific Recognition of
Macroscopic Objects by the Cell Surface: Evidence for a Receptor Density
Threshold Revealed by Micrometric Particle Binding Characteristics. Biophysical
Journal 86, 3291-3303.
Sasaki, T., Takagi, M., Soma, T., and Yoshida, T.  (2002).  3D culture of murine
hematopoietic cells with spatial development of stromal cells in nonwoven
fabrics. Cytotherapy 4(3), 285–91.
265
Sasaki, T., Takagi, M., Soma, T., and Yoshida, T.  (2003).  Analysis of hematopoietic
microenvironment containing spatial development of stromal cells in nonwoven
fabrics. J Biosci Bioeng 96(1), 76–8.
Saxena, M.T., Schroeter, E.H., Mumm, J.S., and Kopan, R.  (2001).  Murine notch
homologs (N1-4) undergo presenilin-dependent proteolysis.  J Biol Chem 276,
40268-40273.
Schmitt, T.M. and J. C. Zuniga-Pflucker.  (2002).  Induction of T cell development from
hematopoietic progenitor cells by delta-like-1 in vitro.  Immunity 17(6), 749-56.
Schmitt, T.M., Ciofani, M., Petrie, H.T., and Zuniga-Pflucker, J.C.  (2004).  Maintenance
of T Cell Specification and Differentiation Requires Recurrent Notch Receptor-
Ligand Interactions.  J Exp Med 200(4), 469-479.
Schmitt, T.M., de Pooter, R.F., Gronski, M.A., Cho, S.K., Ohashi, P.S., and Zuniga-
Pflucker, J.C.  (2004).  Induction of T cell development and establishment of T
cell competence from embryonic stem cells differentiated in vitro. Nat Immunol
5(4), 410-7.
Schuurman, H.  (1997).  Thymic Microenvironment at the Light Microscopic Level.
Microscopy Research and Technique. 38, 216-226.
Sinha, S.  (2006).  Severe Combined Immunodeficiency.  www.emedicine.com
Souhami, R. (2002).  Textbook of Medicine.  Churchill Livingstone.  79-104.
Sternberg, S.S. Histology for Pathologists. 2nd ed. Philadelphia: Lippincott-Raven
Publishers; 1997.
266
Swann, I.D., Dealtry, G.B. and Rickwood, D.  (1992).  Differentiation-related changes in
quantitative binding of immunomagnetic beads. J Immunol Methods 152, 245-51.
Tan, J.B., Visan, I, Yuan, J.S. and Guidos, C.J.  (2005).  Requirement for Notch1 signals
at sequential early stages of intrathymic T cell development.  Nature Immunol 6,
671–679.
Tan-Pertel, H.T., Walker, L., Browning, D., Miyamoto, A., Weinmaster, G., and Gasson,
J.C.  (2000).   Notch signaling enhances survival and alters differentiation of 32D
myeloblasts. J Immunol 165, 4428–4436.
TechNote #101 ProActive® Microspheres.  Bangs Laboratories, Inc. 8/29/99
TechNote #204 ProActive® Microspheres.  Bangs Laboratories, Inc. 8/4/99
Till, J.E. and McCollough, E.A.  (1961).  A direct measurement of the radiation
sensitivity of normal mouse bone marrow cells.  Radiat Res 14, 213-22.
Toki, J., Kumamoto, T., Ogata, H., Kawamura, M., Fukumoto, M., Cherry, Yamamoto,
Y., Than, S., Inaba, M., Himeno, Y., Imura, H., Good, R.A., and Ikehara, S.
(1991).  Analyses of T-cell differentiation from hemopoietic stem cells in the G0
phase by an in vitro method.  PNAS USA 88, 7548-7551.
Trickett, A, and Kwan, Y.L.  (2003).  T cell stimulation and expansion using anti-
CD3/CD28 beads. J Immunol Methods 275(1/2), 251–255.
267
Trickett, A.E., Kwan, Y.L., Cameron, B., and Dwyer, J.M.  (2002).  Ex vivo expansion of
functional T lymphocytes from HIV-infected individuals. J Immunol Methods,
262(1/2), 71–83.
Tsai, R.Y., and McKay, R.D.  (2000).  Cell contact regulates fate choice by cortical stem
cells. J Neurosci 20(10), 3725–35.
Varnum-Finney B., Wu, L., Yu, M., Brashem-Stein, C., Staats, S., Flowers, D., Griffin,
J.D., and Bernstein, I.D.  (2000).  Immobilization of Notch ligand, Delta-1, is
required for induction of Notch signaling.  Journal of Cell Science 113, 4313-
4318.
Varnum-Finney, B., Brashem-Stein, C., and Bernstein, I.D.  (2003).  Combined effects of
Notch signaling and cytokines induce a multiple log increase in precursors with
lymphoid and myeloid reconstituting ability. Blood 101, 1784–1789.
Vituri, C.L., Alvarez-Silva, M., Trentin, A.G., and Borelli, P.  (2000).  Alterations in
proteins of bone marrow extracellular matrix in undernourished mice. Braz J Med
Biol Res 33(8), 889–95.
Vodyanik, M.A., Bork, J.A., Thomson, J.A., and Slukvin, I.I.  (2005).  Human embryonic
stem cell-derived CD34+ cells: efficient production in the coculture with OP9
stromal cells and analysis of lymphohematopoietic potential. Blood 105(2),
617–26.
Weekx, S.F., Snoeck, H.W., Offner, F., De Smedt, M.,  Van Bockstaele, D.R., Nijs, G.,
Lenjou, M., Moulijn, A., Rodrigus, I., Berneman, Z.N., and Plum, J.  (2000).
Generation of T cells from adult human hematopoietic stem cells and progenitors
in a fetal thymic organ culture system: stimulation by tumor necrosis factor-alpha.
Blood 95(9), 2806-12.
268
Wilkinson, B. et al.  (1999).   Factors regulating stem cell recruitment to the fetal thymus.
J Immunol 162, 3873-3881.
Williams, R.L., Hilton, D.J., Pease, S., Willson, T.A., Stewart, C.L., Gearing, D.P., et al.
(1988).  Myeloid leukaemia inhibitory factor maintains the developmental
potential of embryonic stem cells. Nature 336(6200), 684–7.
Wilson, C.E., Dhert, W.J., Van Blitterswijk, C.A., Verbout, A.J., and De Bruijn, J.D.
(2002).  Evaluating 3D bone tissue engineered constructs with different seeding
densities using the alamarBlue assay and the effect on in vivo bone formation. J
Mater Sci Mater Med 13(12), 1265–9.
Wognum, A.W., Eaves, A.C., and Thomas, T.E.  (2003).  Identification and isolation of
hematopoietic stem cells. Arch Med Res 34(6), 461–75.
Yan, X.Q., Sarmiento, U., Sun Y., Huang, G., Guo, J., Juan T., Van G., Qi, M-Y, Scully,
S., Senaldi, G., and Fletcher, F.A.  (2001).  A novel Notch ligand, Dll4, induces
T-cell leukemia/lymphoma when overexpressed in mice by retroviral-mediated
gene transfer. Blood 98, 3793-3799.
Yee, C.   (2006).   Adoptive T-Cell Therapy of Cancer.  Hematol Oncol Clin N Am 20,
711-33.
Yeoman, H., Gress, R.E., Bare, C.V., Leary, A.G., Boyse, E.A., Bard, J., Shultz, L.D.,
Harris, D.T., and DeLuca, D.  (1993).  Human bone marrow and umbilical cord
blood cells generate CD4+ and CD8+ single-positive T cells in murine fetal
thymus organ culture. Proc Natl Acad Sci U S A 90(22), 10778-82.
Zediak, V.P., Maillard, I. and Avinash Bhandoola.  (2005).   Closer to the source: notch
and the nature of thymus-settling cells.  Immunity 23, 245-248.
269
Zhang, S.C., Wernig, M., Duncan, I.D., Brustle, O., and Thomson, J.A.  (2001).  In vitro
differentiation of transplantable neural precursors from human embryonic stem
cells. Nat Biotechnol 19(12), 1129–33.
Zhao, Y., Parkhurst, M.R., Zheng, Z., Cohen, C.J., Riley, J.P., Gattinoni, L., Restifo,
N.P., Rosenberg, S.A., and Morgan, R.A.  (2007).  Extrathymic generation of
tumor-specific T cells from genetically engineered human hematopoietic stem
cells via Notch signaling. Cancer Res 67(6), 2425-9.
Zuniga-Pflucker, J.C. (2004). T-cell development made simple. Nature Reviews
Immunology 4, 67-72.
Zuniga-Pflucker, J.C. and T.M. Schmitt,  (2005).  Unraveling the origin of lymphocyte
progenitors. Eur J Immunol 35(7,) 2016-8.
270
Vita
Sabia Zehra Taqvi is the daughter of Zafar and Nasim Taqvi.  She was born in
Houston, Texas on September 6th 1980 and has two younger siblings, Nazer and Sarah.
She attended elementary, intermediate and high schools in Houston and pursued her
interest in science and math at Texas A&M University in College Station, Texas.  Sabia
graduated with honors with a Bachelor’s in Science degree in biomedical engineering and
a minor in Business Administration in the fall of 2002.
Sabia continued her education with graduate studies in biomedical engineering at
the University of Texas in Austin in the fall of 2002.  Her doctoral studies centered on ex
vivo systems for hematopoietic differentiation applications with a special focus on T cell
differentiation using Notch ligand functionalized microbeads.  Sabia’s efforts led to a
provisional patent, several national conference presentations and two first author
publications in peer-reviewed journals.  Sabia is a NSF IGERT fellow, NIH
Biotechnology trainee and a recipient of Thrust Engineering Graduate Fellowship.  She
was also recognized for her service as a teaching assistant.  In June of 2006, Sabia was
married to Wasif Ali Abidi, a M.D./Ph.D. student at New York University.  Both Wasif
and Sabia’s immediate and extended families have played an instrumental part in her
success and well-being.  Sabia intends to give back to the community through a teaching
career and initiatives in scientific education.
Permanent address:  9874 Sageaspen, Houston, TX 77089
This dissertation was typed by the author.
